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Útdráttur 
Bakgrunnur: Sjúklingar með krabbamein finna fyrir mörgum einkennum 
sem hafa áhrif á lífsgæði þeirra. Krabbameinstengd einkenni orsakast 
ýmist af sjúkdómnum sjálfum eða meðferð hans, en þættir eins og aldur, 
kyn og aðrir sjúkdómar geta einnig haft áhrif á einkennamyndina. 
Einkenna-lífsgæðamódelið sýnir tengslin milli einkenna og lífsgæða hjá 
sjúklingum með krabbamein. 
Tilgangur verkefnis: Að skoða hugtakið lífsgæði og einkennamynd 
krabbameinssjúklinga, að setja fram módel til að lýsa tengslunum milli 
einkenna og lífsgæða og að prófa ákveðna þætti módelsins.  
Þátttakendur: 150 krabbameinssjúklingar á ópíoíðum. Karlar voru 62 
talsins (41%) en konur 88 (59%). Allir þátttakendur voru hvítir. Aldur 
þátttakenda var á bilinu 20-92 ár en meðalaldur (SF) var 64,7 (12,7) ár.  
Rannsóknarnið: Lýsandi, þversniðs, fylgnirannsóknarsnið. 
Niðurstöður: Meðalfjöldi (SF) einkenna síðasta sólarhringinn var 6,2 (2,5) 
en 9,0 (3,3) síðastliðna viku. Algengustu einkenni voru þreyta, verkir og 
slappleiki. Meðalstyrkur (SF) einkenna var 0,7 (0,4)  síðasta sólarhringinn 
en 0,9 (0,5) síðastliðna viku á skalanum 0-3. Fjöldi einkenna, styrkur 
þeirra og heilsu/lífsgæðaskor var ekki tengt kyni eða tilvist annarra 
sjúkdóma. Fjöldi einkenna og styrkur einkenna minnkaði hins vegar með 
hækkandi aldri þótt heilsu/lífsgæðaskor væri óháð aldri. Fjöldi einkenna 
skýrði 25,8% af dreifingunni í heilsu/lífsgæðum þegar leiðrétt hafði verið 
fyrir aldri og kyni. Annað aðhvarfsgreiningarmódel, einnig leiðrétt fyrir 
aldri og kyni, sýndi að verkir, þreyta, svefnleysi og depurð skýrðu 33,6% 
af drefingunni í heilsu/lífsgæðum.  
iv 
Ályktanir: Einkennamynd íslenskra krabbameinssjúklinga á ópíoíðum 
svipar til krabbameinssjúklinga í öðrum löndum. Fjöldi einkenna sem og 
verkir, og einkum þreyta, eru tengd skertum lífsgæðum. Á óvart kom að 
svefnleysi og depurð höfðu ekki marktæk áhrif í 
aðhvarfsgreiningarmódeli. Niðurstöðurnar benda til þess að hægt sé að 
stuðla að bættum lífsgæðum krabbameinssjúklinga með því að meta og 
meðhöndla krabbameinstengd einkenni.  
Lykilorð: einkenni, lífsgæði, krabbamein. 
Abstract  
Background: Cancer patients experience multiple symptoms that affect 
their quality of life (QOL). Cancer related symptoms may be caused by 
the disease itself or its treatment, but factors like age, gender, and 
concurrent diseases may also influence the symptomatology. The 
symptoms-quality of life model shows the relationship between symptoms 
and QOL in cancer patients. 
Goal of project: To review the literature on quality of life and 
symptomatology among cancer patients, to pull together a model that 
explains the relationship between symptoms and quality of life and to test 
selected aspects of the model. 
Participants: 150 cancer patients on opioids, 62 (41%) men and 88 (59%) 
women, all Caucasians. The patients ranged in age from 20-92 years with 
a mean (SD) age of 64,7 (12,7) years. 
Research design: Descriptive, cross-sectional, and correlational. 
Results: The mean (SD) number of symptoms in the past 24 hours was 6,2 
(2,5), and 9,0 (3,3) in the past week. The most common symptoms were 
fatigue, pain, and weakness. Mean (SD) symptom severity was 0,7 (0,4) in 
v 
the past 24 hours and 0,9 (0,5) in the past week on a scale from 0-3. 
Gender and concurrent diseases were not related to number of symptoms, 
symptom severity or QOL, but increased age was associated with fewer 
symptoms and less symptom severity although age difference was not 
found for global health/QOL score. Adjusted for age and gender, number 
of symptoms explained 25,8% of the variance in global health/QOL.  Also 
adjusting for age and gender, pain, fatigue, insomnia, and depression 
explained 33,6% of the variance in global health/QOL. 
Conclusions: The symptomatology of Icelandic cancer patients is similar 
to cancer patients in other countries. Number of symptoms and the 
individual symptoms of pain and notably fatigue are associated with 
diminished QOL. Surprisingly insomnia and depression did not add 
significantly to the regression model. These results indicate that QOL of 
cancer patients may be improved by assessing and treating cancer related 
symptoms.  
Key words: symptoms, quality of life, cancer. 
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Introduction 
Each year approximately 1200 individuals are diagnosed with cancer in 
Iceland and the incidence rate is growing (Krabbameinsskrá 
Krabbameinsfélags Íslands, 2008b). The annual number of cancer cases 
from 1993-1997 to 2018-2022 is predicted to increase by 400 (82%) in 
men and by 286 (62%) in women, mostly due to change in population age 
structure and size, but to a lesser extent because of the change in risk. 
Today the Icelandic population is the youngest among the Nordic 
countries but forecast of population growth suggests that between the 
years 2002 and 2018-2022 the population will have increased by 18%, 
mostly because of greater number of elderly citizens (Moller et al., 2002). 
The prognosis of cancer patients, however, has been improving in the past 
decades with five year relative survival increasing and mortality rates 
declining (Jónasson & Tryggvadóttir, 2004; Krabbameinsskrá 
Krabbameinsfélags Íslands, 2008a; Verdecchia et al., 2007). 
The concept of quality of life is widely used in health care 
practice, especially in the context of cancer and cancer treatment. Quality 
of life is a multidimensional, subjective, dynamic and yet a quantifiable 
construct (Niv & Kreitler, 2001) but despite being a central concept, no 
universal definition of quality of life exists (Jocham, Dassen, 
Widdershoven, & Halfens, 2006; Kaasa & Loge, 2003; King & Hinds, 
1998). Understanding the concept, however, is of importance since one of 
the three main goals of cancer treatment and cancer nursing is to improve 
quality of life (King et al., 1997; Penson, Wenzel, Vergote, & Cella, 
2006).   
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A symptom is a subjective phenomenon that patients perceive as 
an indicator of a change in health status (Rhodes & Watson, 1987). 
Research has shown that cancer patients experience a number of 
unpleasant symptoms related to the disease itself or its treatment 
(Cleeland et al., 2003; Mercadante, Casuccio, & Fulfaro, 2000). 
According to studies the median number of symptoms per patient is often 
between eight and eleven (Chang, Hwang, Feuerman, & Kasimis, 2000; 
Homsi et al., 2006; Peters & Sellick, 2006; Portenoy et al., 1994; 
Sigurdardottir, Hjaltadottir, Gudmannsdottir, & Jonsson, 2006; Tsai, Wu, 
Chiu, Hu, & Chen, 2006; Walsh, Donnelly, & Rybicki, 2000) with the 
most common symptoms being pain, fatigue, lack of energy, weakness 
and appetite loss (Teunissen et al., 2007). Symptom severity in patients 
with advanced cancer tends in most cases to be mild or moderate, 
although comparison between studies is difficult because of different 
scales and measurement tools (Hoekstra, de Vos, van Duijn, Schade, & 
Bindels, 2006; Peters & Sellick, 2006; Tsai et al., 2006). A considerable 
proportion (12-40%) of patients, nevertheless, experience rather severe or 
very severe symptoms in particular for the symptoms of pain and fatigue 
(Chang et al., 2000; Modonesi et al., 2005).  
Symptoms infrequently appear in isolation (Chang et al., 2000) 
and a correlation seems to exist between many of the symptoms 
experienced by cancer patients (Chen & Tseng, 2006). This is not least 
true for the symptoms of pain, depression and fatigue (Chen & Chang, 
2004; Cleeland et al., 2000; Portenoy et al., 1994). This correlation of 
symptoms has given rise to the concept of symptom clusters but the 
existence of such clusters may suggest that symptoms in cancer are caused 
by a shared underlying pathophysiology (Cleeland et al., 2003).  
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Research has shown that the quality of life of cancer patients is 
usually worse than that of the general public (Coates, Porzsolt, & Osoba, 
1997; Klepstad, Borchgrevink, & Kaasa, 2000; Michelson, Bolund, & 
Brandberg, 2000) and the suffering of people with advanced cancer is 
largely determined by the presence of unpleasant symptoms related to 
their disease (Teunissen et al., 2007). Factors affecting quality of life in 
this group of patients are recurrent cancer (Bjordal et al., 2000), advanced 
disease (Hwang, Chang, Fairclough, Cogswell, & Kasimis, 2003) and side 
effects from cancer treatment (Brans et al., 2002) all factors known to 
cause symptoms (Cleeland et al., 2003; Lee et al., 2004; Mercadante et al., 
2000). Among the specific symptoms shown to negatively affect quality 
of life are pain, depression, fatigue and insomnia (Ferrell, 1995; Hofman, 
Ryan, Figueroa-Moseley, Jean-Pierre, & Morrow, 2007; Lis, Gupta, & 
Grutsch, 2008; Peters & Sellick, 2006; Rustøen, Moum, Padilla, Paul, & 
Miaskowski, 2005), but research has also shown that the number of 
symptoms patients experience are important with increasing number of 
symptoms having greater effect on a patients’ quality of life (Chang et al., 
2000; Portenoy et al., 1994). 
In light of this it is important to look at symptoms experienced by 
cancer patients in order to alleviate their suffering and hence improve 
their quality of life (Walsh et al., 2000). The purpose of this master thesis 
is threefold: 
1. To review the literature on quality of life and 
symptomatology among cancer patients. 
2. To pull together a model that explains the relationship 
between symptoms and quality of life. 
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3. To test selected aspects of the model with a secondary 
analysis of data derived from a study of 150 cancer patients 
on opioids. 
The value of the study lies mainly in the fact that it is the first of its kind 
conducted in Iceland. The results will illustrate the symptomatology of 
patients with advanced cancer and their quality of life. Furthermore, the 
information on the relationship between symptoms and quality of life has 
important clinical value since it can be used to improve patient care.  
In the first part of the thesis the theoretical background underlying 
the study is reviewed. The second part consists of the methodology, the 
third part holds the results, and the fourth discussion, conclusion, and 
future studies. 
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Theoretical background 
In this chapter the concepts of quality of life and symptoms will be 
reviewed. First, the concept of quality of life will be introduced and 
explored in relation to its definitions, characteristics, boundaries, 
preconditions and outcomes, followed by a section on the maturity of the 
concept and how it is used in research. Secondly, the concept of symptoms 
is reviewed. The number of symptoms and prevalence will be discussed as 
well as symptom severity, co-occurring symptoms and symptom clusters. 
Thirdly, there is a section regarding the relationship between quality of life 
and symptoms where contributing factors to symptomatology, factors 
affecting quality of life and the quality of life scores of cancer patients are 
reviewed. Fourth, there is a summary of the theoretical background and the 
Symptoms-quality of life model, based on the literature, is presented. 
Finally, the purpose of the current study is introduced and the research 
questions and hypotheses outlined. 
The concept of quality of life in health care 
The concept of quality of life is widely used in health care practice, 
especially in the context of cancer and cancer treatment. This is not 
surprising, since, the three main goals of cancer treatment are: 
improvements in cure rate, lengthening survival time, and last but not least, 
improving the patients' quality of life (Penson et al., 2006).  Better quality 
of life is also one of the main goals of cancer nursing (King et al., 1997) 
and indeed, improving quality of life is the primary goal of any health care 
intervention, not only cancer treatment (Revicki et al., 2000). Quality of life 
is also a widely used concept in social sciences, politics and advertisements, 
6 
as well as in health care. The first measurements of the concept became 
evident around 1960 when there was a growing interest within sociology in 
what factors affected the daily life of the American public. In health care, 
the concept became "popular" as a result of the patients' rights movement 
(Haas, 1999b; Pais-Ribeiro, 2004). In nursing the concept evolved as an 
important outcome measure to evaluate the impact of nursing care on 
patients’ daily life. The interest of the nursing profession in quality of life 
lies not least in the multidimensionality of the concept, discussed later, 
which fits the holistic viewpoint of nursing. In health care in general, 
interest in the concept as an outcome measure has increased and today 
quality of life measurements are used widely for example in the 
development of new cancer drugs (Grant & Dean, 2003).  
When reviewing the health care literature it becomes clear that 
quality of life has been widely studied in the last decade. Entering the 
concept into the PubMed database results in 69.975 items, mostly articles, 
published in the last 10 years. But despite being a central concept, no 
universal definition of quality of life exists (Jocham et al., 2006; Kaasa & 
Loge, 2003; King & Hinds, 1998) and many authors fail to define the 
concept in their work (Haas, 1999b; Taillefer, Dupuis, Roberge, & LeMay, 
2003). What the concept encompasses is, therefore, not easy to apprehend 
and in order to get a clearer understanding of the concept it will be 
discussed in this thesis in accordance with the criteria for concept 
evaluation developed by Morse and colleagues (Morse, Mitcham, Hupcey, 
& Tason, 1996). It has to be noted here, though, that a full concept 
evaluation was by no means attempted. According to Morse (1995, p. 33) 
concepts are "abstract “cognitive representations” of perceptible reality 
formed by direct or indirect experiences" and each concept is built of five 
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main factors: definition, characteristics, boundaries, preconditions and 
outcomes (Morse et al., 1996).   
Definitions of quality of life. 
A definition is the label attached to a concept. It is the prerequisite for the 
concept to be identifiable, to be recognizable, to be referred to, and last but 
not least, to be communicated (Morse et al., 1996). Although, no universal 
definition of quality of life exists (Jocham et al., 2006; Kaasa & Loge, 
2003; King & Hinds, 1998) multiple definitions of the concept are 
nevertheless available. It would be a handful to list every existing definition 
of quality of life and, therefore, only few definitions will be presented here. 
Before looking at the definitions it has to be observed that there are two 
quality of life concepts that repeatedly emerge in the health literature: 
general quality of life and health related quality of life. The term, health 
related quality of life, was introduced in the health literature to distinguish 
between the aspects of quality of life that are not related to health, such as 
political or societal features, in order to focus more clearly on the impact of 
disease and treatment on quality of life (Ferrans, Zerwic, Wilbur, & Larson, 
2005). Health related quality of life is more specific than general quality of 
life encompassing evaluation of symptoms, function and psychological 
wellness as to some extent, existential and spiritual issues (Kaasa & Loge, 
2003). Therefore, the main use of the concept is for those who are being 
treated for some disease (Choe, Padilla, Chae, & Kim, 2001) since it is 
mainly used for those aspects of life affected by healthcare interventions 
(Velikova, Stark, & Selby, 1999). General quality of life, on the other hand, 
is a broader concept that not only considers the impact of disease and its 
treatment on the individual, but rather reflects on the person as a whole 
(Calman, 1984). The two concepts are therefore not one and the same (Pais-
8 
Ribeiro, 2004) but health related quality of life may be viewed as one 
aspect of general quality of life (Kaasa & Loge, 2003).   
One of the most widely used definition of quality of life in the 
health literature is that of Cella and Cherin (1988, p. 70) who define it as 
the “patients' appraisal of, and satisfaction with, their current level of 
functioning as compared to what they perceive to be possible or ideal.” This 
definition was specifically developed as a working definition of quality of 
life to use in the cancer population. It is subjective in nature but also 
considers the evaluative aspect of quality of life as well as the impact of the 
disease on the patient's functioning (Cella & Cherin, 1988). This definition 
may seem to be more in line with health related quality of life definitions, 
reviewed later, than general quality of life with the emphasis on the 
patient’s function. Of note here is that the definition dates back to 1988 
when, it seems, that the term health related quality of life had not yet 
become well-known in the literature. Indeed the definition was modified in 
1995 and became: “health related quality of life (QOL) refers to the extent 
to which one’s usual or expected physical, emotional and social well-being 
are affected by a medical condition or its treatment” (Cella, 1996, p. 234).  
The World Health Organization (WHO-QOL Group, 1993, p. 153) 
defines quality of life as “an individual's perception of their position in life 
in the context of the culture and value system in which they live and in 
relation to their goals, expectations, standards, and concerns.” This 
definition is in line with the multidimensional, multicultural quality of life 
questionnaire, WHOQOL, developed by the organization. The 
questionnaire is based upon statements from patients with various diseases, 
well people, and health professionals on what factors constitute important 
aspects of quality of life, and how quality of life should be inquired about 
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(WHO-QOL Group, 1997). Another definition, presented here, was 
developed by Haas (1999, p.738) who after exploring the concept of quality 
of life in the context of both health and social sciences defined it as "a 
multidimensional evaluation of an individual's current life circumstances in 
the context of the culture in which they live and the values they hold. 
Quality of life is primarily a subjective sense of well-being encompassing 
physical, psychological, social, and spiritual dimensions. In some 
circumstances, objective indicators may supplement or, in the case of 
individuals unable to subjectively perceive, serve as a proxy assessment of 
quality of life". In similar terms, but more focused on the material well-
being, is the definition provided by Felce and Perry (1995, p. 60 & 62) 
where quality of life is "an overall general well-being that comprises 
objective descriptors and subjective evaluations of physical, material, 
social, and emotional well-being together with the extent of personal 
development and purposeful activity, all weighted by a personal set of 
values". Like Haas (1999) Felce and Perry ground their work in social and 
health sciences, mainly in the field of developmental disabilities. Another 
approach to define quality of life is the so-called gap-theory (Calman, 
1984). According to Calman quality of life is the gap between how an 
individual perceives a given situation compared to his expectations 
regarding that situation. A smaller gap, hence, indicates better quality of 
life. Rooted in oncology, the definition was initially proposed as a 
hypothesis to be tested. The underlying presumptions of the definition are 
that quality of life can only be measured in individual terms and the concept 
is based on past experiences, dreams, hopes, ambitions and lifestyle of the 
individual. 
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Picture 1. The revised Wilson and Cleary model of health related 
quality of life  
Source: Ferrans, C.E., Zerwic, J.J., Wilbur, J.E. and Larson, J.L. (2005). 
Conceptual Model of Health-Related Quality of Life. Journal of Nursing 
Scholarship, 37(4), 336-342. Used with permission from Wiley-Blackwell 
Publishing Ltd. 
Embedded in the health sciences, health related quality of life has 
been defined as the subjective assessment of the impact of disease and 
treatment across the physical, psychological, social and somatic domains 
of functioning and well-being (Ware, 1984; Schipper et al., 1996, in 
Revicki et al., 2000). Another definition defines it as a multidimensional 
construct encompassing perceptions of both positive and negative aspects 
of physical, emotional, social, and cognitive functions, as well as the 
negative aspects of somatic discomfort and other symptoms produced by a 
disease or its treatment (Osoba, 1994). Wilson and Cleary (1995) created 
a conceptual model of health related quality of life that was later revised 
by Ferrans and colleagues (Ferrans et al., 2005). The model, based on the 
literature regarding health related quality of life, aims to explain the 
relationship between health and quality of life: biological function leads to 
symptoms that affect functional status, which affects health perceptions 
that finally affect overall quality of life. These factors are then all 
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influenced by individual characteristics as well as characteristics of the 
environment. Picture 1 shows the model. 
According to van der Steen (1993) a definition must be clear, it 
should not include accompanying features, it should refer to present 
features rather than absent ones, it should not be circular and neither too 
broad or too narrow (Morse et al., 1996). Although not being circular or 
including absent or accompanying features none of the definitions above 
clearly define what quality of life actually is. All include subjective 
wording like "appraisal", "satisfaction", "perception", "concern" and 
"ideal" with only two definitions considering an objective aspect of the 
concept (Felce & Perry, 1995; Haas, 1999b). It follows that the quality of 
life definitions are not specific enough and, hence, lack clarity, which 
should not be surprising given the subjectivity of the concept and the 
complexity of the human life in general.  
Characteristics of quality of life.  
Characteristics are those attributes that define a concept. They must be 
present in all instances where the concept is used but they may appear in 
different strength or even form. These characteristics must be abstract 
enough to define the concept in different situations, but yet, they must still 
be unique enough to distinguish between the concept and other related 
concepts. A well-established concept is both easily understood and 
frequently used in everyday language and a concept can be well-
established although its characteristics may not be fully articulated (Morse 
et al., 1996). 
According to Niv & Kreitler (2001), quality of life is a 
multidimensional, subjective, dynamic, evaluative, phenomenological, but 
yet a quantifiable construct. Similarly, Haas (1999), in her concept 
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analysis, has identified five main defining characteristics of quality of life 
as evident in definitions and uses of the concept. According to Haas (p. 
733) quality of life: "a) is an evaluation of an individual's current life 
circumstances, b) is multidimensional in nature, c) is value based and 
dynamic, d) comprises subjective and/or objective indicators, and e) is 
most reliably measured by subjective indicators by persons capable of 
self-evaluation". 
Research varies greatly as to what extend the concept is 
multidimensional and there is a need for deeper exploring of this area 
(King & Hinds, 1998). In his attempt to order chaos, Cummins identified 
173 domain names in the quality of life literature, both found in the health 
literature and in other sciences. He was able to classify 83% of these 
names into seven domains consisting of material well-being (economical 
situation, food, housing), health (general health, function), productivity 
(work, school, success), intimacy (children, family, friends), safety 
(security, privacy, autonomy), community (neighborhood, social life, 
education) and emotional well-being (existential factors, self-esteem, 
recreational factors) (Cummins, 1996).  
In the health related literature, specifically four dimensions are 
most apparent: physical, psychological, social/role functioning, and 
symptoms (King et al., 1997), but other dimensions commonly identified 
are spiritual, disease- and treatment related, functional well-being, and 
development and activity, see table 1. Physical well-being encompasses 
the person's evaluation of his/her physical condition, including symptoms; 
psychological/emotional well-being is the person's emotional response, 
such as anxiety and depression; social well-being is how the person senses 
support from others, and spiritual well-being encompasses the ability of 
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the person to find meaning and purpose in life (Ferrell, Grant, Padilla, 
Vemuri, & Rhiner, 1991; Tang, Aaronson, & Forbes, 2004). Disease- and 
treatment related well-being refers to how the person is affected by the 
disease or its treatment (King & Hinds, 1998) and functional well-being 
encompasses the person's ability to perform the activities of daily living, 
such as bathing, walking and dressing, but also how the person is able to 
respond to personal needs, social role and ambitions (Cella, 1994). 
Finally, development and activity refers to the person's independence, 
his/her ability to choose and control functional activities (e.g. work, 
leisure, education) and the person's productivity and contribution (Felce & 
Perry, 1995). 
Quality of life is largely determined by a person's experience and 
how he/she values and attaches meaning to this experience (Stewart, 
Teno, Patrick, & Lynn, 1999). The concept is, therefore, mainly subjective 
in nature as evident by the use of words such as "appraisal", "satisfaction", 
"perception", "concern" and "ideal" in definitions of the concept, as 
mentioned earlier. Indeed, subjectivity can be classified as a fundamental 
feature of quality of life, alongside multidimensionality (Cella, 1994). 
Subjectivity means that quality of life is a result of a mental processing by 
the individual. The concept can, hence, only be understood in relation to 
the individual's perception (Cella, 1994). Two persons, living in similar 
conditions, may consider their quality of life different, and individuals 
living in what would seem like intolerable situation may, nevertheless, 
report satisfaction with their quality of life (Felce & Perry, 1995). 
However, the concept also has its objective features. Persons with a 
disability or a disease rendering them unable to express their feelings and 
concern, e.g. unconscious persons in the last days of life, have their 
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quality of life despite their lack of ability to subjectively evaluate it (Felce 
& Perry, 1995; Haas, 1999b). Some dimensions of quality of life can also 
be objectively measured like quality of schools, family income, and so on. 
Therefore, to measure quality of life a combination of both subjective and 
objective evaluations is sometimes necessary (Felce & Perry, 1995). 
Indeed, research in health care quite often relies on measures of objective 
aspects of quality of life, like function, as well as subjective aspects of the 
concept (Haas, 1999b). 
Quality of life is a dynamic concept. Therefore, it is amenable to 
changes in the individuals' conditions such as physical or emotional ones. 
That means, when assessing quality of life, the time period, the state of the 
individual, (Haas, 1999b; Niv & Kreitler, 2001) and, even different 
situations have to be considered (Cella, 1994). For instance, a patient 
experiencing excruciating pain is unlikely to rate his quality of life as 
good at that moment. Another issue to consider are the changes related to 
life stages. For example, patients with advanced disease, facing death, find 
spirituality and existential issues usually more important than before 
(Kaasa & Loge, 2003; Stewart et al., 1999). Similarly, patients may value 
personal dignity and the ability to recognize their family and friends more 
than physical functioning when confronting death. The dimensions of 
quality of life remain the same as before, but, their importance change in 
accordance with the course of life (Stewart et al., 1999). Of note here is 
that although a person’s evaluation of quality of life may easily change, 
due to some significant event, it remains a relatively stable concept over 
time (Felce & Perry, 1995).  
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The evaluative aspect of quality of life refers to the individual's 
values, attitudes and the meaning he attaches to his experience (Haas, 
1999b; Stewart et al., 1999). Older patients with cancer, for instance, tend 
to rate their quality of life better than younger patients while the opposite 
is true for the general population. This may stem from the fact that older 
people have different roles than younger people, who are occupied with 
work, rearing children etc., and, hence, the disease may not be as 
disruptive in their lives as it is for the younger (Lundh Hagelin, Seiger, & 
Furst, 2006). Cancer related fatigue, for instance, may be quite disruptive 
in the life of a young person who is usually more active compared to an 
old person with arthritis who is largely immobile (Cella & Cherin, 1988). 
Nevertheless, being evaluative, quality of life does not reveal any specific 
facts like what the health status of the individual is or in what kind of 
circumstances he/she lives in. Furthermore, being multidimensional 
means that when measuring quality of life it has to be considered that it is 
not just a single global measure but rather a number of measures that 
together comprise the concept (Niv & Kreitler, 2001).  
Being quantifiable means that quality of life is measurable and can 
be both assessed and compared between individuals, diseases, and 
countries. Since the concept is mainly subjective, the individual 
himself/herself is the person best capable of evaluating his/her quality of 
life and, therefore, quality of life should be measured by self-report 
questionnaires when possible (Niv & Kreitler, 2001). In those cases where 
proxy ratings are needed it has to be considered that they might not truly 
reflect the individual's quality of life (Jocham et al., 2006). Studies 
indicate that doctors emphasize physiological factors while nurses, social 
workers and significant others rather stress psychosocial factors (Schipper 
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et al., 1990, in King & Hinds, 1998). In a study comparing symptom 
ratings between doctors, nurses and patients in palliative care, doctors 
tended to significantly underestimate the symptoms of drowsiness and 
shortness of breath compared to the patients' and nurses' ratings. This 
difference was also clinically significant with difference in ratings 
exceeding 12 mm on the 100 mm Visual Analogue Scale. The doctors 
also rated pain significantly lower than the patients. Nurses' ratings, 
however, did not differ significantly from those of the patients 
(Nekolaichuk et al., 1999). In general both health care workers and 
significant others tend to rate quality of life and physical functioning of 
patients lower than the patients themselves, but overestimate 
psychological factors like depression and anxiety, as well as other 
symptoms (Sneeuw, Sprangers, & Aaronson, 2002; Sprangers & 
Aaronson, 1992). Indeed it seems that proxy raters have more difficulty 
evaluating factors that have psychological components than physical 
factors (Nekolaichuk, Maguire, Suarez-Almazor, Rogers, & Bruera, 1999) 
or factors that are more tangible and observable (Sprangers & Aaronson, 
1992). In summary, there seems to be difference between ratings of 
patients and proxies regarding symptoms and quality of life, but the 
discrepancy is, however, usually low (Jocham et al., 2006; Nekolaichuk, 
Maguire et al., 1999; Sneeuw et al., 2002). Substantial difference between 
raters seems to be rare but it has to be considered that studies in this field 
are often based on small samples making comparisons between raters 
difficult to evaluate (Sneeuw et al., 2002).  
Quality of life can be assessed by both qualitative and quantitative 
methods (Haberman & Bush, 1998) and there are a number of instruments 
available that have proven to be both reliable and valid in quantitative 
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research. These instruments vary, however, as to how many items, as well 
as what dimensions of quality of life they measure (Niv & Kreitler, 2001) 
and, indeed, there is no single instrument available that completely covers 
all aspects of the concept (Revicki et al., 2000). There are three main 
types of instruments: generic instruments that can be used with any 
population regardless of disease; disease-specific instruments that are used 
with specific groups of patients, such as cancer patients; the third type are 
domain-specific instruments, and these are used to measure any specific 
domain of health related quality of life, such as symptoms (Kaasa & Loge, 
2003).  
The phenomenological aspect of quality of life mainly refers to its 
antecedents and hence, is discussed in the section preconditions and 
outcomes of quality of life on page 20. 
It seems that quality of life is a very broad concept with many 
dimensions.  This multidimensionality is one of the main reasons for the 
complexity of the concept, making it difficult to apprehend and evaluate. 
There seem to be, however, certain core domains: physical, social, 
psychological, material, and spiritual. As well as being multidimensional 
the concept is also dynamic and evaluative with both subjective and 
objective features. All of these factors complicate measures of the concept 
so it is not surprising that no single instrument, designed to measure 
quality of life, completely covers all those aspects. Hence, measures of the 
concept may not reflect all aspects of quality of life.  
Boundaries of quality of life.  
Boundaries are the borders of a concept, refining both what is and what is 
not a part of it. A well developed concept has clear boundaries that 
delineate it from others, while a poorly developed one may overlap with 
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similar concepts (Morse et al., 1996).  There are four concepts that are 
often mistaken as being synonyms of quality of life: functional status, 
well-being, health, and satisfaction with life. None of these concepts fully 
capture what quality of life encompasses, but nevertheless, each of those 
concepts can be considered a part of quality of life.  
Functional status refers to the individual's ability to perform 
activities of daily living, like bathing, walking, cleaning and, getting 
around (Revicki et al., 2000). Like quality of life, the concept is 
multidimensional since function is not only related to physical factors but 
psychological, social and spiritual as well. The main difference between 
quality of life and functional status lies in that the latter is mainly 
measured objectively (Haas, 1999a). Indeed, the difference between the 
two concepts is highlighted in some definitions where functional status is 
viewed as one aspect of quality of life rather than being synonymous with 
it (Niv & Kreitler, 2001). 
Health status is also a multidimensional concept that can be 
evaluated with both objective and subjective methods like quality of life 
(Revicki et al., 2000). Health is often thought of as the most important 
aspect of quality of life, but although being closely related the concepts 
are not synonymous. It is not easy to differentiate between the two 
concepts since they are tightly interwoven and it is not obvious whether 
quality of life is a component of an individual's health, or, health an 
integral part of quality of life. Health is often viewed as being free from 
diseases, despite, the notion that many people with diseases, like e.g. 
diabetes, do not define themselves as unhealthy (Haas, 1999a). Health 
can, nevertheless, be distinguished from quality of life since there are 
other dimensions that comprise the concepts. Quality of life encompasses 
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more than simply health (Revicki et al., 2000). A person may consider his 
health excellent, but yet experience diminished quality of life because of 
undesirable working conditions or family conflicts. Similarly, individuals 
with terminal illness, a state most people would consider unhealthy, may 
experience good quality of life. For instance, a study on 60 American 
patients in hospice care, the majority with cancer, showed that the patients 
rated their quality of life high and, indeed, they had an above average 
quality of life (Tang et al., 2004).  
Another concept that lies closely to the core of quality of life is 
satisfaction with life (Felce & Perry, 1995). The concept, however, differs 
mainly from quality of life in that it is purely subjective in nature (Haas, 
1999a).  
Similar to satisfaction well-being is also a subjective concept and, 
hence, not synonymous with quality of life. The concept is, however, used 
extensively in the quality of life literature, not least, in definitions of the 
concept (Haas, 1999a).  
Preconditions and outcomes of quality of life.  
Every concept must have similar preconditions that are the prerequisite for 
the factors that define the characteristics of the concept (Morse et al., 
1996). Haas (1999) has stated that the antecedent to quality of life is 
mainly life itself, alongside a person capable of evaluating his quality of 
life, since quality of life is present from birth to death. Niv and Kreitler 
(2001), on the other hand, have stated, that because of the 
phenomenological nature of the concept it is like a photograph where one 
can see what is in the picture but not what preceded or caused the moment 
captured. However, there are many factors that influence quality of life 
that may be considered antecedents. To name but a few, violence, poverty, 
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housing and health are all factors known to influence quality of life (Haas, 
1999b). In cancer patients, however, symptoms caused by the disease 
itself or its treatment are important factors affecting quality of life as 
discussed later in the section factors affecting quality of life on page 43. 
 Outcomes refer to what the consequences of the concept are 
(Morse et al., 1996) and since quality of life is always present the 
consequences are the results of an evaluation of the concept (Haas, 
1999b). The evaluation can result in unchanged, diminished or improved 
quality of life. For cancer patients the disease usually affects quality of 
life negatively as discussed in the following section quality of life scores 
of cancer patients on page 52.  
The maturity of the concept of quality of life.    
For a concept to be mature, according to Morse and colleagues (1996), it 
must be clearly defined, its characteristics described, its boundaries 
delineated and the preconditions and outcomes fully described and 
demonstrated.  
Although no single, universal definition of quality of life exists all 
of the definitions discussed earlier point to the multidimensionality of the 
concept where the focus is on the well-being of the individual as evaluated 
by himself/herself, factors that according to Cella (1994) are prerequisite 
to a useful definition of the concept. The problem with defining quality of 
life is the fact that it is mainly subjective, but, also dynamic and, hence, 
amenable to changes, making it difficult to define as a constant entity 
(King et al., 1997). The concept of health related quality of life is 
narrower than general quality of life, and hence, does not capture the 
global meaning of quality of life. Indeed, it can be argued that health 
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related quality of life merely constitutes one aspect of the greater 
construct of quality of life (Kaasa & Loge, 2003).  
The characteristics of quality of life seem to be fairly well 
described, although, the objective feature of the concept is often 
overlooked in the literature. Due to the complexity of quality of life it may 
happen, that not all the characteristics of the concept are apparent at the 
same time indicating a lack of a conceptual structure (Morse et al., 1996). 
This may, however, stem from the dynamic nature of the concept resulting 
in some characteristics being more pronounced in a given situation like 
spirituality in the dying person (Stewart et al., 1999) rather than a lack of 
conceptual structure.  
Similarly, it may seem that the boundaries of quality of life are not 
always clearly delineated with the concept often mistaken to be 
synonymous with functional status, well-being, health, and life 
satisfaction. However, these four concepts are distinguishable from 
quality of life by their characteristics or inherent meaning. Indeed, these 
concepts constitute important aspects of quality of life, although, they may 
also be amenable to independent measurement. Thus the boundaries of 
quality of life may be outlined, although, some authors may fail to 
distinguish between the different concepts. 
The preconditions and outcomes of quality of life are not easy to 
describe and indeed they may not be good indicators of the maturity of the 
concept. Quality of life is a phenomenon that exists throughout life and 
there are no clear indicators of what quality of life should be like. 
However, there are factors that influence quality of life, but since the 
concept is both dynamic and evaluative different factors may be 
influential across individuals and situations. Similarly, the outcomes of 
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quality of life are related to the individual's evaluation and, hence, may be 
different across individuals and situations as well. In light of this, it is 
clear that describing the preconditions and outcomes of quality of life is 
an impossible task. Quality of life simply exists and its outcomes are 
mainly subjective, resulting in improved, diminished or unchanged quality 
of life as perceived by the individual. 
It is evident that the concept of quality of life is a complex one and 
more work is still to be done to understand it better. Unfortunately, this 
lack of conceptualization has its disadvantages. Being so vague, quality of 
life can encompass almost anything as is evident from different definitions 
and dimensions presented in the literature. It also means that some factors 
may be considered a part of quality of life in one study but not in another 
study, thereby, blurring the concept (Taillefer et al., 2003). Despite this 
lack of maturity, the concept is, nevertheless, quite well-established 
(Morse et al., 1996) as evident from its common use in the literature as 
well as in marketing, politics and advertising (Haas, 1999a; Pais-Ribeiro, 
2004). This gives rise to the notion that a concept may be generally 
understood despite being conceptually unclear. Indeed, it has been argued 
that the meaning of a concept cannot be clarified beforehand (Paley, 
1996). According to Paley the meaning of a concept is specified in theory, 
i.e. the theory defines the concept not vice versa. However, being derived 
from one theory does not mean that the concept has been defined finitely. 
Indeed, the concept may have a different meaning when derived from 
another theory. Therefore, concepts are amenable to changes, according to 
the context they are situated in, and, furthermore, two concepts may share 
the same characteristics, but they need not be synonymous with each 
other.  
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The quality of life concept in research. 
Whether unambiguous or not, concepts are theoretically important, and 
the role of a concept in research is dependent on how the researcher 
chooses to use it (Morse, 1995). To counteract the blurring of the concept 
of quality of life it is important for researchers exploring the concept to 
clearly define their perspective of it (Taillefer et al., 2003). According to 
Cella (1996) there is no gold standard in measuring quality of life so the 
operationalization of the concept should be determined by the theoretical 
framework underlying the study (Paley, 1996). When choosing an 
instrument it is of uttermost importance to clearly define the purpose of 
the study and the research questions, since the choice of an instrument 
should rely on these factors rather than vice versa. The instrument must 
also be appropriate to the population under study (Cella, 1996). Another 
thing to consider is that the authors must state how they define quality of 
life and ensure that there is correspondence between the definition, 
instrument chosen, and the dimensions of quality of life the researcher 
wants to study (Jocham et al., 2006; Kaasa & Loge, 2003; King et al., 
1997; Pais-Ribeiro, 2004). Also, in order to try to fully capture a person's 
quality of life it can be useful to include a single rating of overall quality 
of life when measuring the concept. The benefit of such a single rating is 
that it gives the individual opportunity to define quality of life in his/her 
own terms rather than relying on specifically defined aspects of the 
concept (Stewart et al., 1999). 
The concept of symptoms  
A symptom is a subjective phenomenon regarded by individuals as an 
indication of a condition departing from normal function, sensation, or 
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appearance (Rhodes & Watson, 1987). The concept of symptom is 
multidimensional in nature and can be measured separately or in 
combination with other symptoms (Lenz, Pugh, Milligan, Gift, & Suppe, 
1997). A symptom differs from the concept of sign, which is an objective 
phenomenon that is observable and indicates a change in health status 
(Liehr, 2005). 
When reviewing the literature only few theories or models 
regarding symptoms have been described. One example is the middle 
range Theory of Unpleasant Symptoms (Lenz, Suppe, Gift, Pugh, & 
Milligan, 1995; Lenz et al., 1997) which will be discussed here to shed 
some light on the concept of symptoms. The theory is the outcome of 
collaboration between three investigators, two who studied fatigue in 
childbearing women, and a third who studied dyspnea in COPD and 
asthma patients. They generated a theory that could be used for multiple 
symptoms as well as in diverse clinical populations (Lenz et al., 1995). 
The theory is based on the assumption that diverse symptoms have 
enough in common so that it is possible to generate a theory not limited to 
only one symptom. Three components are the cornerstones of the theory: 
influencing factors that either cause symptoms or affect the symptom 
experience, the symptom or symptoms the individual is experiencing, and 
the consequences of experiencing symptoms. The concept of symptoms is 
believed to encompass several dimensions such as severity (intensity), 
duration and frequency, symptom distress, and quality of the symptom. 
According to the theory, symptoms are known to co-occur and they 
interact with one another. The model, illustrating the theory, see picture 2, 
is interactive in nature. The influencing factors cause or affect symptoms 
and the existence of these symptoms leads to worse performance. Worse 
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performance can then affect both the influencing factors as well as the 
symptoms. Symptoms can similarly affect the contributing factors (Lenz 
et al., 1997). 
It has to be noted that the development of the theory was not based 
on symptoms studied in the cancer population. It has, however, been used 
to guide the formation of research questions and selection of variables 
(Gift, Stommel, Jablonski, & Given, 2003) and as framework to 
understand the symptom experience of cancer patients (Redeker, Lev, & 
Ruggiero, 2000). 
 
Picture 2. The Theory of Unpleasant Symptoms. The arrows show the 
relationship between the components. Red arrows indicate influence, 
turquoise arrows indicate feedback and the blue arrows indicate 
interaction.  
Source: Lenz, E.R. Pugh, L.C., Milligan, R.A., Gift, A., and Suppe, F. 
(1997). The Middle-Range Theory of Unpleasant Symptoms: An Update. 
Advances in Nursing Science, 19(3), 14-27. Used with permission from 
Lippincott Williams & Wilkins. 
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The number of symptoms and symptom prevalence. 
The number of symptoms, patients with cancer experience varies greatly 
but research indicate that the median number of symptoms per patient is 
often between eight and eleven (Chang et al., 2000; Homsi et al., 2006; 
Lidstone et al., 2003; Peters & Sellick, 2006; Portenoy et al., 1994; Tsai et 
al., 2006; Walsh et al., 2000), but some patients may experience up to 30 
symptoms at a given time (Chang et al., 2000). Having no symptoms at 
all, however, seems to be rare. In a study of 480 patients with cancer 
attending an outpatient clinic in the UK, only 2% of the participants were 
symptom free (Lidstone et al., 2003). In an Icelandic study of patients 
entering palliative service for the first time, the mean number of 
symptoms ranged from 4,95 in palliative home care service to 7,17 in 
medical/surgical wards (Friðriksdóttir & Sigurðardóttir, 2004, April). 
Another Icelandic study on patients in the last 72 hours of life, in 
palliative care, showed that around 11% of the patients had four or fewer 
symptoms, 30% had 5-7 symptoms, 42% had 8-10 symptoms, and 17% 
had more than 10 symptoms (Sigurdardottir et al., 2006). It is important to 
note that questionnaires and other methods of assessing symptoms vary 
greatly. Some studies use questionnaires that include ten or fewer 
symptoms (Chen & Chang, 2004; Hoekstra et al., 2006; Modonesi et al., 
2005) while a great quantity of symptoms is assessed in other studies 
(Homsi et al., 2006; Walsh et al., 2000). In some cases, the researchers do 
not use validated questionnaires, but design their own, interview the 
patients or use methods commonly used in clinical practice (Homsi et al., 
2006; Tsai et al., 2006; Walsh et al., 2000). 
Cancer patients experience more symptoms than the general 
public, as can be expected (Fu, McDaniel, & Rhodes, 2007; Rhodes, 
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McDaniel, Homan, Johnson, & Madsen, 2000; Schuit et al., 1998). This is 
not at least true for the symptoms of fatigue, depression and pain which 
not only are more prevalent in cancer patients than the general public, but 
also than in other patient populations (Reyes-Gibby et al., 2006). In a 
study evaluating an instrument to measure symptom experience (the 
Adapted Symptom Distress Scale), the symptom occurrence was 
significantly higher in cancer patients compared with healthy individuals 
and medical-surgical patients, although symptom distress did not differ 
between the cancer and medical-surgical patients (Rhodes et al., 2000). It 
is noteworthy, however, that the symptomatology in advanced AIDS, 
heart disease, COPD and kidney diseases is quite similar to that in 
advanced cancer with the symptoms of pain, fatigue and breathlessness 
occurring in more than 50% of patients across the five diseases (Solano, 
Gomes, & Higginson, 2006).  
Teunissen et al. (2007) performed a systematic review, based on 
44 studies, on the symptom prevalence in 25.074 patients with advanced 
cancer. The results showed the five most common symptoms were fatigue, 
pain, lack of energy, weakness, and appetite loss, and that over half of the 
participants experienced these symptoms. Similar results have been 
obtained in other studies. Peters and Sellick (2006) assessed the 
symptomatology in 58 patients in palliative care in Australia. In their 
study the most prevalent symptoms were weakness, fatigue, dry mouth, 
and pain, with about 2/3 of participants experiencing those symptoms. In 
an Icelandic study of cancer patients receiving chemo- and/or 
radiotherapy the symptoms of fatigue, sleep disturbances, dry mouth, 
drowsiness, and pain occurred in over 47% of the participants 
(Skúladóttir, Birgisdóttir, & Friðriksdóttir, 2005). When reviewing the 
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literature there seems to be a core of symptoms that the majority of 
patients with advanced cancer experience. Of note are the symptoms of 
pain and fatigue that seem to be almost universal in this group of patients 
with pain prevalence ranging from 59,0-88,3% and fatigue prevalence 
from 72,5 – 97,4% (Hoekstra et al., 2006; Homsi et al., 2006; Modonesi et 
al., 2005; Peters & Sellick, 2006; Tsai et al., 2006; Walsh et al., 2000). In 
the systematic review, cited above, the pooled prevalence of pain and 
fatigue were 71% and 74% respectively (Teunissen et al., 2007). In a 
recent German study of 4.538 ambulatory cancer patients, however, the 
prevalence of pain was only 30%, while the most frequent symptoms were 
fatigue (60%), hair loss (54%), nausea (51%), sleep disturbance (42%), 
and weight loss (36%) (Feyer, Kleeberg, Steingraber, Gunther, & 
Behrens, 2008).  Table 2 shows the number of symptoms and symptom 
prevalence in a number of studies of cancer patients. 
Symptom severity. 
Symptom severity, also called symptom intensity, defined as the strength 
or amount of the symptom experienced (Lenz et al., 1997), is also an 
important concept when discussing symptoms. However, it is not easy to 
compare symptom severity between studies since various questionnaires 
are used to measure symptoms and different scales are used for severity. 
Some studies measure severity with words such as mild, moderate or 
severe (Chang et al., 2000; Homsi et al., 2006) while others use various 
types of numeric or Likert scales (Modonesi et al., 2005; Peters & Sellick, 
2006; Tsai et al., 2006). In some cases there are even different scales 
within one study (Tsai et al., 2006). It seems, though, that the words mild, 
moderate and severe may be linked to numeric scales. In a study exploring 
this relationship it was found that when pain was assessed on a scale 
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ranging from 0-10, ratings of 1-4 indicated mild pain, moderate pain 
corresponded to ratings of 5-6 and finally, 7-10 indicated severe pain. 
Participants in the study were patients with metastatic cancer experiencing 
pain in the USA, France, China and the Philippines (Serlin, Mendoza, 
Nakamura, Edwards, & Cleeland, 1995). This classification has also been 
used with other symptoms than pain (Cleeland et al., 2000), but a recent 
study (Given et al., 2008) showed that severity cut points differ between 
individual symptoms in cancer, with the symptoms of pain, remembering, 
alopecia, fatigue, and depression being moderate in strength when rated as 
low as 2 on á 0-10 point scale. 
It seems that the symptom severity in patients with advanced 
cancer is, in most cases, mild or moderate in severity. In a study by Peters 
and Sellick (2006) the mean symptom severity was 1,90, on a scale from 
1-41, in home-based patients while it was 2,16 in inpatients. Similarly, the 
mean symptom severity ranged from 3,4-5,6, on a scale from 0-101 in a 
study on 159 patients with advanced cancer in the Netherlands (Hoekstra 
et al., 2006) and a Taiwanese study showed average symptom severity 
ranging from 4,6- 5,9 on a scale of 0-101; 0,1-1,7 on a scale of 0-31; and 
1,7-2,2 on a scale of 1-51 indicating mild to moderate symptom severity 
(Tsai et al., 2006). In an Icelandic study of cancer patients the mean 
symptom severity was 3,98 (on a scale from 0-101) with dry mouth being 
the most severe symptom (4,48) followed by fatigue (4,41) (Skúladóttir et 
al., 2005). Despite this, there are a number of patients who experience 
severe or very severe symptoms. 
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Over 40% of the patients admitted to palliative care, in a study by 
Modonesi et al. (2005), experienced rather intense pain, fatigue, 
depression, anxiety, drowsiness and anorexia, ranging from 7,13-7,46 on a 
scale from 0-1011. Similarly severe pain was mentioned at least once by 
20,3% of a large sample of hospice patients (73,9% of the sample had 
cancer) in the USA (Strassels, Blough, Hazlet, Veenstra, & Sullivan, 
2006). The symptoms of pain, lack of energy, difficulty sleeping, 
shortness of breath, and lack of appetite were also experienced as severe 
or greater in intensity by 12-22% of the patients receiving treatment at a 
Veterans affairs medical center in the USA (Chang et al., 2000). 
Similarly, more than 20% of a large sample (N= 670) of cancer patients in 
the USA, rated the symptoms of dry mouth, lack of appetite, drowsiness, 
disturbed sleep, distress, worrying, weak, not being able to get things 
done, and fatigue as severe or ≥7 on a scale from 0-10 (Cleeland et al., 
2000). However, it is not only different scales and questionnaires that are 
of importance when symptom severity is assessed. In a prospective study 
by Homsi et al. (2006) symptom severity differed as to what method was 
used to assess symptoms. When symptoms were assessed systematically 
(patients directly asked about 48 symptoms) 48% were mild, 35% 
moderate and 17% severe. When patients volunteered their symptoms, 
however, 17% were considered mild, 32% moderate and 51% severe 
indicating that patients report their severe symptoms rather than their mild 
ones. Another factor to consider is the effect of symptom severity. In their 
study, on advanced cancer patients with pain, Serlin and colleagues (1995) 
found that the relationship between pain severity and interference of 
function was non-linear. When pain was assessed with a numeratic rating 
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scale, ranging from 0-10, the steps between 4 and 5 and between 6 and 7 
were significantly more important in relation to interference of function 
than other steps. 
But the severity of symptoms does not quite depict the whole 
picture since the symptom distress, defined as the degree or amount of 
physical or mental upset, anguish, or suffering experienced from a specific 
symptom (Rhodes & Watson, 1987), can be great although the severity of 
symptoms is not. In a study by Homsi et al. (2006) a large percentage of 
symptoms was rated as mild, but yet patients perceived them as 
distressing. Similar results were obtained by Chang et al. (2000) in a study 
of 240 patients with various kinds of cancer. Only 16% of the participants 
rated lack of energy as severe but nevertheless 60% found it distressing. 
Pain was similarly severe in 22% of cases but 52% found the symptom 
distressing. In line with this are the results of a study assessing the "most 
troublesome" (most distressing) symptom among 146 patients in palliative 
care (Hoekstra, Vernooij-Dassen, de Vos, & Bindels, 2007). Although, 
there usually was a relationship between the most troublesome symptom 
and the most severe symptom, the study showed that around 29% of the 
patients rated other symptoms as the most distressing than the most 
prevalent or severe ones. Another study, on 175 patients in palliative care, 
showed comparable results (Stromgren et al., 2006). In that study the 
symptoms the patients found most troublesome were usually the same as 
those rated as most severe, like pain, constipation and dyspnea. Fatigue, 
physical function, role function, and activity, however, were frequently 
mentioned as distressing, despite not being considered severe by the 
patients. 
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Co-occurring symptoms and symptom clusters. 
Patients rarely experience only one symptom at a time (Chang et al., 
2000) and research has shown a correlation between many of the 
symptoms experienced by cancer patients (Chen & Tseng, 2006). It is also 
widely acknowledged that one symptom can lead to another. Pain may, 
for instance, lead to insomnia, because it may interrupt sleep or inhibiting 
the individual from falling asleep. Pain may also lead to depression or 
anxiety that furthermore can lead to insomnia and vice versa. Finally, pain 
may induce fatigue that may lead to insomnia, but insomnia, may also 
lead to fatigue, since people deprived of sleep usually lack energy. Hence, 
one symptom can lead to another, resulting in a vicious cycle of cause and 
effect (Theobald, 2004). This relationship between symptoms was evident 
in a study of the physical symptom profiles of cancer patients with, and 
without depression. The results showed that depressed patients had 
significantly more symptoms than non-depressed patients (3,77 vs. 2,52) 
with the symptoms of insomnia, pain, anorexia and fatigue being 
significantly more prevalent in the former group than the latter (Chen & 
Chang, 2004). Similarly, a moderate but significant relationship has also 
been shown between the symptoms of pain, fatigue and sleep disturbance 
in a study of 84 patients with various cancer diagnoses experiencing pain 
(Beck, Dudley, & Barsevick, 2005). In that study, pain explained 20% of 
the variance in fatigue and it influenced fatigue both directly as well as 
indirectly through its effect on sleep. Other studies have also shown that 
fatigue, pain and depression tend to occur together in cancer patients 
(Cleeland et al., 2000; Portenoy et al., 1994). A significant relationship 
was also found in a study where the prevalence of fatigue was compared 
between patients with advanced cancer (n=95) and volunteers without 
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cancer (n=98). Fatigue severity proved to be significantly related with 
dyspnea and pain scores in the patients as well as with anxiety and 
depression in the control group (Stone et al., 1999). In a study by Chang et 
al. (2000) pain never occurred in isolation and those patients experiencing 
moderate pain had a median number of 11 symptoms compared to the 
median number of 8 symptoms in the whole sample. Patients with pain 
also had an increased relative risk of experiencing nausea, fatigue, dry 
mouth, lack of appetite, dyspnea, and constipation of moderate severity. 
Similar results were obtained for fatigue. Patients with moderately severe 
fatigue experienced 13 other symptoms on average with increased relative 
risk of having moderate dyspnea, nausea, lack of appetite, pain, difficulty 
sleeping, and difficulty swallowing. In accordance with these results the 
symptoms of dry mouth, anorexia, dysphagia, dyspnea, and weight loss 
also seem to occur in relationship with other symptoms. These five 
symptoms have been found to be predictive of earlier mortality in hospice 
patients and when analyzed with other symptoms it showed that as the 
number of these five symptoms grew the number of other symptoms also 
grew. Patients experiencing all these five symptoms had a median of 16 
other symptoms while those who had none of these five symptoms had a 
median of 4 symptoms (Walsh, Rybicki, Nelson, & Donnelly, 2002). 
Research has also begun on the concept of symptom clusters 
(Miaskowski, 2006) a concept closely related to that of co-occurring 
symptoms. The existence of symptom clusters gives rise to the possibility 
of underlying shared pathophysiology of symptoms (Cleeland et al., 2003) 
but the concept has been defined as either two or more symptoms (Kim, 
McGuire, Tulman, & Barsevick, 2005) or three or more concurrent 
symptoms that are related to each other and may or may not have the same 
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etiology (Dodd, Miaskowski, & Paul, 2001). According to Kim et al. 
(2005) symptom clusters are formed by stable groups of symptoms that 
are independent of other clusters and a stronger relationship should exist 
within symptoms in a cluster than between symptoms in other clusters. 
The importance of studying symptom cluster lies in better understanding 
and knowledge of what causes symptoms, the way symptoms affect other 
symptoms and the effects of symptoms on patients' lives (Barsevick, 
Whitmer, Nail, Beck, & Dudley, 2006). Research in this area to date has, 
however, been scarce (Chow, Fan, Hadi, & Filipczak, 2007) and most 
studies so far are secondary analysis of data with different instruments 
used to assess symptoms, as well as different methods used to identify the 
clusters (Bender, Ergyn, Rosenzweig, Cohen, & Sereika, 2005; Chen & 
Tseng, 2006; Gift, Jablonski, Stommel, & Given, 2004; Walsh & Rybicki, 
2006). The data on symptom clustering also vary between studies both in 
number of clusters as well as to what symptoms the clusters consists of. 
However, there seems to be some concordance between clusters in 
different studies. Table 3 shows the results of five studies of symptom 
clusters. 
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Quality of life and symptoms in cancer patients 
According to Teunissen and colleagues (2007) the suffering of people 
with advanced cancer is largely determined by the presence of unpleasant 
symptoms related to their disease. A relationship exist between symptoms 
and quality of life (Chang et al., 2000; Portenoy et al., 1994) so it is not 
surprising to see that the factors most affecting quality of life in advanced 
cancer patients are indeed factors that are known to cause symptoms 
(Bjordal et al., 2000; Brans et al., 2002; Cleeland et al., 2003; Hwang et 
al., 2003; Lee et al., 2004; Mercadante et al., 2000) as well as individual 
symptoms (Ferrell, 1995; Lis et al., 2008; Peters & Sellick, 2006; Rustøen 
et al., 2005). Before looking at what factors influence quality of life in 
cancer patients it is important to look at what factors contribute to the 
symptomatology in this group of patients. 
Factors that cause or influence symptoms.  
Symptoms in cancer patients stem from various reasons, but much is yet 
to be known about the relationship among symptoms and contributing 
factors. Some of the etiological factors are directly related to the tumor, 
e.g. type of cancer and existence of metastases, but treatment, such as 
chemotherapy, radiation and surgery, can also cause symptoms (Cleeland 
et al., 2003; Lee et al., 2004; Mercadante et al., 2000; Morita, Tsunoda, 
Inoue, & Chihara, 1999). Psychological and physical debility may also 
play a role in the symptomatology of patients with advanced cancer, but 
organ failure and metabolic abnormalities secondary to the disease or its 
treatment can also cause symptoms (Mercadante et al., 2000). Recently, 
scientist have become interested in whether the symptoms cancer patients 
experience may be related to cytokines that act on the nervous system, 
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both centrally and peripherally. This hypothesis is supported by the fact 
that patients treated with cytokine therapy often develop symptoms 
similar to those observed in the cancer population (Cleeland et al., 2003; 
Lee et al., 2004). Other factors that may affect the symptomatology in 
cancer patients are age, gender, performance status, and indeed other 
symptoms and their treatment. In Portenoy and colleagues’ (1994) study 
on 243 patients with prostate, ovarian, colon and breast cancer, no 
difference in symptom prevalence was noted in relation to gender, age, 
extent of disease and tumor type, but other studies show different results. 
Regarding the type of cancer, various studies show that lung 
cancer patients tend to experience more dyspnea than other cancer patients 
(Jordhoy et al., 2001; Lundh Hagelin et al., 2006; Mercadante et al., 2000; 
Morita et al., 1999) as well as cough/sputum and death rattle (Morita et 
al., 1999). Lung cancer patients were also the group experiencing both the 
highest number of symptoms as well as the most severe symptoms, 
followed by patients with brain tumors, in the study of Lidstone et al. 
(2003). A study by Morita et al. (1999) on hospice inpatients in Japan 
showed that brain tumors contributed to paralysis and gastric/pancreas 
cancer to abdominal swelling.  
The existence of metastases can also cause symptoms. In Morita 
and colleagues’ (1999) study the existence of bone metastasis contributed 
to pain and paralysis, and peritoneal metastasis contributed to general 
malaise, nausea/vomiting, edema, abdominal swelling and dry mouth. 
Similar findings were obtained in a study by Jordhoy et al. (2001) where 
patients with bone metastases had more pain and constipation as well as 
lower physical functioning than other patients. Furthermore research 
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indicates that patients in an advanced stage of cancer have more 
symptoms than those in remission (Lidstone et al., 2003). 
Treatment is a known etiological factor producing symptoms 
(Cleeland et al., 2003; Lee et al., 2004; Mercadante et al., 2000). In a 
study of patients (N=1.569) in chemotherapy and/or radiotherapy (Henry 
et al., 2008) 88% of the participants reported at least one symptom (side 
effect) of their treatment. Among the symptoms reported fatigue was 
prevalent in 80% of patients and pain, nausea and/or vomiting, anxiety 
and insomnia in 45-48%. Different treatments, however, may cause 
different symptoms. An Icelandic study on 177 patients with prostate 
cancer showed that patients, that had been treated surgically, experienced 
more incontinence symptoms than those treated with hormonal therapy, 
radiation, or were under observation (watchful waiting). Patients treated 
with hormonal therapy or in watchful waiting, on the other hand, 
experienced more irritative urinary symptoms, like hematuria, than 
patients treated with surgery or radiation (Sigurðardóttir, 2006).  
Psychological and physical debility may further play a role in the 
symptomatology of patients with cancer (Mercadante et al., 2000). In 
patients with prostate cancer (N=177) worse health before diagnosis was 
associated with more irritative urinary symptoms and worse bowel 
symptoms. Similarly, patients with two or more diseases other than cancer 
experienced more irritative urinary symptoms than patients with only one 
or no concomitant disease (Sigurðardóttir, 2006). Correspondingly, two 
studies exploring the existence of symptom clusters found that concurrent 
medical conditions increased the risk of both individual symptoms as well 
as symptom clusters (Gift et al., 2004; Reyes-Gibby, Aday, Anderson, 
Mendoza, & Cleeland, 2006). In a longitudinal study of symptom clusters 
41 
in patients with lung cancer, however, comorbid conditions did not affect 
symptoms or symptom clusters (Gift et al., 2003). 
The relationship between symptoms and gender is not clear cut, 
but it seems that some symptoms may be more prevalent in women than 
in men, not least gastro-intestinal symptoms. Women appear to experience 
more symptom distress (McMillan & Small, 2002) than men, but the 
number of symptoms may be the same for both genders (Lidstone et al., 
2003). Research has shown that women more often have diarrhea (Lundh 
Hagelin et al., 2006; Mercadante et al., 2000), nausea and vomiting 
(Jordhoy et al., 2001; Lundh Hagelin et al., 2006; Mercadante et al., 2000; 
Walsh et al., 2000), early satiety (Walsh et al., 2000), and change in 
appetite/weight (Lidstone et al., 2003) than men. Correspondingly, results 
have revealed that women more frequently experience anxiety (Redeker et 
al., 2000; Walsh et al., 2000), feel more tense/worried/fearful, are more 
concerned about their appearance (Lidstone et al., 2003), more often have 
fatigue (Jordhoy et al., 2001; Redeker et al., 2000), pain (Lidstone et al., 
2003), confusion (Mercadante et al., 2000), and have worse physical 
functioning (Jordhoy et al., 2001) than men. On the other hand, men tend 
to more often have hoarseness, more than 10% weight loss, sleep 
problems, and dysphagia (Walsh et al., 2000) as well as dyspnea 
(Mercadante et al., 2000) than women. 
As to age, older patients seem to experience fewer symptoms than 
younger patients. In a study of a large sample of cancer patients (N=480) 
the mean (SD) number of symptoms was 12 (6,5) for the age groups 30-39 
and 40-49, but, decreasing per decade thereafter by an average of 0,82 
(Lidstone et al., 2003). Another study showed that patients younger than 
65 tended to have more symptoms than older patients (Walsh et al., 2000). 
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In addition, older patients experience less symptom distress than those 
who are younger (McMillan & Small, 2002). According to studies 
younger patients have more intense gastric pyrosis, dyspnea (Mercadante 
et al., 2000), insomnia, anxiety, fatigue, and depression (Redeker et al., 
2000) and more frequently experience pain, dry mouth and abdominal 
swelling (Morita et al., 1999), than older patients. Confusion, however, 
was more common in older patients in relation to their performance status 
(Mercadante et al., 2000). This relationship between gender and age on 
the one hand versus symptoms on the other hand was also noted in the 
systematic review by Teunissen et al. (2007). However, the authors 
concluded that this relationship was limited because of lack of studies in 
this area and therefore no conclusions could be drawn about it.   
Various studies show a relationship between performance status 
and symptoms. In the study of Walsh et al. (2000) patients with low 
performance status were more likely to experience blackouts, 
hallucinations, weakness, confusion, sedation, mucositits, anorexia, 
memory problems, dry mouth, and constipation than patients with better 
performance status. Similarly, better performance status was associated 
with less symptoms and a better function, in a study of severely ill cancer 
patients, while the worst ratings were found in patients with the poorest 
status (Jordhoy et al., 2001). Dysphagia, was found to be more intense in 
head and neck cancer patients at Karnofsky performance levels 50 and 40 
compared with patients with other types of cancer in the study of 
Mercadante and colleagues (2000) and in the same study, patients with 
liver and pancreas, urogenital, breast, gastrointestinal, and lung cancer had 
more severe dry mouth at Karnofsky level 40 than patients with other 
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types of cancer. Another study showed that performance status influenced 
general malaise, edema, dyspnea and anorexia (Morita et al., 1999).  
It also has to be considered that one symptom, as discussed earlier, 
and symptom management may lead to the rise of yet another symptom. 
Treatment of pain, such as opioids and some adjuvant medications to 
reduce side effects from opioids, may lead to insomnia. Similarly, 
treatment of fatigue such as use of corticosteroids may further exacerbate 
insomnia (Theobald, 2004). In the Japanese study of hospice patients that 
opioids contributed to dry mouth, myoclonus, and constipation. 
Furthermore, anticholinergic and antidopaminergic medications 
influenced dry mouth and myoclonus respectively (Morita et al., 1999).  
Symptoms may also lead to changes in the biological function of the 
body. Insomnia, for instance, can cause changes in both cytokines and 
stress hormones that may affect the immune function of the body and, 
presumably, result in more symptoms (Theobald, 2004).  
Factors affecting quality of life. 
There seem to be many factors that affect the quality of life in cancer 
patients such as individual symptoms, number of symptoms, impaired 
functioning, symptom severity, symptom distress, age, disease 
progression and recurrence, general health, and treatment side effects. The 
relationship between gender and quality of life is, however, not as clear. 
Among the individual symptoms affecting quality of life are pain, 
fatigue, insomnia and depression. Since pain is one of the most distressing 
symptoms of cancer (Kaasa & Loge, 2003) its negative effect on patients' 
quality of life is not surprising (Ferrell, 1995; Niv & Kreitler, 2001). 
Ferrell and colleagues investigated pain and quality of life in various 
studies both quantitatively and qualitatively. When analyzing the data, the 
44 
authors discovered that pain had an impact on all four dimensions of 
quality of life in their model: physical, psychological, social and spiritual 
well-being (Ferrell et al., 1991). In a review of the literature regarding 
pain and quality of life Niv and Kreitler (2001) concluded that pain affects 
most domains of quality of life, mainly physical and emotional 
functioning, and that effect is based on factors like the extent of the pain, 
acuteness, intensity, duration, affectivity, underlying disease, individual's 
characteristics and meaning of the pain. However, according to Niv and 
Kreitler, the studies done to evaluate pain and quality of life are quite 
diverse and the vast number of variables makes comparison between 
studies difficult. In a study of 320 individuals, aged 16-65, both well, and 
representative of the range of diseases in Britain, a profound impact of 
pain on quality of life was demonstrated (Skevington, 1998). The study, 
using the WHOQOL questionnaire, showed that the physical domain of 
the questionnaire explained 57% of the total variance in quality of life and 
that pain and discomfort were found to play a significant role within that 
domain. Indeed, pain and discomfort were found to be significantly 
important in all the other domains of the questionnaire, except the domain 
on spirituality, religion and personal beliefs. Pain was found to be 
predictive of poorer quality of life, despite the existence of other health 
problems, and the study further showed that the duration of pain was 
associated with diminished quality of life. Pain free participants had the 
best quality of life, followed by those in acute pain, but the poorest quality 
of life was found among participants with chronic pain. The link between 
pain and quality of life has been less clear in other studies. Although pain 
relief was associated with better quality of life in a study by Rustøen et al. 
(2005) this relationship was weak (r=0,17) and when entered into a 
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blockwise hierarchical multiple regression analysis the effect of pain relief 
disappeared. In a study exploring the effects of morphine on the health 
related quality of life in cancer patients (Klepstad et al., 2000) no major 
changes in quality of life were observed despite pain being significantly 
reduced by the treatment. Of note is, however, that the participants in the 
study experienced more fatigue, pain, nausea/vomiting, appetite loss and 
constipation than the general public. In addition, their physical, role and 
social function were also worse than in the general public, as well as their 
global health. The complex symptomatology may, therefore have 
obscured the effect of treating pain. 
Fatigue, like pain, is also both a common and distressing symptom 
for cancer patients. Its impact on quality of life is mainly through its 
effects on physical functioning and self care abilities, although, it also 
influences psychological well-being and even financial status, since 
fatigued patients have limited ability to work (Hofman et al., 2007). In a 
randomized clinical trial, of 98 patients with advanced cancer in the 
Netherlands (Beijer, Kempen, Pijls-Johannesma, de Graeff, & Dagnelie, 
2008), using the EORTC QLQ-C30, fatigue correlated strongly with 
quality of life (r=-0,63). The fatigue scale was also the scale of the 
instrument that explained the largest proportion of the variance in quality 
of life or 39%. In another study, exploring fatigue in cancer patients and 
using the same instrument, fatigue correlated negatively with physical, 
role and social functioning, as well as with the global quality of life score. 
This relationship was, however, not explored further statistically in that 
study (Stone et al., 1999). Fatigue, on the other hand, was a significant 
predictor of quality of life in patients with lung cancer, alongside 
emotional functioning, accounting for 28% of the variance (Östlund, 
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Wennman-Larsen, Gustavsson, & Wengström, 2007). Fatigue, similarly, 
had a moderate negative effect (r=-.50) on quality of life of patients in 
chemotherapy (Redeker et al., 2000).  
Insomnia, the most common sleep disorder in cancer patients, is 
also among those symptoms that have been shown to affect quality of life. 
In a study with a heterogeneous sample of 954 patients, with various types 
of cancer, a 10 unit increase in insomnia resulted in a decreased quality of 
life in the domains of physical, social and economic, psychological and 
spiritual, family and overall quality of life functioning, measured with 
Ferrans and Powers Quality of Life Index (Lis et al., 2008). Insomnia was 
also a contributing factor to poorer quality of life in a study by Redeker et 
al. (2000). 
The prevalence of depression in cancer patients is estimated to lie 
somewhere between 10-25% (Pirl, 2004) and the symptom has proved to 
be an important predictor of quality of life. In a study on patients with 
pain from bone metastases, depression together with physical functioning, 
explained 42,4% of the variance in quality of life (Rustøen et al., 2005). 
Similarly, depression, alongside anxiety, explained 43% of the variance in 
quality of life in patients with various types of cancer in chemotherapy 
(Redeker et al., 2000). An Icelandic study on patients in chemotherapy 
also showed that patients experiencing anxiety and/or depression had a 
significantly worse quality of life than those who did not have these 
symptoms (Saevarsdottir, Fridriksdottir, & Gunnarsdottir, 2008). In line 
with these results are those of Peters and Sellick (2006) who studied 58 
patients with advanced cancer receiving either home-based or inpatient 
palliative care. In their study, the variables that contributed significantly to 
the overall quality of life were global physical condition explaining 73% 
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of the variance, total personal control (encompassing personal control 
over medical care, treatment and symptoms) explaining a further 9,3% 
and finally depression adding 2,1% to the variance in quality of life.  
The number of symptoms a patient experiences is also important. 
In their study on 240 patients with various types of cancer, Chang et al. 
(2000) found that as the number of symptoms per patient grew the poorer 
was their quality of life. Similar results were also obtained in a study of 
246 patients with colon, prostate, ovary and breast cancer (Portenoy et al., 
1994). Symptoms may also affect quality of life indirectly through its 
effect on the patients functioning (Östlund et al., 2007). In a study 
analyzing data from 157 patients with various cancer diagnoses, all 
experiencing pain from bone metastases, better physical and social 
functioning had a positive effect on quality of life (Rustøen et al., 2005). 
Symptom severity (intensity) may as well affect quality of life. In 
a study of 191 patients in active cancer therapy the symptoms of pain, 
fatigue, depression, and sleep disturbance were clustered together 
according to the intensity of the symptoms. The four groups were "all 
low", "low pain high fatigue", "low fatigue high pain" and "all high". The 
results showed that those in the "all high" group had significantly lower 
quality of life scores than the other subgroups and those who were in the 
"all low" group had better quality of life scores than the other subgroups. 
However, the scores of those in the "low pain high fatigue" and "low 
fatigue high pain" were similar to the mean score of the total sample or 
5,9 vs. 5,8. It has to be noted, though, that 50% of the sample belonged to 
these two last groups while only 28 (15%) patients belonged to the "all 
high" group (Miaskowski et al., 2006). Symptom intensity was also the 
main variable affecting quality of life, in a small study on cancer patients 
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who had esophagectomy, with symptom intensity explaining 50% of the 
variance in quality of life scores (Sweed, Schiech, Barsevick, Babb, & 
Goldberg, 2002).  
Yet another factor associated with poorer quality of life is 
symptoms distress. In a sample of 178 adults with advanced cancer, 
receiving palliative homecare, total symptom distress score as well as 
severity of pain, constipation and dyspnea were all negatively related to 
quality of life. Regression analysis, however, showed that only symptom 
distress was significantly related to quality of life, explaining 35% of the 
variance (McMillan & Small, 2002). 
Unlike studies, in the general population, older patients with 
cancer seem to evaluate their quality of life better than younger patients. 
In studies with random samples from the general population in Sweden 
and Norway, global quality of life score was lowest in the those 70 years 
old or older with the exception of Swedish men where the score remained 
similar to other age groups (Hjermstad, Fayers, Bjordal, & Kaasa, 1998a; 
Michelson, Bolund, Nilsson, & Brandberg, 2000). However, patients 60 
years or older had better social and role functioning than younger patients 
in a study on 278 cancer patients in palliative care. The illness also had 
less financial impact on their lives and they rated their general health and 
quality of life significantly better than patients younger than 60 years 
(Lundh Hagelin et al., 2006). Older patients also experienced better 
quality of life than younger patients in an Icelandic study on 144 patients 
in chemotherapy (Saevarsdottir et al., 2008) and in a study on 351 
outpatients with cancer in Texas (Parker, Baile, de Moor, & Cohen, 2003). 
Older cancer patients also seem to have fewer symptoms (Mercadante et 
al., 2000; Morita et al., 1999; Walsh et al., 2000) and/or lower levels of 
49 
symptoms than younger patients (Redeker et al., 2000) contributing to a 
better quality of life. Redeker et al. (2000) have also postulated that the 
same might be true for gender, with women experiencing poorer quality of 
life because of higher levels of symptoms, since, the effect of age and 
gender on quality of life disappeared when included in a regression 
analysis in their study. The relationship between gender and quality of life 
is, however, not clear. A study on 344 rural residents with cancer in Maine 
and Vermont showed that women experienced better quality of life than 
men (Schultz & Winstead-Fry, 2001) and similar results were obtained in 
a study on 146 patients with gastro-intestinal cancer in China (Yan & 
Sellick, 2004). Women, however, reported worse quality of life than men, 
both in the physical as well as the mental domain in the study of Parker et 
al. (2003) but no relationship was found between gender and quality of 
life in the Icelandic study, mentioned earlier (Saevarsdottir et al., 2008). 
In addition, studies are not in accordance whether other demographic 
variables may influence quality of life. In the study of Parker et al. (2003) 
patients with more education and those who were married had better 
quality of life in the mental domain but in the study of Saevarsdottir et al. 
(2008) no relationship existed between education or marital status and 
quality of life.  
Quality of life also seems to get worse as the disease progresses. In 
the before mentioned study by Bjordal et al. (2000) patients with recurrent 
cancer of the head and neck not only had lower quality of life values than 
those who were disease free, but also than those who were newly 
diagnosed. This was true for the general quality of life score, but patients 
with recurrent disease also scored lower on all the functional scales and 
experienced more severe symptoms in all cases except for dyspnea and 
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diarrhea. Longitudinal data similarly suggests that quality of life worsens 
with disease progression. A study assessing the quality of life in 67 
patients with advanced cancer showed that quality of life scores declined 
gradually in the last six months until death. This decline was more 
prominent in the last two to three months of life and psychological 
symptoms increased substantially in this time period (Hwang et al., 2003). 
In accordance with these results are those of Parker et al. (2003). In their 
study on 351 patients with breast, urologic, gynecologic, and gastro-
intestinal cancers those without recurrent disease experienced better 
quality of life in the physical domain and those with less advanced disease 
had better quality of life in the mental domain (Parker et al., 2003). 
Similarly, patients with metastases from prostate cancer experienced 
diminished quality of life in the hormonal/vitality domain of quality of life 
assessed with the The Expanded Prostate Cancer Index Composite (EPIC-
26) compared to patients without metastases (Sigurðardóttir, 2006). 
General health may as well impinge on quality of life. In patients 
with prostate cancer worse health before diagnosis and the existence of 
two or more other concomitant diseases had a negative effect on quality of 
life in the hormonal/vitality quality of life domain (Sigurðardóttir, 2006). 
Multiple chronic health problems were likewise indicative of worse health 
related quality of life in a large sample of the general public in Sweden 
(Michelson, Bolund, & Brandberg, 2000). 
Finally, cancer treatment and its side effects can affect quality of 
life.  Brans et al. (2002) did a feasibility study on 20 patients treated with 
radionuclide therapy for inoperable hepatocellular carcinoma. Quality of 
life was evaluated before (0) treatment and one (1) and three (3) months 
after treatment. The results showed that quality of life was affected by 
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clinical side-effects of the treatment and worsened significantly from 
between both 0-1 month as well as 1-3 months. Physical functioning of 
these patients got worse both between 0-1 and 1-3 months and pain 
increased as well on these time points. Fatigue increased between 0-3 
months but nausea/vomiting got worse between 0-1 months and then 
declined. It has to be noted that these result must be interpreted cautiously 
because of the small sample size. In line with this is the before mentioned 
study of Parker et al. (2003). In that study patients who were not in 
treatment at the study time had a significantly better quality of life in the 
physical domain than those who were in treatment. Treatment also 
affected quality of life in a study by Bjordal et al. (2000). For the patients 
treated with radiotherapy, surgery or chemotherapy, the physical, role and 
social functioning was impaired, the symptoms of fatigue, nausea and 
vomiting, pain, insomnia, appetite loss, and constipation got worse and 
the global quality of life score was lowered to 54 from that of 62 before 
treatment. Similarly, treatment had a negative impact on patients' life in a 
study of adult cancer patients in the USA (Cleeland et al., 2000). For those 
patients who either had blood/bone marrow transplantation (n=30) or 
chemotherapy (n=240) the mean symptom interference was significantly 
greater than in patients not receiving any treatment (n=69), despite that 
the mean symptom severity was similar between the three groups. 
Chemotherapy, correspondingly, had an effect on quality of life in an 
Icelandic study (Saevarsdottir et al., 2008). The study compared the 
quality of life score of patients before (T1) the initiation of chemotherapy 
and again three months later (T2). The results showed that quality of life 
was significantly worse at T2 than T1 with the worst scores in the 
physical and sexual domains. Different from these results are those of a 
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Turkish study on patients with advanced cancer receiving palliative 
radiotherapy (Hicsonmez, Kose, Andrieu, Guney, & Kurtman, 2007). In 
this study the global quality of life scores improved from 55,8 for those 
with better performance status before treatment up to 75,2 at the end of 
the treatment. Similarly the scores for those with worse performance 
status went from 45,8, before treatment, to 61,1 after treatment. It has to 
be noted here that only 20 and 16 patients had low performance status in 
the pre and post treatment groups respectively. Diverse treatments may 
also affect quality of life differently. In a study of patients with prostate 
cancer, the best quality of life in the hormonal/vitality domain was 
experienced by patients in watchful waiting followed by patients treated 
with surgery, then radiation, and finally hormonal therapy. In the sexual 
domain, however, quality of life of patients was mostly affected by 
hormonal therapy, followed by surgery, radiation and watchful waiting 
respectively (Sigurðardóttir, 2006). 
Quality of life scores of cancer patients.  
Quality of life seems to be worse in cancer patients than in the general 
public (Coates et al., 1997; Klepstad et al., 2000; Michelson, Bolund, & 
Brandberg, 2000). Comparing results of studies of quality on life, 
however, is not an easy task. Many quality of life instruments are in use, 
the levels of measurement within each instrument are not always the 
same, and it is unknown which difference in instruments' scores has 
clinical value (Kaasa & Loge, 2003). A common quality of life instrument 
is the EORTC QLQ-C30, further discussed in the methodology section. In 
this instrument a 10% difference in scores is considered a significant 
clinical change. A mean change of 5-10 in raw scores is considered little 
change, a difference between 10-20 moderate; and a difference of 20 or 
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more a great change (Osoba, Rodrigues, Myles, Zee, & Pater, 1998). It 
should be noted that only a fraction of the literature regarding quality of 
life scores of cancer patients will be presented here. The reason for 
choosing primarily studies using the EORTC QLQ-C30 and Icelandic 
studies is to ease the comparison with results from the current study. Since 
the literature on quality of life of cancer patients is very extensive it would 
have been impossible to review in its entirety. 
In a study of 622 patients with head and neck cancer, quality of 
life score, assessed with the EORTC QLQ-C30, was significantly lower 
for patients newly diagnosed or with a recurrent disease compared to 
disease-free patients. In patients with a recurrent disease, indicating a 
more advanced state, the quality of life score was 552 while it was 63 for 
newly diagnosed patients and 73 for those who were disease-free. Patients 
with a recurrent disease also experienced worse pain, fatigue and appetite 
loss than those free of disease and similarly their role, emotional and 
social functioning was worse (Bjordal et al., 2000). A striking difference 
in quality of life was observed in a study comparing patients with 
advanced cancer in palliative care to healthy subjects. Measured with the 
EORTC QLQ-C30 the global quality of life score in cancer patients was 
332, but 83 in healthy individuals. On the five functioning scales (role, 
emotional, physical, cognitive and social) of the instrument the scores of 
the healthy individuals ranged from 83-1002 while the range was 17-67 
for the cancer patients. The cancer patients also experienced much more 
severe symptoms than the healthy group (Stone et al., 1999). Similar 
results were also obtained in a cluster randomized trial in Norway 
(N=395) (Jordhoy et al., 2001), and a Dutch randomized clinical trial 
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(N=98) (Beijer et al., 2008), of patients with advanced cancer, where 
global quality of life score, measured with the EORTC QLQ-C30, was 392 
and of 48,5 respectively. Another Norwegian study, using the same 
instrument, of patients (N=40) being treated with opioids, further showed 
that the global health/quality of life score was 402 for patients treated with 
weak opioids, 49 when the patients were treated with immediate-release 
morphine, and 44 when they were treated with slow release morphine 
(Klepstad et al., 2000).  
A difference between the general population and cancer patients is 
also evident when studies that use the EORTC QLQ-C30 are compared. In 
a large random sample of the Swedish population (n=3.069) the mean 
score for global quality of life for women was 74,73and 78,1 for men 
(Michelson, Bolund, Nilsson et al., 2000). In a random sample of 3.000 
Norwegians, however, the quality of life score was 75,33for the total 
sample, 59,9 for cancer patients, 58,0 for patients with cardiac problems, 
and 86,6 for people reporting no health problems (Hjermstad, Fayers, 
Bjordal, & Kaasa, 1998a). In patients, with advanced chest malignancies 
(n=112) in palliative care in Sweden, the global quality of life score was 
only 50,13 (Nicklasson & Bergman, 2007). In patients receiving palliative 
radiotherapy for advanced cancer in Turkey the same score was 55,83 in 
patients with higher performance status but 45,8 in those with lower 
performance status (Hicsonmez et al., 2007).  
An Icelandic study of 177 patients with prostate cancer 
(Sigurðardóttir, 2006), assessed quality of life with the SF-36 health 
survey. That study showed that quality of life was generally good with 
scores ranging from 62,07-84,723. The lowest score was in the role-
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physical domain but the highest in mental health. The quality of life in this 
patients’ group was comparable to the general USA norm used for 
comparison with the SF-36. The same study further assessed quality of 
life with the EPIC-26. The results indicated good quality of life with 
scores ranging from 86,77-92,613 in all scales except the sexual domain 
were the score was only 24,10 indicating diminished quality of life 
(Sigurðardóttir, 2006). Another Icelandic study, of 144 patients with 
various types of cancer, assessed the impact of chemotherapy on patients’ 
quality of life. Quality of life was measured with the CARES-SF 
instrument and the scores were 0,764 before chemotherapy, but 0,95 after 
three months in treatment, indicating a relatively good quality of life. Of 
individual subscales the worst quality of life was found in the sexual and 
physical domains but the highest in the medical interaction domain 
(Saevarsdottir et al., 2008). 
Summary of the theoretical background 
Quality of life is a complex concept and despite its widespread use no 
collective definition of it exists. The concept is multidimensional in nature 
with the most prominent dimensions in the health literature being: 
physical, psychological, social/role functioning, emotional, and 
symptoms. Quality of life is both dynamic and evaluative, referring to that 
it may change in accordance with the state of the individual and the 
meaning he/she attaches to his/her situation. It is also quantifiable with 
measures of the concept being most reliable when subjectively assessed 
by a person competent of self-evaluation. Although the concept is mainly 
subjective it also has objective features which for some reasons are often 
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overlooked in research. The boundaries of quality of life are not clear cut, 
but, the concepts most often mistaken as being synonymous with quality 
of life are health, functional status, satisfaction and well-being. The 
characteristics of these concepts, however, differentiate them from quality 
of life, but nevertheless, they constitute important aspects of it. Like 
general quality of life, health related quality of life is also loosely defined, 
but the main difference between the concepts lies in the use of health 
related quality of life as an outcome measure to evaluate the impact of 
treatment or diseases on patients. Quality of life is affected by various 
factors, although it can be said that the concept has no preconditions since 
it simply exists throughout life. There are no criteria for what quality of 
life should be like so evaluation of the concept can only result in either 
improved or diminished quality of life. 
 Cancer patients experience around eight to eleven symptoms 
simultaneously that affect their daily life. Factors that cause symptoms are 
the disease itself and its treatment but psychological and/or physical 
factors may also play a role. Research is, however, inconclusive regarding 
the effects of age and gender. The Theory of Unpleasant Symptoms aims 
at explaining the relationship between influencing factors, symptoms and 
function. The most common symptoms experienced by cancer patients are 
fatigue, pain, lack of energy, weakness and appetite loss. The majority of 
symptoms are considered to be mild by cancer patients but nevertheless a 
number of patients experience severe symptoms. Many symptoms seem to 
co-occur and some symptoms seem to be the product of other symptoms. 
This relationship between symptoms has raised questions about the 
existence of symptom clusters. Research in that area is in its early state. 
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 The quality of life of cancer patients is related to their 
symptomatology. Fatigue, insomnia, pain and depression are among the 
symptoms known to affect quality of life but the number of symptoms is 
also important since patients with more symptoms seem to have worse 
quality of life. Symptoms may both act directly to reduce quality of life 
but also through their effects on the functional status of the patient. Other 
factors that have impact on quality of life of cancer patients are the 
progression of the disease as well as side effects from treatment. Research 
has shown that cancer patients generally experience worse quality of life 
than the general public. Of interest is that older patients with cancer seem 
to have better quality of life than younger patients which is opposite to 
what is found in the general public.  
 Although quality of life does not quite fulfill the prerequisites for a 
mature concept according to Morse and colleagues (1996) it is, 
nonetheless, a well-established one. It is widely used in research and it 
seems to be generally understood in the literature. As mentioned earlier 
the role of a concept in research depends on in what way the researcher 
chooses to use. Therefore, it is important for a researcher to define his 
perspective of the concept and the operationalization of it must be 
determined by the underlying theoretical framework of the study. When 
measuring quality of life, the instrument used must be appropriate for the 
population under study, but there also has to be correspondence between 
the instrument, the definition of the concept, and the dimensions of quality 
of life that will be measured.  
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The making of a model 
After reviewing the literature the author has pulled together a model that 
attempts to explain the relationship between symptoms and quality of life, 
hereafter called the Symptoms-quality of life model. The first part of the 
Symptoms-quality of life model, see picture 3, shows the factors that may 
cause symptoms in cancer patients like the type of disease, metastases, 
cytokines etc. The second part displays the symptoms and factors 
associated with them that play a role in how the individual perceives his 
symptoms, like distress, severity, duration and number of symptoms. The 
third part, influencing factors, points out factors like age and gender, 
which may affect the symptomatology of the individual and how he/she 
evaluates his/her quality of life. The fourth part depicts quality of life and 
the dimensions of the concept. The model shows that causative factors set 
off symptoms and those symptoms can affect the well-being of the 
individual and, hence, affect all the dimensions of his/her quality of life. 
Influencing factors further modify how symptoms and quality of life are 
perceived. It has to be noted that one symptom may cause another 
symptom and that the model is reciprocal in such a way that symptoms 
may affect the causative factors and changes in quality of life may also 
influence how the individual experiences his symptoms.  
The Symptoms-quality of life model bears some resemblance to 
the Theory of Unpleasant Symptoms (Lenz et al., 1997). In both instances 
there are influencing factors that affect symptoms and there are factors, 
like distress, that affect how the individual perceives the symptoms. The 
discrepancy, however, is that the former is based on the cancer literature 
and specifically shows the factors that affect symptoms in this patient 
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cohort. Furthermore the model illustrates how symptoms may modify 
patients’ quality of life. 
 
 
Picture 3. The Symptoms-quality of life model. The arrows show the 
relationship between the factors of the model. The parts of the model 
that will be tested in this study are colored green.  
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A resemblance is also found between the Symptoms-quality of life 
model and the revised health related quality of life model (Ferrans et al., 
2005). The similarity is that both models show how biological function 
induces symptoms that ultimately affect the quality of life of the 
individual. The dissimilarity between the models, however, is that in the 
health related quality of life model symptoms influence the functional 
status which in turn affects the general health perceptions of the individual 
that finally affects the overall quality of life. In the symptom-quality of 
life model, however, symptoms need not affect health perceptions or 
function in order to influence quality of life. Another discrepancy between 
the models is that in the health related quality of life model the 
components of the model are affected by individual and environmental 
characteristics like body mass index, developmental status, culture, and 
neighborhood. In the symptom-quality of life model, however, no attempt 
has been made to review such relationships.  
Purpose and value of study, definition and measurements 
of quality of life, research questions and hypotheses 
The purpose of this study is to assess symptoms and quality of life among 
Icelandic patients diagnosed with advanced cancer. The prevalence of 
symptoms will be assessed as well as symptom severity. The relationship 
between symptoms and quality of life will be examined as well as the 
association of both the number of symptoms and individual symptoms 
with quality of life. The aims of the study are to add knowledge to the 
growing body of evidence regarding symptoms and quality of life in 
cancer patients and to test some parts of the Symptoms-quality of life 
model. However, since this study is a secondary analysis of data it was not 
designed to test the Symptoms-quality of life model. Therefore, many 
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factors that are included in the model are not amenable for testing in this 
study. The parts of the model, however, that will be tested in this study are 
the relationship between different types of cancers and the symptoms 
patients experience; the association of number of symptoms and symptom 
severity with quality of life; how the existence and severity of the 
individual symptoms of pain, fatigue, insomnia, and depression are 
associated with quality of life; and the difference in both symptoms and 
quality of life in relationship with age, gender and number of concurrent 
diseases. 
The value of the study lies mainly in the fact that the study is the 
first of its kind conducted in Iceland. The results will illustrate the 
symptomatology of patients with advanced cancer and their quality of life. 
Furthermore, the information on the relationship between symptoms and 
quality of life has important clinical value since it can be used to improve 
patient care.  
 In this study quality of life is used as an outcome measure to 
evaluate the impact of cancer on patients. Therefore, the definition of the 
concept used here is the one by Cella (1996) where health related quality 
of life (QOL) is defined as to what extent one’s usual or expected 
physical, emotional and social well-being are affected by a medical 
condition or its treatment. This definition emphasizes how a disease, such 
as cancer, affects the quality of life of patients which is in line with the 
purpose of the study. Furthermore, the dimensions covered in the 
definition are in accordance with the dimensions of quality of life, 
assessed with the EORTC QLQ-C30 questionnaire, used in the study. The 
EORTC QLQ-C30 instrument is a questionnaire that has been widely used 
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in the cancer population, discussed in detail later, and hence, is 
appropriate for the participants in this study. 
The research questions are:  
1. How many symptoms do patients with advanced cancer 
experience? 
2. What symptoms are most prevalent in patients with advanced 
cancer? 
3. What is the symptom severity in patients with advanced cancer? 
4. What is the quality of life score of patients with advanced cancer? 
5. Do patients with different cancer diagnoses experience dissimilar 
symptoms? 
6. Is there a relationship between gender and number of symptoms, 
symptom prevalence, symptom severity, and quality of life score 
in patients with advanced cancer? 
7.  Is there a relationship between age and number of symptoms, 
symptom prevalence, symptom severity, and quality of life score 
in patients with advanced cancer? 
8. Is there a relationship between number of concurrent diseases and 
number of symptoms, symptom severity, and quality of life score 
in patients with advanced cancer? 
The research hypotheses are: 
1. Number of symptoms is associated with worse quality of life in 
patients with advanced cancer. 
2. The symptoms of pain, depression, fatigue, and poor sleep are 
associated with worse quality of life in patients with advanced 
cancer. 
 
  
63 
Methodology 
In this chapter the methodology of the study is introduced. The topics 
discussed in this chapter are the research design, the European 
Pharmacogenetic Opioid Study, participants and sample, instruments used 
in the study, demographic and clinical data, study procedure, ethical 
aspects and data analysis. 
Research design 
The research design is cross sectional, descriptive and correlational. It is a 
secondary analysis of data from the European Pharmacogenetic Opioid 
Study (described later). Correlational design is applicable when there is 
supported evidence that a relationship exists between variables (Brink & 
Wood, 1998). Descriptive, cross sectional design, however, is used to 
describe, observe and document phenomenona as they naturally occur at 
one time point. Descriptive correlational design can, hence, be used to 
describe the relationship between variables, in this study the relationship 
between symptoms and quality of life. However, this method is not 
suitable for inferring about cause and effect (Polit & Beck, 2004). 
European Pharmacogenetic Opioid Study (EPOS) 
This study is a part of a large international study, European 
Pharmacogenetic Opioid Study (EPOS), conducted in 10 European 
countries. The study sample consists of 3.000 participants, of which 150 
come from Iceland (Klepstad et al., n.d.). The main purpose of EPOS is to 
examine: 
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• The pharmacogenetics of opioids, especially mutations that may 
have effect on the pharmacokinetics and receptors of opioid pain 
medications  
• The serum concentration of opioide medication and their efficacy 
• What types of opioides are used in clinical practice and in what 
doses  
• The patients' evaluation of their pain and quality of life as well as 
the relationship between these factors  
• Patients' barriers to pain treatment.  
Participants and sample 
The sample in this study is the convenience sample of 150 Icelandic 
patients recruited for the EPOS study. A convenience sample consists of 
the people most available to the researcher and although this sampling 
method is the weakest one (Beck et al., 2005) it is often the only possible 
way in the context of very sick populations. The size of the sample was 
chosen by the steering committee of the EPOS study with 150 being the 
minimum number of participants from each center (Klepstad et al., n.d.). 
The participants in this study were patients, 18 years or older who had a 
confirmed diagnosis of malignant disease and had been taking opioid pain 
medication for three days or more. Excluded were those who did not 
understand Icelandic or were otherwise unable to fill out the 
questionnaires because of confusion or illness.  
Instruments  
Instruments used in this study were the Icelandic version of the EORTC 
QLQ-C30 and a questionnaire assessing 17 symptoms and their severity, 
hereafter called the Symptom Checklist. 
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The EORTC QLQ-C30. 
The EORTC QLQ-C30, version 3.0, is a 30 item quality of life instrument 
developed by the European Organization for Research and Treatment of 
Cancer (EORTC) and based on several preceding versions, the first in 
1987 (Fayers & Bottomley, 2002). The purpose of the questionnaire is to 
measure general aspects of health related quality of life (Hjermstad, Fossa, 
Bjordal, & Kaasa, 1995; Lundh Hagelin et al., 2006; Michelson, Bolund, 
Nilsson et al., 2000) and it was designed to be cancer specific, appropriate 
for self administration, multidimensional and applicable in various 
cultural settings (Fayers & Bottomley, 2002).  The EORTC QLQ-C30 is a 
core questionnaire designed to be used with additional modules. Today 
various types of disease specific modules are available such as breast, 
lung and ovarian, as well as modules specific to treatment modality or a 
quality of life dimension (EORTC, n.d.a). The dimensions covered in the 
questionnaire are physical, psychological and social but the main focus is 
on physical functioning and symptoms (Bruley, 1999). 
The EORTC QLQ-C30 consists of both multi-item and single 
scales. There are five functional scales: physical (5 items), emotional (4 
items), social (2 items), role (2 items) and cognitive (2 items); three 
symptom scales: fatigue (3 items), nausea and vomiting (2 items) and pain 
(2 items); two global scales for health status and quality of life; and finally 
six single item scales for the symptoms of dyspnea, insomnia, appetite 
loss, constipation, diarrhea, and financial difficulties, resulting in total of 
30 questions/items (EORTC, n.d.b). The global scales for health and 
quality of life are rated on a visual analogue scale ranging from 1 ("very 
poor") to 7 ("excellent"). All other scales, however, are four point Likert 
scales answered by the participants with "not" (1), "a little" (2), "quite a 
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bit" (3), and "very much" (4). The time frame is the past week (Brans et 
al., 2002; Michelson, Bolund, Nilsson et al., 2000). Examples of questions 
from the EORTC QLQ-C30: 
 Not at 
all 
A little Quite a 
bit 
Very much 
     Do you have any trouble taking 
     a short walk outside of the 
house? 
1 2 3 4 
During the past week:     
     Have you had pain? 1 2 3 4 
     Did you feel irritable? 1 2 3 4 
  
The EORTC QLQ-C30 has been translated and validated in 81 
languages, including Icelandic (Valgerður Sigurðardóttir, unpublished 
data) and has been used in around 3.000 studies worldwide (EORTC, 
n.d.a). The questionnaire has consistently been well accepted by patients 
with low percentage of missing items (Bjordal et al., 2000; Brans et al., 
2002; Rodary et al., 2004). In studies of the general population, in Norway 
and Sweden, the percentage of missing items has ranged from 1,1 - 4,0% 
(Hjermstad, Fayers, Bjordal, & Kaasa, 1998a; Michelson, Bolund, Nilsson 
et al., 2000) and in studies on cancer patients the range of missing items 
has been about 3-5% (Bjordal et al., 2000; Rodary et al., 2004). Older 
people seem to leave more items behind than young people, ranging from 
4,3% up to 12,5%, and women tend to leave more questions unanswered 
than men at least in the general population (Hjermstad et al., 1998a). It 
takes approximately 10-13 minutes to complete the list and most patients 
do not need assistance with completion (Aaronson et al., 1993; Bjordal et 
al., 2000). Patients also seem to understand the questions in a similar way 
as the researchers interpreting the results. In a study, where an observers 
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rating of the answers of patients during an interview was compared to the 
patients self assessment on the EORTC QLQ-C30, the general agreement 
was good with mean kappa=0.85 (range 0,49-1,0) (Groenvold, Klee, 
Sprangers, & Aaronson, 1997). Furthermore, the questions are non-
threatening and hence do not impose psychological distress on the 
participants (Brans et al., 2002; Rodary et al., 2004).  
The reliability of the EORTC QLQ-C30 has proved to be 
adequate. The test/retest reliability of the EORTC QLQ-C30, measured 
with the Pearson's correlation coefficient, ranged from .82-.91 on the 
functional scales, .63-.86 on the symptom scales and single item scales 
ranged from .72-.84 in a study on 190 patients with various kinds of 
cancer. Pearson's r for global health related quality of life was .85 
(Hjermstad et al., 1995). Internal consistency of the EORTC QLQ-C30 
has also been good with Cronbach's alpha usually over .70 in various 
studies (Bruley, 1999) indicating an acceptable reliability (Fredheim, 
Borchgrevink, Saltnes, & Kaasa, 2007). In a study of lung cancer patients, 
performed in 12 countries, Cronbach's alpha ranged from .54-.86 before 
the start of treatment but .52-.89 during treatment (Aaronson et al., 1993).  
The validity of the EORTC QLQ-C30 has also been tested. In a 
multicenter study the questionnaire had acceptable discriminant validity 
and furthermore the questionnaire turned out to be both reliable and valid 
for assessing the quality of life in cancer patients in various cultural 
settings (Aaronson et al., 1993). The EORTC QLQ-C30 has also been 
shown to have an adequate construct validity with scales of the 
questionnaire converging and diverging where appropriate (Niezgoda & 
Pater, 1993). In addition, the questionnaire can be used to assess the 
clinical difference between groups (Bjordal et al., 2000). The EORTC 
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QLQ-C30 has, however, been criticized for not measuring spiritual and/or 
existential issues indicating a lack of construct validity (Bruley, 1999). 
This lack of existential issues also raises questions as to whether the 
instrument can be used in palliative care. Recently, however, the 
questionnaire was tested in the palliative care setting and turned out be 
both reliable and valid for this patient group except for cognitive 
functioning (Nicklasson & Bergman, 2007). A shorter version of the C-30 
has also been developed: the EORTC QLQ-C15-PAL, a core 
questionnaire that is appropriate for patients with advanced disease in 
palliative care (Groenvold et al., 2006).  
The Symptom Checklist. 
The Symptom Checklist consists of 17 symptoms common in cancer 
patients, such as, fatigue, anxiety, depression, dyspnea, constipation and 
nausea. The questionnaire was to be completed by the research nurse, 
according to the study plan, who asked the patients if they had the 
symptoms and if they did they were asked how severe their symptoms 
were. The scoring range is 0-3 with 0 being not experiencing the 
symptom, 1 is mild severity, 2 moderate, and 3 indicates that the symptom 
is severe. The time frame is the past 24 hours. 
A drawback of the questionnaire is that it does not have an 
established reliability or validity. However, the choice of items in the 
questionnaire was based upon the European Association for Palliative 
Care (EAPC) research network 2002 survey (P. Klepstad, personal 
communication, June 24th 2008) and have been used to assess symptoms 
and symptom severity before (Klepstad et al., 2005). In addition, studies 
using lists with similar content have yielded results that are in line with 
results of other studies using validated symptom questionnaires (Homsi et 
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al., 2006; Tsai et al., 2006; Walsh et al., 2000). Homsi et al. (2006) have 
even criticized the instruments available for the lack of number of 
symptoms assessed and hence ignoring many common symptoms in 
patients with generalized cancer.   
Demographic and clinical data 
Demographic data regarding gender and age, and clinical data regarding 
diagnosis, existence of metastases, and concurrent diseases were also 
gathered, both from the patients themselves as well as from their medical 
charts. 
Study procedure  
A research nurse was responsible for recruitment of 150 participants 
according to the study plan. The nurse worked in close collaboration with 
the oncology ward (11E), hematology ward (11G), outpatients ward 
(11B), gynoncology ward (21A), and the hospital palliative care team in 
Landspítali University Hospital, palliative inpatient-wards in Kopavogur 
and in Landakot, and the palliative home care units of Landspítali 
Universtiy Hospital and the privately funded Karitas. If an eligible patient 
was in care in these units the nurse and/or doctor responsible for the 
patient's care introduced the study to the patient. If the patient was 
interested in participating the research nurse sent out or gave the patient a 
letter of introduction to the study. In the palliative units, responsible nurse 
gave an introduction letter to the patients explaining the study and if the 
patient wanted to participate the nurse notified the research nurse. In all 
cases where the patient was willing to participate the research nurse met 
with the patient and explained the study to him/her. After signing an 
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informed consent the research nurse administered the questionnaires and 
gathered information from the patient at a time suitable for him/her. This 
took about 1-1 1/2 hours where about 40 minutes were spent on answering 
the questionnaires (a total of 6 questionnaires were used in the EPOS 
study). The research nurse also collected information from medical charts 
and took blood samples for the EPOS study. Patients only needed to 
answer questionnaires and donate a blood sample once. The research 
nurse, however, usually met every participant at least twice, once to do the 
interview and administer the questionnaires and a second time to collect 
the blood sample. Participants met with the research nurse either at the 
hospital wards or in their own home. Recruitment began in October 2005 
and ended in March 2008. 
Ethical aspects 
To minimize the pressure to participate in the study the research nurse did 
not approach the patient until a member of staff had spoken to the patient 
and checked if he/she was interested in participating. Consent from the 
patient's responsible doctor was also obtained and all participants signed 
an informed consent before participating in the study. Both the informed 
consent, and the data gathering procedure, were in accordance with 
regulation set by the Data Protection Authority regarding informed 
consent in health science research (Reglur um upplýst samþykki í 
vísindarannsókn á heillbrigðissviði Nr. 170/2001). The patients did not get 
paid for their participation nor were they compensated in any other way.  
It can be both physically and psychologically difficult to 
participate in a study, not least for patients with a generalized disease. 
Filling out questionnaires and answering questions can cause or increase 
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fatigue and some questions may be worrisome for individual patients. In 
this study the research nurse, who gathered all the data, was both an 
experienced nurse and a deacon. Therefore, she was well suited to both 
assess the patients’ physical and mental state, as well as to deal with the 
patients’ worries and questions. To minimize the burden of participation 
the research nurse collected data in close collaboration with the patients. 
Although the patients only needed to answer questionnaires and donate a 
blood sample once, data gathering was time consuming and the patients 
easily tired. Therefore, the research nurse met each participant more than 
once, according to his/hers wishes, so that he/she would not get too tired. 
To reduce the amount of discomfort from needle stabs blood samples for 
the study were preferably collected by during routine blood tests. 
The study was approved by the National Bioethics Committee, 
The Data Protection Authority, and the Chief Medical Executive of 
Landspítali University Hospital. 
Data analysis 
Statistics. 
Descriptive statistics were used to describe the number of symptoms, 
symptom prevalence, symptom severity, quality of life and demographic 
data. Categorical variables were summarized as frequencies and 
percentages, but the mean, standard deviation (SD), median, and range 
were reported for continuous variables. Of inferential statistics the T-test 
for independent samples was used to compare means between 
dichotomous and continuous variables, but One way ANOVA was used to 
compare means of categorical (three or more) and continuous variables. 
When the dependent variable was not normally distributed Mann-Whitney 
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and Kruskal-Wallis tests were also used, in addition to T-test and One way 
ANOVA respectively, to compare means between groups. Chi-square test 
was used to test the difference between nominal and ordinal variables. 
Pearson’s r and Spearman’s ρ were used to assess correlations between 
continuous and ordinal variables respectively. Multiple linear regression 
was used to model the association between a) number of symptoms and 
quality of life, and b) the individual symptoms of pain, fatigue, poor sleep, 
and depression, and quality of life. In the latter case hierarchical method 
was used, with variables entered into the model based on their importance. 
For the inferential statistics the significance level was set at p= 0,05. The 
SPSS software 16.0 was used for analysis.  
Variables.  
Age was either used as a continuous variable or categorized into four 
groups, 20-55, 56-65, 66-75, and 76 years and older. The reasons for this 
categorization were several. In the first place, very few patients were 
younger than 50 years making statistical testing less accurate. Secondly, 
this grouping reflects different aspects of the life stages. Patients 55 years 
and younger are generally working full time and many still have children 
living at home. People 56-65 are still working full time but entering the 
role of grandparents. The age group 66-75 represents retirement and 
adjustment to old age. Finally the 76+ group corresponds to the elderly. 
Similar categorization has been reported elsewhere (Jordhoy et al., 2001). 
 Cancer diagnoses were categorized into eight groups: Prostate, 
breast, female reproductive, lung, gastro/intestinal, multiple, other, and 
unknown cancers. Multiple cancers include those with more than one 
cancer diagnoses. Other cancers, however, contains hematological 
cancers, urological cancers other than prostate, and other cancers not 
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specified. Because of the sample size further categorization was not 
possible. 
Concurrent diseases were tested as: a) no disease versus one or 
more diseases, b) no-two diseases versus three-six diseases, c) no disease, 
one-two diseases, and three-six diseases, and d) as a continuous variable. 
Further categorization was not optional because of few patients having 
more than three concurrent diseases. 
In the regression models the global health/quality of life scale of 
the EORTC QLQ-C30 was used as the outcome (dependent) variable. The 
predictor (independent/covariates) variables, however, were number of 
symptoms in the model in research hypothesis one, but pain, fatigue, poor 
sleep, and depression in the model in research hypothesis two. In both 
models age and gender were adjusted for as recommended by Hjermstad 
and colleagues (1998). 
Use of questionnaires. 
Number of symptoms, prevalence, and severity was reported for both the 
Symptom Checklist and the EORTC QLQ-C30. The reason for using both 
questionnaires to evaluate the symptomatology of the participants is that 
the Symptom Checklist assessed symptoms the last 24 hours but the time 
frame in the EORTC QLQ-C30 is the past week. 
The Symptom Checklist was used to assess symptoms in the past 
24 hours. The research nurse asked the patients if they had a symptom 
assessed with the list and if so the patient rated the severity of the 
symptom as mild, moderate, or severe. If patients were unable to answer 
these questions, because of illness or for other reasons, data was gathered 
from the ward nurse, who was taking care of the patient, according to 
study protocol. This was only done on less than five occasions.  
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The EORTC QLQ-C30 was used to evaluate the symptoms and 
quality of life in the past week. Patients filled out the questionnaire 
themselves, but many patients needed assistance with filling it out because 
they felt too weak to do so themselves. This should, however, not lessen 
data quality since according to Aaronson et al. (1993) patients’ responses 
are not influenced by being interviewed instead of filling out the 
questionnaire themselves. Raw scores of the questionnaire were converted 
into 0-100 scales according to the EORTC QLQ-C30 scoring manual 
(Fayers et al., 2001). For the five functional scales and the global health 
status/quality of life scales a higher score indicates better function and 
quality of life. For the symptom scales and single items a higher score, 
however, indicates more symptom severity or symptom burden (Fredheim 
et al., 2007). When interpreting the scores of the EORTC QLQ-C30, as 
previously mentioned, a mean change of 5-10 is considered a little 
change; a difference of 10-20 is deemed to be moderate; and finally, a 
difference of 20 or more is considered a great change in scores. However, 
10% difference represents a significant clinical change in scores (Osoba et 
al., 1998). 
To explore the relationship between symptoms and quality of life 
the symptoms assessed with the EORTC QLQ-C30 were used in the 
regression models. The reason for not using the symptom checklist was 
the different time frame of the questionnaires, rendering it illogical to 
evaluate the quality of life in the past week based on symptoms in the last 
24 hours. The EORTC QLQ-C30 evaluates 16 symptoms, see table 4 and 
although the questionnaire was not designed as a symptom assessment 
tool it, nonetheless, covers many of the most common symptoms in cancer 
(Stromgren, Groenvold, Pedersen, Olsen, & Sjogren, 2002). Four 
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symptoms are included in the EORTC QLQ-C30 that are not in the 
Symptom Checklist and five of the seventeen symptoms of the checklist 
are not found in the EORTC QLQ-C30. Table 4 shows the symptoms 
assessed with both questionnaires and the correlation between the 
symptoms. In line with Stromgren and colleagues’ (2002) categorization 
of the symptoms in the EORTC QLQ-C30 tiredness was chosen as a 
synonym of fatigue and weakness as synonymous with generalized 
weakness.  
The reason for using individual symptoms instead of the symptom 
scales in the EORTC QLQ-C30 is that the scales evaluate both the 
symptom as well as the impact of the symptom on the individual or other 
symptoms. Depression is for instance included in the emotional function 
scale, alongside worry, feeling tense, and feeling irritable. The pain scale 
includes pain and the interference of pain on the patient’s daily activities. 
Finally, the fatigue scale incorporates feeling tired, weakness and the need 
to rest. Since it was the researcher’s intension to evaluate the relationship 
between the individual symptoms and quality of life this method was 
chosen. The scores for the individual symptoms were used on their 
original scale, 1-4 (not converted into 0-100). 
Unlike the symptom checklist in the EORTC QLQ-C30 the patient 
is asked to rate if he/she experiences a symptom as “a little”, “quite a bit” 
and “very much”, but not as mild, moderate or severe. In both 
questionnaires, however, the questions are scaled on a four point Likert 
scale and to aid in comparison these scales were converted to 0-3 (instead 
of 1-4) where 0 means no symptom, 1 = a little/mild, 2 = quite a 
bit/moderate, 3 = very much/severe. As to whether “a little” connotes to 
76 
mild etc. is not certain, but since the scaling is the same it is reasonable to 
use them in comparison of symptom severity. 
 
Table 4. Correlation between symptoms in the Symptom Checklist 
(the past 24 hours) and the EORTC QLQ-C30 (the past week) 
Symptom Checklist Spearman’s ρ EORTC QLQ C-30  
Symptoms that do match in the questionnaires 
 
pain ρ (144) = .568, p=0,000 pain 
fatigue ρ (143) = .492, p=0,000 tiredness 
generalized 
weakness ρ (143) = .501, p=0,000 weakness 
anxiety ρ (144) = .529, p=0,000 worry 
anorexia ρ (145) = .780, p=0,000 lack of appetite 
depression ρ (145) = .541, p=0,000 depression 
constipation ρ (145) = .634, p=0,000 constipation 
poor sleep ρ (143) = .416, p=0,000 insomnia 
dyspnea ρ (145) = .584, p=0,000 short of breath 
nausea ρ (145) = .674, p=0,000 nausea 
vomiting ρ (145) = .416, p=0,000 vomiting 
diarrhea ρ (144) = .370, p=0,000 diarrhea 
   
Symptoms that do not match in the questionnaires 
 
itching  difficulty remembering 
hallucination  difficulty concentrating 
hiccups  feeling tense 
local weakness  irritation 
confusion   
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Results 
Demographics 
One hundred and fifty patients were included in the study. Of those, 62 
(41%) were men and 88 (59%) women, all Caucasians. The patients’ age 
ranged from 20-92 years with the mean (SD) age of 64,7 (12,7) years. 
Most participants were out-patients (67%), attending day- and ambulatory 
care and/or homecare, and the main cancer diagnoses, covering two-thirds 
of the participants, were gastro/ intestinal (n=33), lung (n=24), breast 
(n=22), and prostate (n=21) cancer. The vast majority had metastases 
(91,3%) and a large number of patients (81,3%) had a concurrent disease, 
other than cancer, mainly heart (41%) and vascular diseases (43%). 
Demographic data and clinical characteristics are in table 5.  
Data quality 
The Symptom Checklist. 
The Symptom Checklist was used to assess symptoms in the past 24 
hours. Data was missing from one patient and in addition two patients did 
not answer the question if they had poor sleep or not.  
The internal consistency of the symptom checklist in this study, 
measured with Cronbach’s α, was .74, indicating an acceptable reliability.  
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Table 5. Main demographic and clinical characteristics of patients 
with advanced cancer (N=150) 
  n (%)♠ 
Age 20-55 years 31 (20,7) 
 56-65 years 42 (28,0) 
 66-75 years 46 (30,7) 
 76 years and older 31 (20,7) 
Gender Male 62 (41,3) 
 Female 88 (58,7) 
Ward Palliative care unit/hospice 31 (20,7) 
 General oncology ward 15 (10,0) 
 Surgical ward  4 (2,7) 
 Out-patients clinic/homecare 100 (66,7) 
Cancer diagnoses Female reproductive 17 (11,3) 
 Lung 24 (16,0) 
 Breast 22 (14,7) 
 Prostate 21 (14,0) 
 Gastro/intestinal 33 (22,0) 
 Other 16 (10,7) 
 More than one type of cancer 10 (6,7) 
 Unknown 7 (4,7) 
Number of concurrent 
diseases 
 
none 
 
28 (18,7) 
 1-2 73 (48,7) 
 3-6 49 (32,7) 
Metastases yes 137 (91,3) 
 no 13 (8,7) 
♠ due to rounding percentage may exceed 100% 
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The EORTC QLQ-C30. 
 The EORTC QLQ-C30 was used to evaluate the symptoms and quality of 
life in the past week. Five patients were unable to complete the 
questionnaire, three women and two men, all because they felt they were 
too sick to answer. The lowest response rate was found for the questions 
“were you tired” and “have you felt weak”, or 95,3%.  
  
 
The Cronbach’s α for the total EORTC QLQ-C30 was .82. Of 
individual scales cognitive functioning and social functioning had 
Cronbach’s α lower than .70. The internal consistency of the scales in the 
questionnaire is presented in table 6. 
 
 
Table 6. Internal consistency coefficients/ 
Cronbach’s α for the EORTC QLQ-C30 subscales 
 
Scale 
  
Cronbach’s α 
Functional scales  
 Physical functioning .85 
 Role functioning .74 
 Emotional functioning .82 
 Cognitive functioning* .49 
 Social functioning* .69 
Symptom scales  
 Fatigue .79 
 Nausea and vomiting .76 
 Pain .73 
Global scale  
 Global health status/QOL .78 
* Chronbach’s α lower than .70 
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Question 1. How many symptoms do patients with advanced 
cancer experience? 
Number of symptoms in the past 24 hours. 
The Symptom Checklist, which includes a total of 17 symptoms, was used 
to assess symptoms in the past 24 hours. The number of symptoms per 
patient ranged from 0-12. Only one patient (0,7%) had no symptoms at 
all, but 15 (10,2%) patients had experienced 10 or more symptoms in the 
past 24 hours. The mean (SD) number of symptoms for the total sample 
was 6,2 (2,5). Women had a mean (SD) of 6,5 (2,7) symptoms, but men 
5,9 (2,2). Descriptive statistics for the number of symptoms is presented in 
tables 7 and 8.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7. Number of advanced cancer 
patients (N=148) with symptoms in the 
past 24 hours assessed with the 
Symptom Checklist 
number of symptoms  n (%) 
0-3 symptoms 20 (13,5) 
4-6 symptoms  60 (40,5) 
7-9 symptoms  53 (35,8) 
10-12 symptoms  15 (10,2) 
13 or more 0 (0,0) 
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Table 8. Mean (SD), median, and range of number of symptoms of 
advanced cancer patients according to age and gender in the past 24 
hours, assessed with the Symptom Checklist 
  N mean (SD) median range 
All patients   148 6,2  (2,5) 6,0 0-12 
Gender men 62 5,9 (2,2) 6,0 1-12 
 women 86 6,5 (2,7) 6,5 0-12 
Age 20-55 years old 30 6,4 (2,9) 7,0 1-12 
 56-65 years old 42 6,6 (2,3) 7,0 2-12 
 66-75 years old 45 6,6 (2,5) 6,0 2-12 
 76 years and older 31 4,9 (2,3) 5,0 0-11 
 
Number of symptoms in the past week. 
 
 
 
 
 
 
 
 
 
 
Number of symptoms in the past week was evaluated with the EORTC 
QLQ-C30. The questionnaire contains a total of 16 symptoms. The 
number of symptoms per patient ranged from 1-16. The mean (SD) 
number of symptoms for the total sample was 9,0 (3,3) and 60 (42,5%) 
Table 9. Number of advanced cancer 
patients (N=148) with symptoms in the past 
week assessed with the EORTC QLQ-C30 
number of symptoms  n (%) 
0-3 symptoms 8 (5,8) 
4-6 symptoms  26 (18,4) 
7-9 symptoms  47 (33,3) 
10-12 symptoms  36 (25,5) 
13 and more 24 (17,0) 
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patients had 10 or more symptoms in the past week. The mean (SD) 
number of symptoms for men was 8,8 (2,8) but 9,1 (3,7) for women. 
Descriptive statistics for the number of symptoms is presented in table 9 
and 10.  
 
Table 10. Mean (SD), median, and range of number of symptoms of 
advanced cancer patients according to age and gender in the past 
week, assessed with the EORTC QLQ-C30 
  N mean (SD) median range 
All patients   141 9,0 (3,3) 9 1-16 
 
Gender men 58 8,8 (2,8) 9 3-15 
 women 83 9,1 (3,7) 9 1-16 
 
Age 20-55 years old 27 9,7 (3,8) 10 1-16 
 56-65 years old 41 9,7 (3,1) 10 3-16 
 66-75 years old 42 8,9 (3,2) 9 3-15 
 76 years and older 31 7,6 (3,0) 8 3-15 
 
Question 2. What symptoms are most prevalent in patients with 
advanced cancer? 
Prevalence of symptoms in the past 24 hours. 
The five most common symptoms for the whole sample were fatigue 
(85,2%), pain (82,6%), generalized weakness (81,9%), dyspnea (54,4%), 
and anorexia (51,7%), measured with the Symptom Checklist. For women 
pain (90,8%) was the most common symptom followed by fatigue 
(83,9%), but for men, fatigue (87,1%) was the most prevalent symptom 
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followed by generalized weakness (83,9%). The least prevalent symptoms 
were hallucinations, vomiting, and hiccups, with less than 10% of the 
patients experiencing these symptoms. Table 11 shows the symptom 
prevalence in the past 24 hours.  
 
Table 11. Symptom prevalence in patients with advanced cancer in the 
past 24 hours, assessed with the Symptom Checklist, for total sample 
and men and women respectively   
Symptom  Total sample N(%) Men n(%) Women n(%) 
Fatigue 127 (85,2) 54 (87,1)1 73 (83,9) 2 
Pain 123 (82,6) 44 (71,0) 3 79 (90,8) 1 
Generalized weakness 122 (81,9) 52 (83,9) 2 70 (80,5) 3 
Dyspnea 81 (54,4) 33 (53,2) 4 48 (55,2) 5 
Anorexia 77 (51,7) 28 (45,2) 5 49 (56,3) 4 
Local weakness 63 (42,3) 26 (41,9) 37 (42,5) 
Constipation 53 (35,6) 22 (35,5) 31 (35,6) 
Nausea 52 (34,9) 16 (25,8) 36 (41,4) 
Anxiety 49 (32,9) 20 (32,3) 29 (33,3) 
Depression 43 (28,9) 16 (25,8) 27 (31,0) 
Poor sleep 32 (21,6) 12 (19,4) 20 (23,3) 
Itching 29 (19,5) 11 (17,7) 18 (20,7) 
Diarrhea 26 (17,4) 9 (14,5) 17 (19,5) 
Confusion 20 (13,4) 10 (16,1) 10 (11,5) 
Hiccups 10 (6,7) 4 (6,5) 6 (6,9) 
Vomiting 9 (6,0) 3 (4,8) 6 (6,9) 
Hallucination 8 (5,4) 3 (4,8) 5 (5,7) 
Numbers in circles indicate the rank within gender 
 
Prevalence of symptoms in the past week. 
The five most common symptoms for the whole sample were fatigue 
(90,9%), pain (90,3%), weakness (89,5%), memory loss (68,3%), and loss 
of appetite (62,8), measured with the EORTC QLQ-C30. For women, pain 
(92,9%) was the most common symptom followed by fatigue (90,5%) , 
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but for men, fatigue and weakness were the most prevalent symptoms 
(91,5%) followed by pain (86,4%). Of the sixteen symptoms assessed, 
only vomiting and irritation were experienced by less than 30% of the 
participants the past week. Table 12 shows the symptom prevalence the 
past week and comparison of symptom prevalence in the past 24 hours 
versus in the past week is presented in table 13. 
 
Table 12. Symptom prevalence in patients with advanced cancer in 
the past week, assessed with the EORTC QLQ-C30, for total sample 
and men and women respectively  
Symptom  Total sample N(%) Men n(%) Women n(%) 
Fatigue 130 (90,9) 54 (91,5) 12 76 (90,5) 2 
Pain 130 (90,3) 51 (86,4) 3 79 (92,9) 1 
Weakness 128 (89,5) 54 (91,5) 12 74 (88,1) 3 
Memory loss 99 (68,3) 39 (65,0) 45 60 (70,6) 4 
Loss of appetite 91 (62,8) 39 (65,0) 45 52 (61,2) 5 
Constipation 85 (58,6) 38 (63,3) 47 (55,3) 
Worry (anxiety) 84 (58,3) 35 (58,3) 49 (58,3) 
Dyspnea 82 (56,6) 35 (58,3) 47 (55,3) 
Lack of 
concentration 
80 (55,2) 33 (55,0) 47 (55,3) 
Feeling tense 71 (49,0) 27 (45,0) 44 (51,8) 
Depression 70 (48,3) 28 (46,7) 42 (49,4) 
Nausea 66 (45,5) 26 (43,3) 40 (47,1) 
Diarrhea 61 (42,4) 31 (51,7) 30 (35,7) 
Insomnia 57 (39,6) 22 (37,3) 35 (41,2) 
Irritation 42 (29,0) 13 (21,7) 29 (34,1) 
Vomiting 27 (18,6) 7 (11,7) 
20 (23,5) 
 
Numbers in circles indicate the rank within gender 
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Table 13. Comparison of symptoms in patients with advanced cancer 
in the past 24 hours versus the past week, assessed with two different 
questionnaires  
Symptoms in the past 24 hours♠ Symptoms in the past week♦ 
Symptom  n (%) Symptom  n (%) 
Fatigue 127 (85,2) Fatigue 130 (90,9) 
Pain 123 (82,6) Pain 130 (90,3) 
Generalized 
weakness 
122 (81,9) Weakness 128 (89,5) 
Dyspnea 81 (54,4) Memory loss 99 (68,3) 
Anorexia 77 (51,7) Loss of appetite 91 (62,8) 
Local weakness 63 (42,3) Constipation 85 (58,6) 
Constipation 53 (35,6) Worry (anxiety) 84 (58,3) 
Nausea 52 (34,9) Dyspnea 82 (56,6) 
Anxiety 49 (32,9) Lack of 
concentration 
80 (55,2) 
Depression 43 (28,9) Feeling tense 71 (49,0) 
Poor sleep 32 (21,6) Depression 70 (48,3) 
Itching 29 (19,5) Nausea 66 (45,5) 
Diarrhea 26 (17,4) Diarrhea 61 (42,4) 
Confusion 20 (13,4) Insomnia 57 (39,6) 
Hiccups 10 (6,7) Irritation 42 (29,0) 
Vomiting 9 (6,0) Vomiting 27 (18,6) 
Hallucination 8 (5,4)   
♠ assessed with the Symptom Checklist 
♦assessed with the EORTC QLQ-C30  
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Question 3. What is the symptom severity in patients with 
advanced cancer? 
Symptom severity in the past 24 hours. 
The mean (SD) symptom severity was 0,7 (0,4) on a scale from 0-35 for 
the total sample. The symptoms that had the highest mean severity were: 
generalized weakness, fatigue, pain, dyspnea, and anorexia. The mean 
(SD) symptom severity for women was 0,7 (0,4) versus 0,6 (0,3) for men. 
The mean symptom severity is presented in table 14.   
 
Table 14. Mean (SD) symptom severity in advanced cancer patients in the 
past 24 hours of the five most severe symptoms and all symptoms combined 
for the total sample, gender, and age  
Symptom Total 
sample: 
Gender: Age:    
  men women 20-55 56-65 66-75 76+ 
Generalized 
weakness 
1,91 
(1,1) 
1,95 
(1,1) 
1,87 
(1,2) 
1,87 
(1,1) 
2,00 
(1,1) 
1,96 
(1,2) 
1,74 
(1,2) 
Fatigue 1,83 
(1,1) 
1,82 
(1,0) 
1,84 
(1,1) 
2,07 
(1,0) 
1,98 
(0,9) 
1,87 
(1,1) 
1,35 
(1,1) 
Pain 1,39 
(1,0) 
1,03 
(0,9) 
1,64 
(0,9) 
1,47 
(0,9) 
1,55 
(1,0) 
1,35 
(0,9) 
1,16 
(0,9) 
Dyspnea 1,07 
(1,2) 
1,10 
(1,2) 
1,05 
(1,1) 
1,20 
(1,1) 
1,40 
(1,2) 
1,04 
(1,2) 
0,52 
(1,0) 
Anorexia 1,03 
(1,2) 
0,85 
(1,1) 
1,15 
(1,2) 
0,87 
(1,3) 
0,93 
(1,0) 
1,24 
(1,2) 
1,00 
(1,2) 
All symptoms 0,7 
(0,4) 
0,6 
(0,3) 
0,7 
(0,4) 
0,7 
(0,5) 
0,8 
(0,4) 
0,7 
(0,4) 
0,5 
(0,3) 
                                                 
5 0 means no symptom,1 mild, 2 moderate, and 3 a severe symptom 
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Table 15. Proportion of advanced cancer patients with none, mild, 
moderate, and severe symptoms in the past 24 hours, measured with 
the Symptom Checklist 
Symptom N Symptom severity   % (n) 
  None Mild  Moderate Severe 
Generalized 
weakness 
149 18,1 (27) 14,8 (22) 25,5 (38) 41,6 (62) 
Fatigue 149 14,8 (22) 20,8 (31) 30,9 (46) 33,6 (50) 
Anorexia 149 48,3 (72) 19,5 (29) 13,4 (20) 18,8 (28) 
Dyspnea 149 45,6 (68) 20,1 (30) 16,1 (24) 18,1 (27) 
Constipation 149 64,4 (96) 9,4 (14) 8,7 (13) 17,4 (26) 
Pain 149 17,4 (26) 41,6 (62) 25,5 (38) 15,4 (23) 
Local weakness 149 57,7 (86) 19,5 (29) 14,1 (21) 8,7 (13) 
Nausea 149 65,1 (97) 19,5 (29) 6,7 (10) 8,7 (13) 
Depression 149 71,1 (106) 16,8 (25) 6,7 (10) 5,4 (8) 
Anxiety 149 67,1 (100) 13,4 (20) 14,1 (21) 5,4 (8) 
Poor sleep 148 78,4 (116) 9,5 (14) 6,8 (10) 5,4 (8) 
Itching 149 80,5 (120) 10,7  (16) 3,4 (5) 5,4 (8) 
Vomiting 149 94,0 (140) 2,0 (3) 0,7 (1) 3,4 (5) 
Confusion 149 86,6 (129) 8,7 (13) 2,0 (3) 2,7 (4) 
Diarrhea 149 82,6 (123) 11,4 (17) 4,0 (6) 2,0 (3) 
Hallucination 149 94,6 (141) 4,7 (7) 0,0 (0) 0,7 (1) 
Hiccups 149 93,3 (139) 4,7 (7) 1,3 (2) 0,7 (1) 
 
The total number of symptoms, in the past 24 hours, reported by 
the whole sample was 924. Of these, 368 (39,8%) were rated as mild, 268 
(29,0%) as moderate, and 288 (31,2%) as severe. The highest prevalence 
of severe symptoms were generalized weakness (41,6%), fatigue (33,6%), 
anorexia (18,8%), dyspnea (18,1), and constipation (17,4%). Vomiting, 
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hallucinations, hiccups, diarrhea, and confusion were, however, 
considered severe by less than five percent of the patients. Table 15 shows 
the portion of patients with none, mild, moderate, and severe symptoms.  
Symptom severity in the past week. 
The mean (SD) symptom severity was 0,9 (0,5) on a scale from 0-36 for 
the total sample. The symptoms that had the highest mean severity were: 
weakness, fatigue, pain, loss of appetite, and constipation respectively. 
The mean (SD) symptom severity for women was 1,0 (0,5) versus 0,9 
(0,5) for men. The mean symptom severity is presented in table 16.  
 
Table 16. Mean (SD) symptom severity in advanced cancer patients in the 
past week of the five most severe symptoms and all symptoms combined for 
the total sample, gender, and age 
Symptom 
Total 
sample: Gender:  Age:    
  men women 20-55 56-65 66-75 76+ 
Weakness 1,87 
(1,0) 
1,83 
(1,0) 
1,90 
(1,0) 
1,89 
(0,9) 
2,10 
(0,9) 
1,86 
(1,0) 
1,58 
(1,1) 
Fatigue 1,73 
(1,0) 
1,69 
(1,0) 
1,76 
(1,0) 
1,89 
(0,8) 
1,95 
(0,9) 
1,67 
(0,9) 
1,39 
(1,1) 
Pain 1,56 
(0,9) 
1,47 
(0,9) 
1,61 
(0,8) 
1,46 
(0,9) 
1,78 
(1,0) 
1,41 
(0,6) 
1,55 
(0,9) 
Loss of 
appetite 
1,10 
(1,1) 
1,02 
(1,0) 
1,16 
(1,2) 
0,93 
(1,0) 
1,00 
(1,2) 
1,29 
(1,1) 
1,13 
(1,1) 
Constipation 1,04 
(1,1) 
1,13 
(1,1) 
0,98 
(1,1) 
1,07 
(1,1) 
1,00 
(1,1) 
0,89 
(1,0) 
1,29 
(1,2) 
All symptoms 0,9 
(0,5) 
0,9 
(0,5) 
1,0 
(0,5) 
1,0 
(0,5) 
1,1 
(0,4) 
0,9 
(0,5) 
0,8 
(0,5) 
 
                                                 
6 0 means no symptom, 1 a little, 2 quite a bit, and 3 very much symptoms 
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The total number of symptoms, for the whole sample, in the past 
week was 1303. Of these, 692 (53,1%) symptoms were experienced by 
patients as “a little”, 349 (26,8%) as “quite a bit” and 262 (20,1) as “very 
much”. The highest prevalence of symptoms perceived as “very much” 
were weakness (35,0%), fatigue (26,6%), loss of appetite (16,6), 
constipation (16,6) and pain (15,3). Depression, memory loss, vomiting, 
and irritation were, however, only considered severe by less than five 
percent of the patients. Table 17 shows the portion of patients with none, a 
little, quite a bit, and very much symptoms.  
 
Table 17. Proportion of advanced cancer patients with none, a little, 
quite a bit, and very much symptoms the past week, measured with 
the EORTC QLQ-C30 
Symptom N Symptom severity   % (n) 
  None A little Quite a bit Very much 
Weakness 143 10,5 (15) 26,6 (38) 28,0 (40) 35,0 (50) 
Fatigue 143 9,1 (13) 35,0 (50) 29,4 (42) 26,6 (38) 
Loss of appetite 145 37,2 (54) 31,7 (46) 14,5 (21) 16,6 (24) 
Constipation 145 41,4 (60) 29,7 (43) 12,4 (18) 16,6 (24) 
Pain 144 9,7 (14) 40,3 (58) 34,7 (50) 15,3 (22) 
Lack of concentration 145 44,8 (65) 24,8 (36) 17,2 (25) 13,1 (19) 
Dyspnea 145 43,4 (63) 26,9 (39) 19,3 (28)  10,3 (15) 
Insomnia 144 60,4 (87) 19,4 (28) 10,4 (15) 9,7 (14) 
Feeling tense 145 51,0 (74) 29,7 (43) 11,7 (17) 7,6 (11) 
Diarrhea 144 57,6 (83) 26,4 (38) 9,0 (13) 6,9 (10) 
Worry (anxiety) 144 41,7 (60) 36,1 (52) 16,7 (24) 5,6 (8) 
Nausea 145 54,5 (79) 27,6 (40) 12,4 (18) 5,5 (8) 
Depression 145 51,7 (75) 35,9 (52) 7,6 (11) 4,8 (7) 
Memory loss 145 31,7 (46) 51,7 (75) 12,4 (18) 4,1 (6) 
Vomiting 145 81,4 (118) 11,7 (17) 3,4 (5) 3,4 (5) 
Irritation 145 71,0 (103) 25,5 (37) 2,8 (4) 0,7 (1) 
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Question 4. What is the quality of life score of patients with 
advanced cancer? 
 
Quality of life was assessed with the EORTC QLQ-C30. The mean (SD) 
global health/quality of life score for the total sample was 41,6 (23,8). The 
mean (SD) score for men was 39,0 (24,6) but 43,5 (23,3) for women. 
Table 18 shows the global health/quality of life scores for patients based 
on age and gender, but table 19 shows the mean scores for the total 
EORTC QLQ-C30 scales.  
 
Table 18. Mean (SD) global health/quality of life score of advanced 
cancer patients based on gender and age  
Gender Age n Mean (SD) Min Max 
Men 20-55 years 9 39,8 (21,6) 8,3 66,7 
 56-65 years 13 27,6 (21,9) 0 66,7 
 66-75 years 22 38,3 (26,2) 0 100 
 76 years and older 16 49,0 (23,7) 0 75,0 
 Total 60 39,0 (24,6) 0 100 
Women 20-55 years 19 43,9 (23,2) 16,7 100 
 56-65 years 28 38,1 (21,9) 0 75,0 
 66-75 years 22 51,1 (20,9) 0 83,3 
 76 years and older 15 41,7 (27,8) 0 83,3 
 Total 84 43,5 (23,3) 0 100 
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Question 5. Do patients with different cancer diagnoses 
experience dissimilar symptoms?  
Symptoms in the past 24 hours based on cancer diagnosis. 
The difference between symptoms based on cancer diagnoses was 
explored, but because there were too few patients in the groups statistical 
testing was not an option. Table 20 shows the proportion of patients with 
symptoms in the past 24 hours based on cancer diagnosis.  
Symptoms in the past week based on cancer diagnosis.  
The difference between symptoms based on cancer diagnoses was 
explored, but because there were too few patients in the groups statistical 
testing was not an option. Table 21 shows the proportion of patients with 
symptoms in the past week based on cancer diagnosis. 
Question 6. Is there a relationship between gender and number 
of symptoms, symptom prevalence, symptom severity, and 
quality of life score in patients with advanced cancer? 
Gender difference was not found for number of symptoms or symptom 
severity in either the past 24 hours or in the past week. Similarly no 
statistical significance was found between genders in global health/quality 
of life score or scores in any other scale of the EORTC QLQ-C30, tested 
both with t-test and Mann Whitney U. 
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Table 20. Proportion (%) of advanced cancer patients with symptoms in 
the past 24 hours based on cancer diagnoses 
Symptom Cancer diagnoses      
 
Pr
os
ta
te
  (
n=
21
) 
B
re
as
t (
n=
22
) 
Fe
m
al
e 
re
pr
od
uc
tiv
e 
 
(n
=1
7)
 
Lu
ng
 (n
=2
4)
  
G
as
tro
/ i
nt
es
tin
al
 (n
=3
3)
 
M
ul
tip
le
 c
an
ce
rs
 (n
=1
0)
 
 
O
th
er
 c
an
ce
rs
 (n
=1
6)
 
U
nk
no
w
n 
(n
=7
) 
 
 % % % % % % % % 
Pain 66,7 95,5 87,5 83,3 87,9 80,0 81,2 57,1 
Fatigue 76,2 81,8 100,0 91,7 78,8 100,0 81,2 85,7 
Generalized 
weakness 
76,2 72,7 100,0 83,3 81,8 70,0 87,5 85,7 
Anxiety 14,3 40,9 43,8 29,2 30,3 50,0 31,2 42,9 
Anorexia 38,1 54,5 81,2 45,8 54,5 40,0 50,0 42,9 
Depression 19,0 27,3 31,2 33,3 33,3 20,0 25,0 42,9 
Constipation 28,6 31,8 50,0 29,2 45,5 30,0 31,2 28,6 
Poor sleep 4,8 27,3 31,2 16,7 21,9 30,0 25,0 28,6 
Dyspnea 47,6 50,0 56,2 79,2 36,4 70,0 62,5 42,9 
Local 
weakness 
47,6 40,9 56,2 37,5 39,4 30,0 50,0 28,6 
Nausea 19,0 45,5 50,0 33,3 36,4 30,0 25,0 42,9 
Confusion 19,0 0,0 12,5 25,0 15,2 10,0 12,5 0,0 
Vomiting 0,0 4,5 6,2 0,0 12,1 10,0 6,2 14,3 
Diarrhea 9,5 4,5 25,0 8,3 24,2 40,0 12,5 42,9 
Itching 14,3 18,2 25,0 12,5 18,2 30,0 31,2 14,3 
Hallucinations 9,5 4,5 6,2 8,3 0,0 10,0 0,0 14,3 
Hiccups 0,0 4,5 12,5 4,2 12,1 0,0 6,2 14,3 
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Table 21. Proportion (%) of advanced cancer patients with symptoms in 
the past week based on cancer diagnoses 
Symptom Cancer diagnoses  
 
Pr
os
ta
te
 (n
=2
1)
 
B
re
as
t (
n=
22
) 
Fe
m
al
e 
re
pr
od
uc
tiv
e 
 
(n
=1
7)
 
Lu
ng
 (n
=2
4)
 
G
as
tro
/ i
nt
es
tin
al
 (n
=3
3)
 
M
ul
tip
le
 c
an
ce
rs
 (n
=1
0)
 
O
th
er
 c
an
ce
rs
 (n
=1
6)
 
U
nk
no
w
n 
(n
=7
) 
 
 % % % % % % % % 
Weakness 95,0 85,7 100 87,5 84,8 100 87,5 83,3 
Fatigue 95,0 95,2 100 87,5 84,8 100 93,8 66,7 
Loss of appetite 60,0 59,1 71,4 58,3 75,8 50,0 56,2 50,0 
Constipation 75,0 59,1 64,3 58,3 51,5 50,0 68,8 16,7 
Pain 85,0 100 85,7 87,5 96,9 80,0 87,5 83,3 
Lack of 
concentration 60,0 59,1 57,1 50,0 57,6 40,0 62,5 33,3 
Dyspnea 60,0 72,7 50,0 62,5 45,5 40,0 56,2 66,7 
Insomnia 20,0 54,5 42,9 33,3 48,5 33,3 43,8 16,7 
Feeling tense 40,0 59,1 35,7 45,8 45,5 80,0 62,5 16,7 
Diarrhea 50,0 33,3 42,9 29,2 48,5 80,0 25,0 50,0 
Worry (anxiety) 50,0 57,1 50,0 54,2 54,5 100 68,8 50,0 
Nausea 35,0 45,5 57,1 58,3 39,4 40,0 50,0 33,3 
Depression 35,0 50,0 35,7 41,7 57,6 60,0 62,5 33,3 
Memory loss 55,0 72,7 57,1 70,8 69,7 90,0 68,8 66,7 
Vomiting 5,0 40,9 35,7 12,5 15,2 20,0 6,2 16,7 
Irritation 20,0 40,9 28,6 25,0 30,3 30,0 31,2 16,7 
 
Regarding symptom prevalence gender difference was found for 
two symptoms in the past 24 hours assessed by the Symptom Checklist: 
pain, (χ2(1, N=149)=9,89, p=0,002), and nausea, (χ2(1, N=149)=3,86, 
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p=0,049). In both instances more women than men experienced the 
symptoms. Symptom prevalence, however, did not differ between genders 
in the past week. 
Question 7. Is there a relationship between age and number of 
symptoms, symptom prevalence, symptom severity, and quality 
of life score in patients with advanced cancer?  
A weak, but significant, negative correlation was found between age and 
number of symptoms, (r(148) = -.23, p=0,004), in the past 24 hours, as 
well as in the past week, (r(141) = -.28, p=0,001). 
As for symptom prevalence, age difference in the past 24 hours 
was noted for the symptoms of anxiety, (χ2(3, N=149)=7,93, p=0,047), 
depression, (χ2(3, N=149)=8,20, p=0,042), and dyspnea, (χ2(3, 
N=149)=11,55, p=0,009). In all cases the symptoms were less prevalent in 
the patients aged 76 years and older than other age groups. In the past 
week, however, age difference was noted for the symptoms of dyspnea, 
(χ2(3, N=145)=9,55, p=0,023), and feeling tense, (χ2(3, N=145)=13,73, 
p=0,003). In both instances the symptoms were less prevalent in the 
patients aged 76 years and older than other age groups.   
Symptom severity was negatively associated with age in the past 
24 hours, that is, severity lessened with increasing age although the 
correlation was weak, (r(148)= -.24, p=0,004). Similarly, symptom 
severity was negatively associated with age in the past week, (r(141)= -
.25, p=0,003).  
Global health/quality of life scores did not change with age. 
Physical function, however, declined with increasing age, (r(145)= -.18, 
p=0,034), but emotional, (r(145)= .29, p=0,000), and social functioning, 
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(r(145)= .29, p=0,001), were better among older than younger patients. Of 
the symptom scales fatigue, (r(144)= -.21, p=0,010), dyspnea, (r(145)= -
.25, p=0,002), insomnia, (r(144)= -.21, p=0,012), and financial problems, 
(r(145)= -.27, p=0,001), were negatively associated with age, that is older 
patients scored lower on the symptom scales than younger patients, 
indicating less symptomatology.  
Question 8. Is there a relationship between number of 
concurrent diseases and number of symptoms, symptom 
severity, and quality of life score in patients with advanced 
cancer? 
No relationship was found between number of concurrent diseases and 
number of symptoms and symptom severity in neither the past 24 hours 
nor in the past week. Similarly, no difference was found for quality of life 
score regardless of whether concurrent diseases were grouped into no 
diseases versus one or more disease; no-two diseases versus three-six 
diseases; or as no disease, one-two diseases, and three or more diseases. 
Hypothesis 1. Number of symptoms is associated with worse 
quality of life in patients with advanced cancer  
The relationship between number of symptoms in the past week and 
global health/quality of life (QL2), measured by the EORTC QLQ-C30, 
was linear with a moderate, negative correlation, (r(140)= -.50, p=0,000). 
When entered into a multiple linear regression model the number of 
symptoms added significantly to the model, (p= 0,000), and explained 
25,8% of the variance in global health/quality of life, adjusted for gender 
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and age. The model shows that with each symptom the predicted value of 
global health/quality of life is lowered by 3,60 for a 65 year old male. The 
hypothesis of an association between number of symptoms and 
diminished quality of life was, therefore, supported. Table 22 shows the 
regression model. 
 
Table 22. Regression model showing the association 
between number of symptoms and quality of life in 
advanced cancer patients (N=140)  
 
Variable 
 
B 
 
SE 
 
β• 
 
t 
 
p 
Constant (QL2) 70,80 5,7  12,4 0,000 
Number of 
symptoms  
-3,60 0,6 -.50 -6,5 0,000 
Age (c65)♠ -0,02 0,1 -.01 -0,1 0,887 
Gender∗ 5,46 3,6 .11 1,5 0,134 
 
F (3,139) = 15,76, p = 0,000.  
R2 = 25,8, adjusted R2 = 24,2 
•Standardized β. 
♠age centered at 65 years 
∗ gender was coded 0 for male, 1 for female
  
Hypothesis 2. The symptoms of pain, depression, fatigue, and 
poor sleep are associated with worse quality of life in patients 
with advanced cancer  
The second regression model shows the association of fatigue, pain, poor 
sleep, and depression with global health/quality of life (QL2), measured 
with the EORTC QLQ-C30. All four symptoms were linearly and 
negatively related with global health/quality of life indicating lower 
quality of life scores with the presence and increased severity of the 
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symptoms. For pain, insomnia, and depression the relationship was weak, 
but for fatigue the association was moderate. A significant correlation also 
existed between the four symptoms. In all instances the relationship was 
weak and positive, suggesting that the presence and strength of one 
symptom was associated with the presence and strength of the other 
symptom. The correlation between the variables is shown in table 23. 
 
Table 23. Correlation between variables in a regression model 
showing the association between fatigue, pain, insomnia and 
depression with quality of life in patients with advanced cancer 
(N=141) 
 
Q
L2
 
fa
tig
ue
 
pa
in
 
in
so
m
ni
a 
de
pr
es
si
on
 
ge
nd
er
 
ag
e 
(c
65
) 
QL2 1,00 -0,49* 0,38* -0,32* -0,27* 0,10 0,11 
fatigue 0,4* 1,00 0,34* 0,33* 0,25* 0,04 0,21° 
pain 0,38* 0,34* 1,00 0,22° 0,19° 0,08 -0,07 
insomnia 0,32* 0,33* 0,22° 1,00 0,35* 0,03 0,21° 
depression 0,27* 0,25* 0,19° 0,35* 1,00 0,01 0,20° 
gender 0,10 0,04 0,08 0,03 -0,01 1,00 0,17° 
age (c65) ♠ 0,11 -0,21° -0,07 -0,21° -0,20° 0,17° 1,00 
° p < 0,05    
* p ≤ 0,001    
♠age centered at 65 years
 
The model was built in five steps using hierarchical method. In the first 
step only fatigue was added to the model. As seen in table 24 fatigue 
explained 24,2% of the variance in global health/quality of life. In the 
second step age and gender were entered, but these variables did not have 
a significant influence on the model. In the third step pain was added to 
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the model and together the two symptoms explained 31,0% of the 
variance in global health/quality of life, adjusted for age and gender. Pain 
was confounding for fatigue. In the fourth step insomnia was included in 
the model and, as seen in table 25, all three symptoms significantly 
contributed to the model with R2 increasing by further 2.0%. Insomnia 
was confounding for age in step four. Depression was added in the fifth 
step, contributing to a further 0,7% in the variance in global health/quality 
of life which was not significant. Depression was confounding for both 
insomnia and age. Until the final step age had a positive value and as 
depression was included in the model the contribution of insomnia was no 
longer significant. The hypothesis that the four symptoms were associated 
with worse quality of life was, therefore, only partially supported. The 
final model shows that the four symptoms, adjusted for age and gender, 
explained 33,6% of the variance in global health/quality of life. The 
model (step five), adjusted for gender and age, shows that the presence of 
“a little” pain, fatigue, insomnia, and depression in a 65 year old male 
lowered the predicted value of global health/quality of life by 20,6. Table 
25 shows the predicted values of global health/quality of life, adjusted for 
age and gender, based on the existence and severity of pain and fatigue 
(step three). As seen in the table global health quality of life scores are 
lowered as the severity of the symptoms increase. 
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Table 24. Regression model showing the association between fatigue, 
pain, insomnia, and depression with quality of life in patients with 
advanced cancer (N=141)  
Step Variable B SE β• t p R2 F (df) 
Step 1 Constant (QL2) 75,00 5,3  14,2 0,000 0,242° 44,3 (1)* 
 Fatigue  -12,19 1,8 -.49 -6,7 0,000   
Step 2 Constant (QL2) 71,52 5,8  12,3 0,000 0,256 15,7 (3)* 
 Fatigue  -12,16 1,9 -.49 -6,5 0,000   
 Gender♦ 5,79 3,6 .12 1,6 0,111   
 Age (c65) ♠ 0,05 0,1 .03 0,3 0,743   
Step 3 Constant (QL2) 82,55 6,5  12,6 0,000 0,310° 15,2 (4)* 
 Fatigue  -10,08 1,9 -.41 -5,3 0,000   
 Pain -6,75 2,1 -.25 -3,3 0,001   
 Gender♦ 6,68 3,5 .14 1,9 0,059   
 Age (c65) ♠ 0,05 0,1 .03 0,4 0,702   
Step 4 Constant (QL2) 84,73 6,6  12,9 0,000 0,330° 13,3 (5)* 
 Fatigue  -9,09 2,0 -.37 -4,6 0,000   
 Pain -6,23 2,1 -.23 -3,0 0,003   
 Insomnia -3,63 1,8 -.15 -2,0 0,046   
 Gender♦ 6,54 3,5 .14 1,9 0,061   
 Age (c65) ♠ 0,01 0,1 .01 0,1 0,942   
Step 5 Constant (QL2) 87,00 6,8  12,7 0,000 0,336 11,3 (6)* 
 Fatigue  -8,86 2,0 -.36 -4,5 0,000   
 Pain -6,01 2,1 -.22 -2,9 0,004   
 Insomnia -3,06 1,9 -.13 -1,6 0,104   
 Depression -2,65 2,3 -.09 -1,2 0,247   
 Gender♦ 6,35 3,5 .13 1,8 0,069   
 Age (c65) ♠ -0,01 0,1 -.01 -0,1 0,946   
 
° significant F change at step 
* p = 0,000 
adjusted R2 for step 5 = 0,307 
•Standardized β 
♠age centered at 65 years 
♦gender was coded 0 for male, 1 for female 
df = degrees of freedom 
101 
Table 25. Predicted value of global health/quality of life score of 
advanced cancer patients, according to the existence and severity of 
pain and fatigue, adjusted for age and gender (N=141) 
 
 
  
Men 
  
Women 
   Pain  Agegroup  Pain  
 
  
  1 2 3 4  1 2 3 4   
Fa
tig
ue
 1 84 77 70 63 76+ 90 83 77 70 1 
Fa
tig
ue
 
2 73 67 60 53  80 73 67 60 2 
3 63 57 50 43  70 63 57 50 3 
4 53 47 40 33  60 53 46 40 4 
             
Fa
tig
ue
 1 83 76 69 63 66-75 90 83 76 69 1 
Fa
tig
ue
 
2 73 66 59 52  79 73 66 59 2 
3 63 56 49 42  69 63 56 49 3 
4 53 46 39 32  59 53 46 39 4 
             
Fa
tig
ue
 1 82 76 69 62 56-65 89 82 76 69 1 
Fa
tig
ue
 
2 72 65 59 52  79 72 65 59 2 
3 62 55 49 42  69 62 55 49 3 
4 52 44 39 32  59 52 45 39 4 
             
Fa
tig
ue
 1 81 74 68 61 20-55 88 81 74 68 1 
Fa
tig
ue
 
2 71 64 58 51  78 71 64 58 2 
3 61 54 48 41  68 61 54 47 3 
4 51 44 37 31  58 51 44 37 4 
             
Scale 0-100, higher score indicates better quality of life   
1 = no pain/fatigue 
2 = little pain/fatigue 
3 = quite a bit pain/fatigue 
4 = very much pain/fatigue 
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Discussion  
In this chapter the results of the present study will be discussed and 
compared to other studies in this field. The strength and limitations of the 
study will be addressed and finally there are conclusions and suggestions 
for future studies. 
Symptomatology and quality of life scores  
Being symptom free was rare in this study which is in line with Lidstone’s 
et al. (2003) study of a similar group of patients. Only one patient (0,7%) 
had experienced no symptoms at all in the past 24 hours and all the 
patients had at least one symptom in the past week. The median number of 
symptoms in the past week was higher than in the past 24 hours which 
was not an unexpected finding. As can be anticipated, symptoms may 
fluctuate with patients experiencing e.g. insomnia for one night, but not 
the other, and the same is true for most other symptoms except, perhaps, 
fatigue and weakness that tend to be more constant over time. The median 
number of nine (mean 9,0) symptoms in the past week was similar to 
findings of several other studies (Chang et al., 2000; Homsi et al., 2006; 
Lidstone et al., 2003; Peters & Sellick, 2006; Portenoy et al., 1994; Tsai et 
al., 2006; Walsh et al., 2000), despite different time frames (at the 
moment or in the past 24 hours versus the past week). The median number 
of six (mean 6,2) symptoms in the past 24 hours in this study, however, 
was somewhat lower than found in other studies, but nonetheless in line 
with another Icelandic study of patients entering palliative service where 
the mean number of symptoms ranged from 4,95-7,17 (Friðriksdóttir & 
Sigurðardóttir, 2004, April). In the present study the proportion of patients 
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with 10 or more symptoms the past week (42,5%) was noticeably higher 
than in the past 24 hours (10,2%). This is also higher than the proportion 
of patients in the last 72 hours of life (17%) in another Icelandic study 
(Sigurdardottir et al., 2006). The proportion of patients in the past 24 
hours (10,2%), on the other hand, is rather lower. The difference between 
the two studies may stem from different assessment methods, self reported 
versus nurse assessed. In the last hours of life people are often 
unconscious and, therefore, evaluation of symptoms is more troublesome 
since symptoms are primarily a subjective phenomenon (Rhodes & 
Watson, 1987). The different time frames may also explain the difference, 
since the proportion of patients with 10 or more symptoms in the past 24 
hours was lower than in patients in the last 72 hours of life.   
The most prevalent symptoms in the past 24 hours in this study 
were fatigue, pain, generalized weakness, dyspnea, and anorexia. For the 
past week, however, memory loss took the place of dyspnea. These results 
are in line with a systematic review by Teunissen et al. (2007) where pain, 
fatigue, weakness, and anorexia were among the five most common 
symptoms. Dyspnea has also been among the five most prevalent 
symptoms in other studies (Chang et al., 2000; McMillan & Small, 2002; 
Friðriksdóttir & Sigurðardóttir, 2004, April). However, no studies were 
found where memory loss was among the most common symptoms, 
possibly because it is a symptom that often is not assessed. It can also be 
speculated that memory loss may be a salient symptom that is difficult for 
patients to acknowledge, since cognitive impairment is generally 
associated with considerable stigma in the society.  
 Resembling other studies, the prevalence of fatigue, pain, and 
weakness was quite high (Chen & Tseng, 2006; McMillan & Small, 2002; 
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Tsai et al., 2006) with over 80% of the patients experiencing these 
symptoms in the past 24 hours and around 90% in the past week. These 
numbers are somewhat higher than the pooled prevalence of pain (71%) 
and fatigue (74%) in Teunissen’s et al. (2007) systematic review, but 
nonetheless, they conform to the notion of these two symptoms being 
nearly universal in patients with advanced cancer (Hoekstra et al., 2006; 
Homsi et al., 2006; Modonesi et al., 2005; Peters & Sellick, 2006; Tsai et 
al., 2006; Walsh et al., 2000). It should be noted here, however, that to 
participate in the present study patients had to be on opioid pain 
medications. The results might, therefore, me skewed in the direction of 
higher pain prevalence than found in other studies. 
Symptom severity in this study was usually mild or moderate, and 
the mean severity was in line with other studies (Skúladóttir et al., 2005; 
Hoekstra et al., 2006; Peters & Sellick, 2006; Tsai et al., 2006). 
Nonetheless, one third of the patients had severe symptoms in the past 24 
hours, and one fifth had “very much” symptoms in the past week. 
Comparing the results with other studies is, however, difficult because of 
different scaling in different studies.  
The symptoms with the highest mean severity in the past 24 hours 
were the same as the five most common symptoms: generalized weakness, 
fatigue, pain, dyspnea, and anorexia. For the past week, the same 
symptoms had the highest mean severity, but with constipation taking the 
place of dyspnea. These symptoms were also among those most 
frequently rated as severe, with severe fatigue and weakness prevalent in 
about one third of the participants, but the other symptoms in little less 
than one fifth. These results are in line with other studies that show these 
symptoms as being frequently rated as severe by cancer patients (Chang et 
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al., 2000; Cleeland et al., 2000; Modonesi et al., 2005; Strassels et al., 
2006).  
The results of this study illustrate a diminished quality of life in 
Icelandic patients with advanced cancer. The mean global health/quality 
of life score was considerably lower than data from the general population 
(Hjermstad, Fayers, Bjordal, & Kaasa, 1998a; Michelson, Bolund, Nilsson 
et al., 2000), but similar to results of studies of patients with advanced 
cancer (Jordhoy et al., 2001), and cancer patients treated with opioids 
(Klepstad et al., 2000). The quality of life score in the current study was 
also similar to scores found in patients with advanced cancer in palliative 
care, although slightly higher (41,6 vs. 33) (Stone et al., 1999). These 
findings, however, differ from two Icelandic studies, evaluating the 
quality of life in men with prostate cancer (Sigurðardóttir, 2006) and 
patients with various types of cancer in chemotherapy (Saevarsdottir et al., 
2008) where the scores indicated a generally good quality of life.  These 
results might stem from different samples in the three studies and of note 
is also that different instruments were used in the studies making 
comparison between them more complicated.  
The association between symptoms and quality of life, 
testing of the Symptoms-quality of life model 
One of the goals of the present study was to test the relationship between 
symptoms, selected demographic and clinical variables, and quality of 
life.  
Testing for difference in symptomatology based on cancer 
diagnose was not possible because of the sample size. Comparison with 
other studies is difficult for the same reason. Looking at the proportion of 
patients with symptoms, based on diagnosis, it shows that fatigue is 
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present in the vast majority. It can also be speculated that diarrhea may be 
more common in patients with multiple cancers, and that anorexia/loss of 
appetite is common in women with female reproductive cancers.  
Symptom severity did not differ between genders and 
corresponding to Lidstone’s et al. (2003) study neither did number of 
symptoms. Similarly, the prevalence of symptoms in the past week did not 
differ between genders, but of symptoms in the past 24 hours, pain and 
nausea were more common in women than men. Pain was also more 
prevalent among women than men in Lidstone’s et al. (2003) study, and 
similarly nausea has been found to be more frequent in women than men 
in various studies (Jordhoy et al., 2001; Lundh Hagelin et al., 2006; 
Mercadante et al., 2000; Walsh et al., 2000). It must be noted here that in 
these studies vomiting was often assessed alongside nausea. In this study, 
though, gender difference was not found for vomiting, possibly because of 
few patients (9 in 24 hours, 27 in a week) with the symptom. Why pain 
and nausea were more prevalent among women than men in this study is 
not clear. Nausea may be related to female reproductive cancers, since 
surgical and radiation treatments of those cancers are usually aimed at the 
pelvis and hence may disrupt bowel function resulting in nausea. The 
same, however, is true for prostate cancer. Unfortunately, testing of the 
prevalence of nausea between cancer diagnoses was not possible because 
of small sample size as previously mentioned. Nausea is also a frequent 
side effect of chemotherapy which might explain some of the difference 
between genders. One third of the men in the current study had prostate 
cancer which is infrequently treated with chemotherapy. As for pain in the 
past 24 hours, there is no obvious reason for it being more prevalent in 
women than men. Perhaps this difference is simply coincidental since 
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gender difference was not apparent for any symptoms in the past week. 
The same might also be true for nausea. 
Studies have shown that women may either experience better 
(Schultz & Winstead-Fry, 2001; Yan & Sellick, 2004) or worse (Parker et 
al., 2003) quality of life than men. In this study, however, gender 
difference was not apparent for either global health/quality of life score or 
any other EORTC QLQ-C30 scale. The results are, however, in line with 
another Icelandic study where quality of life did not differ between 
genders (Saevarsdottir et al., 2008). 
 As previous studies have shown (Lidstone et al., 2003; Walsh et 
al., 2000) number of symptoms decreased with increasing age in the 
current study and so did symptom severity.  It may seem strange that older 
people have fewer symptoms than younger, since older people usually 
have poorer health and hence it would appear normal that they had more 
symptoms. A possible explanation to this finding is that older people may 
adapt better to symptoms than younger people. Because of their age and 
already diminishing health older people might have become accustomed 
to several symptoms and therefore they might not acknowledge, 
experience, or report them. 
In line with other studies anxiety/feeling tense, depression (only in 
the past 24 hours, not in the past week) (Redeker et al., 2000), and 
dyspnea (Mercadante et al., 2000), were less prevalent in the oldest age 
group (76 years and older) in the current study. This might stem from the 
previously mentioned adaption to symptoms of older people. Having 
cancer may inspire more depression and anxiety in younger people, since 
the disease may be more disrupting in their lives. The oldest age group is 
already settling in to old age, expecting diseases to occur. Younger 
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people, however, have the responsibility of working, are perhaps still 
rearing children and so forth, and are therefore less prepared to deal with a 
difficult disease like cancer (Cella & Cherin, 1988). 
Surprisingly, global health/quality of life did not differ depending 
on age, a finding that is in contrast with several other studies (Lundh 
Hagelin et al., 2006; Parker et al., 2003; Saevarsdottir et al., 2008). On the 
other hand, older patients had better emotional and social functioning, as 
well as lower scores on the fatigue, dyspnea, insomnia, and financial 
problems symptom scales than younger patients, similar to what was 
found in the study of Lundh Hagelin et al. (2006). As could be expected, 
however, older patients had worse physical functioning than younger 
patients, which is in line with data from both the general population 
(Hjermstad, Fayers, Bjordal, & Kaasa, 1998b) as well as patients with 
cancer (Jordhoy et al., 2001). 
Concurrent diseases were not related to number of symptoms or 
symptom severity. These were surprising findings since it seems logical 
that the number and severity of symptoms should increase in line with 
number of concurrent diseases. Perhaps this can be explained by the fact 
that symptomatology is already high in this patients cohort. Because of the 
advanced cancer, the symptoms related to concurrent diseases might be 
obscured by the cancer related symptoms. The results were, nonetheless, 
in accordance with a longitudinal study of patients with lung cancer (Gift 
et al., 2003) were number of symptoms was not related to number of 
concurrent diseases. The findings differed, however, from several other 
studies that have shown the reverse (Gift et al., 2004; Sigurðardóttir, 
2006; Reyes-Gibby et al., 2006). Similarly, the number of concurrent 
diseases was not associated with any of the EORTC QLQ-C30 scales. 
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This was also an unexpected finding and in contrast with other studies that 
have shown the opposite, both in patients with cancer (Chang et al., 2000; 
Portenoy et al., 1994) and in the general population (Michelson, Bolund, 
& Brandberg, 2000). 
 When entered into a regression model, adjusted for age and 
gender, the number of symptoms explained 25,8% of the variance in 
global health/quality of life. The study, therefore, supported the 
hypothesis of an association between number of symptoms and worse 
quality of life. Comparable to the studies of Portenoy and colleagues 
(1994) and Chang and colleagues (2000), there was a highly significant 
correlation between number of symptoms and quality of life, indicating 
worse quality of life with increasing number of symptoms.  
The second regression model shows the relationship between the 
existence and severity of four individual symptoms, adjusted for age and 
gender, with quality of life. All of the symptoms were significantly 
correlated with quality of life and with each other. Fatigue was the 
symptom that explained the largest proportion of the variance in quality of 
life, followed by pain. Insomnia also added significantly to the model 
until depression was entered. Gender and age were, however, not 
significant in the model. The complete model explained 33,6% of the 
variance in global health/quality of life. The results, therefore, only 
partially supported the hypothesis of an association between the four 
symptoms and worse quality of life. 
The importance of fatigue in relation to quality of life was not an 
unexpected finding, since several studies have shown fatigue to be either 
moderately or strongly correlated with quality of life (Redeker et al., 
2000; Stone et al., 1999) or explaining a substantial proportion of the 
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variance in it (Beijer et al., 2008; Östlund et al., 2007). Similarly, pain has 
been shown to be negatively related to quality of life (Ferrell et al., 1991; 
Skevington, 1998). This is also in line with studies that show the 
importance of symptom distress in relation with quality of life (McMillan 
& Small, 2002; Portenoy et al., 1994). Fatigue and pain are both 
symptoms that have been found to be very distressing (Chang et al., 2000; 
Hoekstra et al., 2007) and, hence, it comes of no surprise that they explain 
a large amount of the variance in quality of life in this study.  
Insomnia (Lis et al., 2008; Redeker et al., 2000) and depression 
(Peters & Sellick, 2006; Redeker et al., 2000; Rustøen et al., 2005; 
Saevarsdottir et al., 2008) are symptoms that have also been linked to 
reduced quality of life so the lack of significant contribution to the 
regression model in this study was surprising. A possible explanation for 
this might be the low prevalence of patients who experienced “quite a bit” 
(N=11) or “very much” (n=7) depression in the past week, compared to 75 
without depression and 52 who experienced it as “little”. Therefore, it 
might be that there were too few patients with more severe depression to 
detect a difference. The same might be true for insomnia, since only about 
one third of the sample (n=57) had the symptom, and thereof, only 15 
experienced it as “quite a bit” and 14 as “very much”. Another 
explanation is that perhaps the patients who experienced depression were 
not clinically depressed and, hence, depression was not significant in the 
model. It must be noted that the EORTC QLQ-C30 was not designed to 
diagnose clinically significant depression and, hence the results should not 
be interpreted as such. Studies that have shown a relationship between 
depression and quality of life, however, have used instrument designed for 
measuring depression, either the Profile of Mood States (POMS) (Redeker 
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et al., 2000; Rustøen et al., 2005) or the Hospital Anxiety and Depression 
Scale (HADS) (Peters & Sellick, 2006; Saevarsdottir et al., 2008). 
Nonetheless, the proportion of patients who said they felt either quite a bit 
(7,6 %) or very much (4,8%) depression in the last week in this study was 
similar to another Icelandic study of cancer patients (Saevarsdottir et al., 
2008), were rate of depressive symptoms was 4% at the initiation of 
chemotherapy and 6% three months later. A third explanation of this 
finding might be that the contribution of insomnia and depression to the 
variance in quality of life might have become diluted because of 
correlation between the two symptoms. Of note, however, is that the 
correlation between depression and insomnia was only slightly higher 
than the correlation with the other symptoms, but the correlation of 
depression with global health/quality of life was the lowest of the four 
symptoms. 
 Although depression did not enter as significant in the regression 
model, the results of the study are similar to another study, of 102 patients 
with advanced cancer, where depressive symptomatology was not related 
to quality of life (Mystakidou et al., 2007). On the other hand they differ 
from two other studies, one of patients with various cancers in 
chemotherapy (Redeker et al., 2000), the other of patients with high grade 
glioma (Fox, Lyon, & Farace, 2007), where depression explained the 
largest proportion of the variance in quality of life while the contribution 
of fatigue was only moderate or minimal.  
Testing of the relationship between symptoms, selected 
demographic and clinical variables, and quality of life showed that the 
number of symptoms and symptom severity lessened with increasing age. 
Furthermore, the number of symptoms and the individual symptoms of 
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pain and fatigue were associated with diminished quality of life. The 
Symptoms-quality of life model was, therefore, only partially supported. 
Strength and limitations of the study 
The strengths of the study lie in a very consistent and rigorous data 
collection with low amount of missing data. Furthermore, there was a 
correspondence between the purpose of the study, research questions and 
hypotheses, definition of quality of life and instruments used in the study 
as recommended by several authors (Jocham et al., 2006; Kaasa & Loge, 
2003; King et al., 1997; Pais-Ribeiro, 2004). The instruments used were 
also appropriate to the population under study (Cella, 1996). The main 
advantage of the study is that it is the first study specifically exploring the 
relationship between symptoms and quality of life in Icelandic patients 
with advanced cancer. It therefore adds knowledge to a previously little 
explored area, and hopefully the results can be used in clinical practice to 
improve quality of life of Icelandic cancer patients. 
 The study has its limitations as well. Firstly, it is a secondary 
analysis of data. Data analyzing and testing of the Symptoms-quality of 
life model was therefore restricted to the data available. Secondly the 
study design was descriptive and correlational, based on a convenience 
sample consisting solely of Caucasians. Consequently, it was not possible 
to explore the prognostic value of symptoms on quality of life. It must be 
observed here, however, that convenience sample is often the only 
available sample in patients with advanced cancer, not least in small 
communities like Iceland. Thirdly, the sample size did not allow for the 
testing of some relationships like between cancer diagnosis and 
symptoms. Finally, the Symptom Checklist did not have an established 
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reliability or validity. The internal consistency of the symptom checklist 
in this study (α=.74), however, indicates an acceptable reliability. 
Furthermore, the consistency between the Symptom Checklist and the 
EORTC QLQ-C30 strengthens the results of the study. 
Conclusions  
This study shows that the symptomatology of Icelandic patients with 
advanced cancer is similar to cancer patients in other countries. The 
patients experience multiple symptoms, and although symptoms severity 
is usually mild, both fatigue and weakness were considered severe in 
about one third of the participants. The study further showed that there is 
an association between symptoms and quality of life, with pain and 
fatigue explaining nearly one third of the variance in quality of life. 
Surprisingly, however, insomnia and depression did not add significantly 
to the regression model. The number of symptoms patients experience is 
also related to quality of life, with quality of life scores diminishing with 
each additional symptom. These results indicate that quality of life of 
patients with advanced cancer may be improved by assessing, and 
treating, cancer related symptoms.  
Testing of the Symptoms-quality of life model supported the 
association between number of symptoms and quality of life. 
Furthermore, the relationship of the existence and severity of fatigue and 
pain with quality of life was sustained, but the study failed to show a 
significant contribution of depression and insomnia to quality of life. 
Testing of difference between cancer diagnoses was not possible because 
of few participants in each category. No association between gender or 
concurrent diseases with symptoms or quality of life was found, although, 
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pain and nausea were more prevalent in women than in men. Similarly, 
age was not related to quality of life, but some difference was, however, 
found between age and symptomatology with older patients having fewer 
symptoms and less symptom severity. Due to the limited number of 
patients at each end of the age line the results must be interpreted with 
caution. In light of this, further studies are warranted to test the 
Symptoms-quality of life model. 
Recognizing and treating symptoms is an important nursing and 
medical intervention and understanding the symptomatology of cancer 
patients helps medical professionals to assess patients’ needs and aids in 
clinical decision making and evaluation of treatment (Higginson & 
Addington-Hall, 2005). Assessing quality of life is also imperative since 
one of the main goal of cancer nursing is to improve quality of life, as 
mentioned before (King et al., 1997). Of note, however, is that evaluating 
quality of life per se is inadequate in order to improve quality of life of 
cancer patients, but the concept should rather be used as an outcome 
measure to assess the effect of treatment aimed at improving quality of 
life (Rosenbloom, Victorson, Hahn, Peterman, & Cella, 2007).  
The role of nursing is to enhance health, relieve suffering, and 
improve well-being of patients (Félag íslenskra hjúkrunarfræðinga, 2007). 
Since quality of life is associated with the symptomatology of cancer 
patients, nurses need to evaluate, and treat, the symptoms of cancer 
patients in order to improve their quality of life and hence their well-
being. This is not least true for the symptoms of pain and especially 
fatigue which are both common in this patients’ cohort and explain a great 
amount of the variance in quality of life. Of note are also dyspnea, 
weakness, constipation, and anorexia that were both common and rated as 
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severe in this study. Memory loss is also a symptom worth noticing. 
Although it was only severe in small proportion of patients it was 
surprisingly common and it may be a symptom difficult for patients to 
acknowledge. Nurses should also be alert to the number of symptoms 
patients endure, since increased number of symptoms is associated with 
reduced quality of life. Nursing interventions should, therefore, aim at 
reducing individual symptoms as well as the number of symptoms and 
symptom severity. Vigilant treatment of pain is important and specific 
interventions should be targeted at reducing fatigue. 
Future studies 
Further studies are needed to both evaluate the relationship between 
symptoms and quality of life as well as studies to gain a deeper 
understanding of what the concept of quality of life encompasses for 
cancer patients. In this study the relationship between individual 
symptoms and quality of life was only tested with four symptoms, but 
other symptoms may affect quality of life as well. Future studies should 
also be aimed at exploring further the relationship between age, gender 
and concurrent diseases with both symptoms and quality of life. Similarly, 
studies are needed to evaluate symptom clusters, their etiology, which 
symptoms cluster together, and the effect of symptom clusters on cancer 
patients. There is also a need to look at the importance of individual 
domains of quality of life to explore how important they are for cancer 
patients. This is not least true for the spiritual/existential domain which 
seems to become more vital as patients are nearing end of life. There is 
also need to assess the importance of various symptom factors, such as 
severity, distress, number of symptoms, symptom clusters, and/or 
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individual symptoms, in relation to quality of life. Last, but not least, 
studies are needed on interventions to improve symptom evaluation and 
management. 
  
118 
  
119 
References 
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., 
Duez, N. J., et al. (1993). The European Organization for Research 
and Treatment of Cancer QLQ-C30: A quality-of-life instrument for 
use in international clinical trials in oncology. Journal of the 
National Cancer Institute, 85(5), 365-376.  
Barsevick, A. M., Whitmer, K., Nail, L. M., Beck, S. L., & Dudley, W. N. 
(2006). Symptom cluster research: Conceptual, design, 
measurement, and analysis issues. Journal of Pain and Symptom 
Management, 31(1), 85-95.  
Beck, S. L., Dudley, W. N., & Barsevick, A. (2005). Pain, sleep 
disturbance, and fatigue in patients with cancer: Using a mediation 
model to test a symptom cluster. Oncology Nursing Forum, 32(3), 
E48-55.  
Beijer, S., Kempen, G. I., Pijls-Johannesma, M. C., de Graeff, A., & 
Dagnelie, P. C. (2008). Determinants of overall quality of life in 
preterminal cancer patients. International Journal of Cancer, 123(1), 
232-235.  
Bender, C. M., Ergyn, F. S., Rosenzweig, M. Q., Cohen, S. M., & Sereika, 
S. M. (2005). Symptom clusters in breast cancer across 3 phases of 
the disease. Cancer Nursing, 28(3), 219-225.  
Bjordal, K., de Graeff, A., Fayers, P. M., Hammerlid, E., van 
Pottelsberghe, C., Curran, D., et al. (2000). A 12 country field study 
of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer 
specific module (EORTC QLQ-H&N35) in head and neck patients. 
European Journal of Cancer, 36(14), 1796-1807.  
Brans, B., Lambert, B., De Beule, E., De Winter, F., Van Belle, S., Van 
Vlierberghe, H., et al. (2002). Quality of life assessment in 
radionuclide therapy: A feasibility study of the EORTC QLQ-C30 
questionnaire in palliative (131)I-lipiodol therapy. European Journal 
of Nuclear Medicine and Molecular Imaging, 29(10), 1374-1379.  
Brink, P. J., & Wood, M. J. (Eds.). (1998). Advanced design in nursing 
research (2nd ed.). Thousand Oaks: SAGE Publications. 
120 
Bruley, D. K. (1999). Beyond reliability and validity: Analysis of selected 
quality-of-life instruments for use in palliative care. Journal of 
Palliative Medicine, 2(3), 299-309.  
Calman, K. C. (1984). Quality of life in cancer patients-an hypothesis. 
Journal of Medical Ethics, 10(3), 124-127.  
Cella, D. F. (1994). Quality of life: Concepts and definition. Journal of 
Pain and Symptom Management, 9(3), 186-192.  
Cella, D. F. (1996). Quality of life outcomes: Measurement and 
validation. Oncology, 10(Suppl 11), 233-246.  
Cella, D. F., & Cherin, E. A. (1988). Quality of life during and after 
cancer treatment. Comprehensive Therapy, 14(5), 69-75.  
Chang, V. T., Hwang, S. S., Feuerman, M., & Kasimis, B. S. (2000). 
Symptom and quality of life survey of medical oncology patients at a 
Veterans affairs medical center: A role for symptom assessment. 
Cancer, 88(5), 1175-1183.  
Chen, M. L., & Chang, H. K. (2004). Physical symptom profiles of 
depressed and nondepressed patients with cancer. Palliative 
Medicine, 18(8), 712-718.  
Chen, M. L., & Tseng, H. C. (2006). Symptom clusters in cancer patients. 
Supportive Care in Cancer, 14(8), 825-830.  
Choe, M. A., Padilla, G. V., Chae, Y. R., & Kim, S. (2001). The meaning 
of health-related quality of life in a Korean sample. International 
Journal of Nursing Studies, 38(5), 557-566.  
Chow, E., Fan, G., Hadi, S., & Filipczak, L. (2007). Symptom clusters in 
cancer patients with bone metastases. Supportive Care in Cancer, 
15(9), 1035-1043.  
Cleeland, C. S., Bennett, G. J., Dantzer, R., Dougherty, P. M., Dunn, A. 
J., Meyers, C. A., et al. (2003). Are the symptoms of cancer and 
cancer treatment due to a shared biologic mechanism? A cytokine-
immunologic model of cancer symptoms. Cancer, 97(11), 2919-
2925.  
121 
Cleeland, C. S., Mendoza, T. R., Wang, X. S., Chou, C., Harle, M. T., 
Morrissey, M., et al. (2000). Assessing symptom distress in cancer 
patients: The M.D. Anderson Symptom Inventory. Cancer, 89(7), 
1634-1646.  
Coates, A., Porzsolt, F., & Osoba, D. (1997). Quality of life in oncology 
practice: Prognostic value of EORTC QLQ-C30 scores in patients 
with advanced malignancy. European Journal of Cancer, 33(7), 
1025-1030.  
Cummins, R. A. (1996). The domains of life satisfaction: An attempt to 
order chaos. Social Indicators Research, 38(3), 303-328.  
Dodd, M., Janson, S., Facione, N., Faucett, J., Froelicher, E. S., 
Humphreys, J., et al. (2001). Advancing the science of symptom 
management. Journal of Advanced Nursing, 33(5), 668-676.  
Dodd, M. J., Miaskowski, C., & Paul, S. M. (2001). Symptom clusters and 
their effect on the functional status of patients with cancer. Oncology 
Nursing Forum, 28(3), 465-470.  
EORTC. (n.d.a). EORTC QLQ-C30. Retrieved 11/5, 2007, from 
http://groups.eortc.be/qol/questionnaires_qlqc30.htm  
EORTC. (n.d.b). Glossary. Retrieved 11/6, 2007, from 
http://groups.eortc.be/qol/glossary.htm  
Fayers, P., & Bottomley, A., on behalf of the EORTC Quality of Life 
Group, & Quality of Life Unit. (2002). Quality of life research 
within the EORTC-the EORTC QLQ-C30. European Journal of 
Cancer, 38(Suppl 4), S125-133.  
Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & 
Bottomley,A., on behalf of the EORTC Quality of Life Group. 
(2001). The EORTC QLQ-C30 scoring manual (3rd ed.). Brussels: 
European Organization for Research and Treatment of Cancer. 
Félag íslenskra hjúkrunarfræðinga. (2007). Siðareglur hjúkrunarfræðinga. 
Retrieved 07/02, 2008, from http://www.hjukrun.is/?PageID=117  
Felce, D., & Perry, J. (1995). Quality of life: Its definition and 
measurement. Research in Developmental Disabilities, 16(1), 51-74.  
122 
Ferrans, C. E., Zerwic, J. J., Wilbur, J. E., & Larson, J. L. (2005). 
Conceptual model of health-related quality of life. Journal of 
Nursing Scholarship, 37(4), 336-342.  
Ferrell, B. (1995). The impact of pain on quality of life. A decade of 
research. The Nursing Clinics of North America, 30(4), 609-624.  
Ferrell, B., Grant, M., Padilla, G., Vemuri, S., & Rhiner, M. (1991). The 
experience of pain and perceptions of quality of life: Validation of a 
conceptual model. The Hospice Journal, 7(3), 9-24.  
Feyer, P., Kleeberg, U. R., Steingraber, M., Gunther, W., & Behrens, M. 
(2008). Frequency of side effects in outpatient cancer care and their 
influence on patient satisfaction-a prospective survey using the 
PASQOC questionnaire. Supportive Care in Cancer, 16(6), 567-575.  
Fox, S. W., Lyon, D., & Farace, E. (2007). Symptom clusters in patients 
with high-grade glioma. Journal of Nursing Scholarship, 39(1), 61-
67.  
Fredheim, O. M., Borchgrevink, P. C., Saltnes, T., & Kaasa, S. (2007). 
Validation and comparison of the health-related quality of life 
instruments EORTC QLQ-C30 and SF-36 in assessment of patients 
with chronic nonmalignant pain. Journal of Pain and Symptom 
Management, 34(6), 657-665. 
Friðriksdóttir, N., & Sigurðardóttir, V. (2004, April). Mat á einkennum 
sjúklinga í líknarmeðferð. Lecture.  
Fu, M. R., McDaniel, R. W., & Rhodes, V. A. (2007). Measuring 
symptom occurrence and symptom distress: Development of the 
symptom experience index. Journal of Advanced Nursing, 59(6), 
623-634.  
Gift, A. G., Jablonski, A., Stommel, M., & Given, C. W. (2004). 
Symptom clusters in elderly patients with lung cancer. Oncology 
Nursing Forum, 31(2), 202-212.  
Gift, A. G., Stommel, M., Jablonski, A., & Given, W. (2003). A cluster of 
symptoms over time in patients with lung cancer. Nursing Research, 
52(6), 393-400.  
123 
Given, B., Given, C. W., Sikorskii, A., Jeon, S., McCorkle, R., Champion, 
V., et al. (2008). Establishing mild, moderate, and severe scores for 
cancer-related symptoms: How consistent and clinically meaningful 
are interference-based severity cut-points? Journal of Pain and 
Symptom Management, 35(2), 126-135.  
Grant, M. M., & Dean, G. E. (2003). Evolution of quality of life in 
oncology and oncology nursing. In C. R. King, & P. S. Hinds (Eds.), 
Quality of life from nursing and patient perspectives: Theory, 
research, practice (second ed., pp. 3-27). Sudbury, MA: Jones and 
Bartlett. 
Groenvold, M., Klee, M. C., Sprangers, M. A., & Aaronson, N. K. (1997). 
Validation of the EORTC QLQ-C30 quality of life questionnaire 
through combined qualitative and quantitative assessment of patient-
observer agreement. Journal of Clinical Epidemiology, 50(4), 441-
450.  
Groenvold, M., Petersen, M. A., Aaronson, N. K., Arraras, J. I., Blazeby, 
J. M., Bottomley, A., et al. (2006). The development of the EORTC 
QLQ-C15-PAL: A shortened questionnaire for cancer patients in 
palliative care. European Journal of Cancer, 42(1), 55-64.  
Haas, B. K. (1999a). Clarification and integration of similar quality of life 
concepts. Image-the Journal of Nursing Scholarship, 31(3), 215-220.  
Haas, B. K. (1999b). A multidisciplinary concept analysis of quality of 
life. Western Journal of Nursing Research, 21(6), 728-742.  
Haberman, M. R., & Bush, N. (1998). Quality of life. Methodological and 
measurement issues. In C. R. King, & P. S. Hinds (Eds.), Quality of 
life from nursing and patient perspectives: Theory, research, 
practice (pp. 117-139). Sudbury, MA: Jones and Bartlett. 
Henry, D. H., Viswanathan, H. N., Elkin, E. P., Traina, S., Wade, S., & 
Cella, D. (2008). Symptoms and treatment burden associated with 
cancer treatment: Results from a cross-sectional national survey in 
the U.S. Supportive Care in Cancer, 16(7), 791-801.  
Hicsonmez, A., Kose, K., Andrieu, M. N., Guney, Y., & Kurtman, C. 
(2007). The European Organization for Research and Treatment of 
Cancer core quality of life questionnaire (QLQ-C30 version 3.0 
124 
Turkish) in cancer patients receiving palliative radiotherapy. 
European Journal of Cancer Care, 16(3), 251-257.  
Higginson, I. J., & Addington-Hall, J. M. (2005). The epidemiology of 
death and symptoms. In D. Doyle, G. Hanks, N. Cherny & K. 
Calman (Eds.), Oxford textbook of palliative medicine (3rd ed., pp. 
14-24). New York: Oxford University Press. 
Hjermstad, M. J., Fayers, P. M., Bjordal, K., & Kaasa, S. (1998a). Health-
related quality of life in the general Norwegian population assessed 
by the European Organization for Research and Treatment of Cancer 
core quality-of-life questionnaire: The QLQ=C30 (+ 3). Journal of 
Clinical Oncology, 16(3), 1188-1196.  
Hjermstad, M. J., Fayers, P. M., Bjordal, K., & Kaasa, S. (1998b). Using 
reference data on quality of life-the importance of adjusting for age 
and gender, exemplified by the EORTC QLQ-C30 (+3). European 
Journal of Cancer, 34(9), 1381-1389.  
Hjermstad, M. J., Fossa, S. D., Bjordal, K., & Kaasa, S. (1995). Test/retest 
study of the European Organization for Research and Treatment of 
Cancer core quality-of-life questionnaire. Journal of Clinical 
Oncology, 13(5), 1249-1254.  
Hoekstra, J., de Vos, R., van Duijn, N. P., Schade, E., & Bindels, P. J. 
(2006). Using the Symptom Monitor in a randomized controlled 
trial: The effect on symptom prevalence and severity. Journal of 
Pain and Symptom Management, 31(1), 22-30.  
Hoekstra, J., Vernooij-Dassen, M. J., de Vos, R., & Bindels, P. J. (2007). 
The added value of assessing the 'most troublesome' symptom 
among patients with cancer in the palliative phase. Patient Education 
and Counseling, 65(2), 223-229.  
Hofman, M., Ryan, J. L., Figueroa-Moseley, C. D., Jean-Pierre, P., & 
Morrow, G. R. (2007). Cancer-related fatigue: The scale of the 
problem. The Oncologist, 12(Suppl 1), 4-10.   
Homsi, J., Walsh, D., Rivera, N., Rybicki, L. A., Nelson, K. A., Legrand, 
S. B., et al. (2006). Symptom evaluation in palliative medicine: 
Patient report vs systematic assessment. Supportive Care in Cancer, 
14(5), 444-453.  
125 
Hwang, S. S., Chang, V. T., Fairclough, D. L., Cogswell, J., & Kasimis, 
B. (2003). Longitudinal quality of life in advanced cancer patients: 
Pilot study results from a VA medical cancer center. Journal of Pain 
and Symptom Management, 25(3), 225-235.  
Jocham, H. R., Dassen, T., Widdershoven, G., & Halfens, R. (2006). 
Quality of life in palliative care cancer patients: A literature review. 
Journal of Clinical Nursing, 15(9), 1188-1195.  
Jónasson, J.G., & Tryggvadóttir, L. (Ritstj.). (2004). Krabbamein á 
Íslandi. Reykjavík: Krabbameinsfélagið. 
Jordhoy, M. S., Fayers, P., Loge, J. H., Saltnes, T., Ahlner-Elmqvist, M., 
& Kaasa, S. (2001). Quality of life in advanced cancer patients: The 
impact of sociodemographic and medical characteristics. British 
Journal of Cancer, 85(10), 1478-1485.  
Kaasa, S., & Loge, J. H. (2003). Quality of life in palliative care: 
Principles and practice. Palliative Medicine, 17(1), 11-20.  
Kim, H. J., McGuire, D. B., Tulman, L., & Barsevick, A. M. (2005). 
Symptom clusters: Concept analysis and clinical implications for 
cancer nursing. Cancer Nursing, 28(4), 270-282.  
King, C. R., Haberman, M., Berry, D. L., Bush, N., Butler, L., Dow, K. 
H., et al. (1997). Quality of life and the cancer experience: The state-
of-the-knowledge. Oncology Nursing Forum, 24(1), 27-41.  
King, C. R., & Hinds, P. (Eds.). (1998). Quality of life from nursing and 
patient perspectives : Theory, research, practice. Sudbury, MA: 
Jones and Bartlett. 
Klepstad, P., Kaasa, S., Dale, O., Skorpen, F., Cherny, N., Hanks, G., et 
al. (n.d.). European Pharmacogenetic Opioid Study (EPOS). [Study 
protocol]. Unpublished document. 
Klepstad, P., Borchgrevink, P. C., & Kaasa, S. (2000). Effects on cancer 
patients' health-related quality of life after the start of morphine 
therapy. Journal of Pain and Symptom Management, 20(1), 19-26.  
Klepstad, P., Kaasa, S., Cherny, N., Hanks, G., de Conno, F., & Research 
Steering Committee of the EAPC. (2005). Pain and pain treatments 
126 
in European palliative care units. A cross sectional survey from the 
European Association for Palliative Care Research Network. 
Palliative Medicine, 19(6), 477-484.  
Krabbameinsskrá Krabbameinsfélags Íslands. (2008a). Öll mein. ICD 
10:Coo-C96. Retrieved 3/20, 2008, from 
http://www.krabbameinsskra.is/index.jsp?icd=C00-C96  
Krabbameinsskrá Krabbameinsfélags Íslands. (2008b). Tölfræði 
krabbameina á Íslandi. Retrieved 03/05, 2008, from 
http://www.krabbameinsskra.is/  
Lee, B. N., Dantzer, R., Langley, K. E., Bennett, G. J., Dougherty, P. M., 
Dunn, A. J., et al. (2004). A cytokine-based neuroimmunologic 
mechanism of cancer-related symptoms. Neuroimmunomodulation, 
11(5), 279-292.  
Lenz, E. R., Pugh, L. C., Milligan, R. A., Gift, A., & Suppe, F. (1997). 
The middle-range Theory of Unpleasant Symptoms: An update. 
Advances in Nursing Science, 19(3), 14-27.  
Lenz, E. R., Suppe, F., Gift, A. G., Pugh, L. C., & Milligan, R. A. (1995). 
Collaborative development of middle-range nursing theories: 
Toward a Theory of Unpleasant Symptoms. Advances in Nursing 
Science, 17(3), 1-13.  
Lidstone, V., Butters, E., Seed, P. T., Sinnott, C., Beynon, T., & Richards, 
M. (2003). Symptoms and concerns amongst cancer outpatients: 
Identifying the need for specialist palliative care. Palliative 
Medicine, 17(7), 588-595.  
Liehr, P. (2005). Looking at symptoms with a middle-range theory lens. 
Advanced Studies in Nursings, 3(4), 152-157.  
Lis, C. G., Gupta, D., & Grutsch, J. F. (2008). The relationship between 
insomnia and patient satisfaction with quality of life in cancer. 
Supportive Care in Cancer, 16, 261-266. 
Lundh Hagelin, C., Seiger, A., & Furst, C. J. (2006). Quality of life in 
terminal care-with special reference to age, gender and marital 
status. Supportive Care in Cancer, 14(4), 320-328.  
127 
McDaniel, R. W., & Rhodes, V. A. (1995). Symptom experience. 
Seminars in Oncology Nursing, 11(4), 232-234.  
McMillan, S. C., & Small, B. J. (2002). Symptom distress and quality of 
life in patients with cancer newly admitted to hospice home care. 
Oncology Nursing Forum, 29(10), 1421-1428.  
Mercadante, S., Casuccio, A., & Fulfaro, F. (2000). The course of 
symptom frequency and intensity in advanced cancer patients 
followed at home. Journal of Pain and Symptom Management, 
20(2), 104-112.  
Miaskowski, C. (2006). Symptom clusters: Establishing the link between 
clinical practice and symptom management research. Supportive 
Care in Cancer, 14(8), 792-794.  
Miaskowski, C., Cooper, B. A., Paul, S. M., Dodd, M., Lee, K., 
Aouizerat, B. E., et al. (2006). Subgroups of patients with cancer 
with different symptom experiences and quality-of-life outcomes: A 
cluster analysis. Oncology Nursing Forum, 33(5), E79-89.  
Michelson, H., Bolund, C., & Brandberg, Y. (2000). Multiple chronic 
health problems are negatively associated with health related quality 
of life (HRQoL) irrespective of age. Quality of Life Research, 9(10), 
1093-1104.  
Michelson, H., Bolund, C., Nilsson, B., & Brandberg, Y. (2000). Health-
related quality of life measured by the EORTC QLQ-C30-reference 
values from a large sample of Swedish population. Acta Oncologica, 
39(4), 477-484.  
Modonesi, C., Scarpi, E., Maltoni, M., Derni, S., Fabbri, L., Martini, F., et 
al. (2005). Impact of palliative care unit admission on symptom 
control evaluated by the Edmonton Symptom Assessment System. 
Journal of Pain and Symptom Management, 30(4), 367-373.  
Moller, B., Fekjaer, H., Hakulinen, T., Tryggvadottir, L., Storm, H. H., 
Talback, M., et al. (2002). Prediction of cancer incidence in the 
Nordic countries up to the year 2020. European Journal of Cancer 
Prevention, 11(Suppl 1), S1-96.  
128 
Morita, T., Tsunoda, J., Inoue, S., & Chihara, S. (1999). Contributing 
factors to physical symptoms in terminally-ill cancer patients. 
Journal of Pain and Symptom Management, 18(5), 338-346.  
Morse, J. M. (1995). Exploring the theoretical basis of nursing using 
advanced techniques of concept analysis. Advances in Nursing 
Science, 17(3), 31-46.  
Morse, J. M., Mitcham, C., Hupcey, J. E., & Tason, M. C. (1996). Criteria 
for concept evaluation. Journal of Advanced Nursing, 24(2), 385-
390.  
Mystakidou, K., Tsilika, E., Parpa, E., Pathiaki, M., Galanos, A., & 
Vlahos, L. (2007). The relationship between quality of life and levels 
of hopelessness and depression in palliative care. Depression and 
Anxiety. Epub ahead of print, retrieved 12/2, 2008. 
doi:10.1002/da.20319. 
National Cancer Institute. (n.d.). Dictionary of cancer terms. Retrieved 
3/25, 2008, from 
http://www.cancer.gov/templates/db_alpha.aspx?expand=A  
Nekolaichuk, C. L., Bruera, E., Spachynski, K., MacEachern, T., Hanson, 
J., & Maguire, T. O. (1999). A comparison of patient and proxy 
symptom assessments in advanced cancer patients. Palliative 
Medicine, 13(4), 311-323.  
Nekolaichuk, C. L., Maguire, T. O., Suarez-Almazor, M., Rogers, W. T., 
& Bruera, E. (1999). Assessing the reliability of patient, nurse, and 
family caregiver symptom ratings in hospitalized advanced cancer 
patients. Journal of Clinical Oncology, 17(11), 3621-3630.  
Nicklasson, M., & Bergman, B. (2007). Validity, reliability and clinical 
relevance of EORTC QLQ-C30 and LC13 in patients with chest 
malignancies in a palliative setting. Quality of Life Research, 16(6), 
1019-1028.  
Niezgoda, H. E., & Pater, J. L. (1993). A validation study of the domains 
of the core EORTC quality of life questionnaire. Quality of Life 
Research, 2(5), 319-325.  
129 
Niv, D., & Kreitler, S. (2001). Pain and quality of life. Pain Practice, 
1(2), 150-161.  
Osoba, D. (1994). Lessons learned from measuring health-related quality 
of life in oncology. Journal of Clinical Oncology, 12(3), 608-616.  
Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998). 
Interpreting the significance of changes in health-related quality-of-
life scores. Journal of Clinical Oncology, 16(1), 139-144.  
Pais-Ribeiro, J. L. (2004). Quality of life is a primary end-point in clinical 
settings. Clinical Nutrition, 23(1), 121-130.  
Paley, J. (1996). How not to clarify concepts in nursing. Journal of 
Advanced Nursing, 24(3), 572-578.  
Parker, P. A., Baile, W. F., de Moor, C., & Cohen, L. (2003). 
Psychosocial and demographic predictors of quality of life in a large 
sample of cancer patients. Psycho-Oncology, 12(2), 183-193.  
Penson, R. T., Wenzel, L. B., Vergote, I., & Cella, D. (2006). Quality of 
life considerations in gynecologic cancer. FIGO 6th annual report on 
the results of treatment in gynecological cancer. International 
Journal of Gynaecology and Obstetrics, 95(Suppl 1), S247-257.  
Peters, L., & Sellick, K. (2006). Quality of life of cancer patients 
receiving inpatient and home-based palliative care. Journal of 
Advanced Nursing, 53(5), 524-533.  
Pirl, W. F. (2004). Evidence report on the occurrence, assessment, and 
treatment of depression in cancer patients. Journal of the National 
Cancer Institute Monographs, 32, 32-39.  
Polit, D. F., & Beck, C. T. (2004). Nursing research: Principles and 
methods (7th ed.). Philadelphia: Lippincott Williams & Wilkins. 
Portenoy, R. K., Thaler, H. T., Kornblith, A. B., Lepore, J. M., 
Friedlander-Klar, H., Coyle, N., et al. (1994). Symptom prevalence, 
characteristics and distress in a cancer population. Quality of Life 
Research, 3(3), 183-189.  
130 
Redeker, N. S., Lev, E. L., & Ruggiero, J. (2000). Insomnia, fatigue, 
anxiety, depression, and quality of life of cancer patients undergoing 
chemotherapy. Scholarly Inquiry for Nursing Practice, 14(4), 275-
290.  
Reglur um upplýst samþykki í vísindarannsókn á heillbrigðissviði nr. 
170/2001.  
Revicki, D. A., Osoba, D., Fairclough, D., Barofsky, I., Berzon, R., Leidy, 
N. K., et al. (2000). Recommendations on health-related quality of 
life research to support labeling and promotional claims in the 
United States. Quality of Life Research, 9(8), 887-900.  
Reyes-Gibby, C. C., Aday, L. A., Anderson, K. O., Mendoza, T. R., & 
Cleeland, C. S. (2006). Pain, depression, and fatigue in community-
dwelling adults with and without a history of cancer. Journal of Pain 
and Symptom Management, 32(2), 118-128.  
Reyes-Gibby, C. C., Ba Duc, N., Phi Yen, N., Hoai Nga, N., Van Tran, T., 
Guo, H., et al. (2006). Status of cancer pain in Hanoi, Vietnam: A 
hospital-wide survey in a tertiary cancer treatment center. Journal of 
Pain and Symptom Management, 31(5), 431-439.  
Rhodes, V. A., McDaniel, R. W., Homan, S. S., Johnson, M., & Madsen, 
R. (2000). An instrument to measure symptom experience, symptom 
occurrence and symptom distress. Cancer Nursing, 23(1), 49-54.  
Rhodes, V. A., & Watson, P. M. (1987). Symptom distress-the concept: 
Past and present. Seminars in Oncology Nursing, 3(4), 242-247.  
Rodary, C., Pezet-Langevin, V., Garcia-Acosta, S., Lesimple, T., 
Lortholary, A., Kaminsky, M. C., et al. (2004). Patient preference for 
either the EORTC QLQ-C30 or the FACIT quality of life (QOL) 
measures: A study performed in patients suffering from carcinoma of 
an unknown primary site (CUP). European Journal of Cancer, 
40(4), 521-528.  
Rosenbloom, S. K., Victorson, D. E., Hahn, E. A., Peterman, A. H., & 
Cella, D. (2007). Assessment is not enough: A randomized 
controlled trial of the effects of HRQL assessment on quality of life 
and satisfaction in oncology clinical practice. Psycho-Oncology, 16, 
1069-1079. 
131 
Rustøen, T., Moum, T., Padilla, G., Paul, S., & Miaskowski, C. (2005). 
Predictors of quality of life in oncology outpatients with pain from 
bone metastasis. Journal of Pain and Symptom Management, 30(3), 
234-242.  
Saevarsdottir, T., Fridriksdottir, N., & Gunnarsdottir, S. (2008). Quality of 
life and symptoms of anxiety and depression of Icelandic patients 
receiving cancer chemotherapy at two time points. Manuscript 
submitted for publication. 
Schuit, K. W., Sleijfer, D. T., Meijler, W. J., Otter, R., Schakenraad, J., 
van den Bergh, F. C., et al. (1998). Symptoms and functional status 
of patients with disseminated cancer visiting outpatient departments. 
Journal of Pain and Symptom Management, 16(5), 290-297.  
Schultz, A. A., & Winstead-Fry, P. (2001). Predictors of quality of life in 
rural patients with cancer. Cancer Nursing, 24(1), 12-19.  
Serlin, R. C., Mendoza, T. R., Nakamura, Y., Edwards, K. R., & Cleeland, 
C. S. (1995). When is cancer pain mild, moderate or severe? Grading 
pain severity by its interference with function. Pain, 61(2), 277-284.  
Sigurdardottir, V., Hjaltadottir, I., Gudmannsdottir, G. D., & Jonsson, P. 
V. (2006). The last 72 hours - symptom assessment in palliative care 
services in Iceland using the minimal data set - palliative care (MDS-
PC) instrument [Abstract]. Palliat.Med., 20(3) 271.  
Sigurðardóttir, G. (2006). Validation of the Icelandic translation of the 
Expanded Prostate Cancer Index Composite-26-item v. Unpublished 
MS-thesis: Hjúkrunarfræðideild, Háskóli Íslands. 
Skevington, S. M. (1998). Investigating the relationship between pain and 
discomfort and quality of life, using the WHOQOL. Pain, 76(3), 
395-406.  
Skúladóttir, F.B., Birgisdóttir, Ó.I., & Friðriksdóttir, V. (2005). Mat á 
einkennum hjá sjúklingum með krabbamein: Forprófun á M.D. 
Anderson Symptom Inventory (MDASI). Unpublished BS-thesis: 
Háskóli Íslands, Hjúkrunarfræðideild. 
Sneeuw, K. C., Sprangers, M. A., & Aaronson, N. K. (2002). The role of 
health care providers and significant others in evaluating the quality 
132 
of life of patients with chronic disease. Journal of Clinical 
Epidemiology, 55(11), 1130-1143.  
Solano, J. P., Gomes, B., & Higginson, I. J. (2006). A comparison of 
symptom prevalence in far advanced cancer, AIDS, heart disease, 
chronic obstructive pulmonary disease and renal disease. Journal of 
Pain and Symptom Management, 31(1), 58-69.  
Sprangers, M. A., & Aaronson, N. K. (1992). The role of health care 
providers and significant others in evaluating the quality of life of 
patients with chronic disease: A review. Journal of Clinical 
Epidemiology, 45(7) 743-760.  
Stewart, A. L., Teno, J., Patrick, D. L., & Lynn, J. (1999). The concept of 
quality of life of dying persons in the context of health care. Journal 
of Pain and Symptom Management, 17(2), 93-108.  
Stone, P., Hardy, J., Broadley, K., Tookman, A. J., Kurowska, A., & 
A'Hern, R. (1999). Fatigue in advanced cancer: A prospective 
controlled cross-sectional study. British Journal of Cancer, 79(9-10), 
1479-1486.  
Strassels, S. A., Blough, D. K., Hazlet, T. K., Veenstra, D. L., & Sullivan, 
S. D. (2006). Pain, demographics, and clinical characteristics in 
persons who received hospice care in the United States. Journal of 
Pain and Symptom Management, 32(6), 519-531.  
Stromgren, A. S., Groenvold, M., Pedersen, L., Olsen, A. K., & Sjogren, 
P. (2002). Symptomatology of cancer patients in palliative care: 
Content validation of self-assessment questionnaires against medical 
records. European Journal of Cancer, 38(6), 788-794.  
Stromgren, A. S., Sjogren, P., Goldschmidt, D., Petersen, M. A., 
Pedersen, L., & Groenvold, M. (2006). Symptom priority and course 
of symptomatology in specialized palliative care. Journal of Pain 
and Symptom Management, 31(3), 199-206.  
Sweed, M. R., Schiech, L., Barsevick, A., Babb, J. S., & Goldberg, M. 
(2002). Quality of life after esophagectomy for cancer. Oncology 
Nursing Forum, 29(7), 1127-1131.  
133 
Taillefer, M. C., Dupuis, G., Roberge, M. A., & LeMay, S. (2003). 
Health-related quality of life models: Systematic review of the 
literature. Social Indicators Research, 64(2), 293-323.  
Tang, W. R., Aaronson, L. S., & Forbes, S. A. (2004). Quality of life in 
hospice patients with terminal illness. Western Journal of Nursing 
Research, 26(1), 113-128.  
Teunissen, S. C., Wesker, W., Kruitwagen, C., de Haes, H. C., Voest, E. 
E., & de Graeff, A. (2007). Symptom prevalence in patients with 
incurable cancer: A systematic review. Journal of Pain and Symptom 
Management, 34(1), 94-104.  
Theobald, D. E. (2004). Cancer pain, fatigue, distress, and insomnia in 
cancer patients. Clinical Cornerstone, 6(Suppl 1D), S15-21.  
Tsai, J. S., Wu, C. H., Chiu, T. Y., Hu, W. Y., & Chen, C. Y. (2006). 
Symptom patterns of advanced cancer patients in a palliative care 
unit. Palliative Medicine, 20(6), 617-622.  
Velikova, G., Stark, D., & Selby, P. (1999). Quality of life instruments in 
oncology. European Journal of Cancer, 35(11), 1571-1580.  
Verdecchia, A., Francisci, S., Brenner, H., Gatta, G., Micheli, A., 
Mangone, L., et al. (2007). Recent cancer survival in Europe: A 
2000-02 period analysis of EUROCARE-4 data. The Lancet 
Oncology, 8(9), 784-796.  
Walsh, D., Donnelly, S., & Rybicki, L. (2000). The symptoms of 
advanced cancer: Relationship to age, gender, and performance 
status in 1,000 patients. Supportive Care in Cancer, 8(3), 175-179.  
Walsh, D., & Rybicki, L. (2006). Symptom clustering in advanced cancer. 
Supportive Care in Cancer, 14(8), 831-836.  
Walsh, D., Rybicki, L., Nelson, K. A., & Donnelly, S. (2002). Symptoms 
and prognosis in advanced cancer. Supportive Care in Cancer, 10(5), 
385-388.  
WHO-QOL Group. (1993). Study protocol for the World Health 
Organization project to develop a quality of life assessment 
instrument (WHOQOL). Quality of Life Research, 2(2), 153-159.  
134 
WHO-QOL Group. (1997). WHOQOL - measuring quality of life. World 
Health Organization. Retrieved 3/19, 2008, from 
http://www.who.int/mental_health/media/68.pdf 
Yan, H., & Sellick, K. (2004). Quality of life of Chinese patients newly 
diagnosed with gastrointestinal cancer: A longitudinal study. 
International Journal of Nursing Studies, 41(3), 309-319.  
Östlund, U., Wennman-Larsen, A., Gustavsson, P., & Wengström, Y. 
(2007). What symptom and functional dimensions can be predictors 
for global ratings of overall quality of life in lung cancer patients? 
Supportive Care in Cancer, 15(10), 1199-1205.   
135 
Appendix 
 
 
Definitions of concepts 
 
  
136 
  
137 
Definitions of concepts 
This appendix contains defintions of concepts that commonly appear in 
the thesis. 
Advanced cancer: Cancer that has spread to other places in the body and 
usually cannot be cured or controlled with treatment (National Cancer 
Institute, n.d.). 
Health related quality of life: A multidimensional construct encompassing 
perceptions of both positive and negative aspects of physical, emotional, 
social, and cognitive functions, as well as the negative aspects of somatic 
discomfort and other symptoms produced by a disease or its treatment 
(Osoba, 1994). 
Health related quality of life (QOL): refers to the extent to which one’s 
usual or expected physical, emotional and social well-being are affected 
by a medical condition or its treatment (Cella, 1996). 
Quality of life: Patients' appraisal of, and satisfaction with, their current 
level of functioning as compared to what they perceive to be possible of 
ideal (Cella & Cherin, 1988).  
Symptom: Subjective phenomenon regarded by individuals as an 
indication of a condition departing from normal function, sensation, or 
appearance (Rhodes & Watson, 1987). 
Sign: An objective phenomenon that is observable and indicates a change 
in health status (Liehr, 2005)  
Symptom severity: The strength or amount of the symptom being 
experienced (Lenz, Pugh, Milligan, Gift, & Suppe, 1997) 
Symptom distress: The degree or amount of physical or mental upset, 
anguish, or suffering experienced from a specific symptom (Rhodes & 
Watson, 1987). 
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Symptom occurrence: The frequency and severity with which the 
symptom occurs and the duration or persistence of the symptom 
(McDaniel & Rhodes, 1995).  
Symptom experience: An individual's perception of a symptom, 
evaluation of the meaning of a symptom and response to a symptom (M. 
Dodd et al., 2001). 
Symptom cluster:  
a) Three or more concurrent symptoms that are related to each other, 
which may or may not have the same etiology (M. J. Dodd, 
Miaskowski, & Paul, 2001). 
b) Two or more symptoms that are related to each other and that 
occur together. Symptoms clusters are composed of stable groups 
of symptoms are relatively independent of other clusters, and may 
reveal specific underlying dimensions of symptoms. Relationships 
among symptoms within a cluster should be stronger than 
relationships among symptoms across different clusters. 
Symptoms in a cluster may or may not share the same etiology 
(Kim, McGuire, Tulman, & Barsevick, 2005). 
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